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BACKGROUND: Genetic diagnosis is recommended for all pheochromocytoma (PCC) and 
paraganglioma (PGL) cases (PPGL), as 65-80% are explained by a driver mutation in one of the 34 
genes described so far. Several genetic testing algorithms have been proposed, but they usually 
exclude sporadic-PPGLs (S-PPGLs) and none include somatic testing. Moreover, as the list of PPGL 
related genes expands yearly, genetic diagnosis becomes a time-consuming task, and targeted 
gene panels using next generation sequencing (Targeted-NGS) have emerged as cost-effective 
tools.  
AIMS: We aimed to elucidate the genetic heterogeneity of PPGL development through a 
systematic genetic study. This study was carried out in two consecutive parts.   
MATERIAL AND METHODS: Part I included 329 probands and was focused on the genetic 
characterization of S-PPGL using Sanger sequencing (SS), and gross deletions of PPGL genes in 
which the mutational mechanism is relevant. Ninety-nine tumors from patients negative for 
germline mutations (GM) were available and tested for somatic mutations (SM) in RET, VHL, HRAS, 
EPAS1, MAX and SDHB. Part II addressed a blind genetic screening of PPGL based on 2 customized 
targeted-NGS assays. One of these panels allowed the study in germline and frozen tumor DNA, 
and the second one was specifically designed for DNA extracted from FFPE tissue. This second 
study included 453 PPGL patients (30 of them controls with known pathogenic mutations, and 275 
had been partially screened by SS (WTPS)).  
RESULTS: Part I: GM were found in 46 (14%) patients, being more prevalent in PGLs (28.7%) than 
in PCCs (4.5%) (p=6.62×10-10). Head and neck PGLs (HN-PGLs) and thoracic-PGLs (T-PGLs), more 
commonly had GMs (p=2.0×10-4 and p=0.027, respectively), but not abdominal-PGLs (A-PGLs). SM 
were found in 43% of those tested, being more prevalent in PCCs (48.5%) than in PGLs (32.3%) 
(p=0.13). Five metastatic cases and a quarter of S-PPGLs had a SM, regardless of age at onset. Part 
II: NGS assay sensitivity was ≥99.4%, regardless of DNA source. We identified 45 variants of 
unknown significance and 89 mutations, GMs in 29 (7.2%), and SMs in 58 (31.7%) of the 183 
tumors studied (being 37 mutations found in WTPS).   
CONCLUSIONS: We recommend prioritizing testing of GM in patients with single HN-PGLs and T-
PGLs, and for SM in those with single PCC. Catecholamine phenotype and SDHB-IHC should guide 
genetic screening, mainly in A-PGLs. Pediatric and metastatic cases should not be excluded from 
somatic screening. Both targeted-NGS assays are an efficient and accurate alternative to SS, 
facilitating the study of “minor” PPGL genes, and enabling genetic diagnoses in patients with 
incongruent or missing clinical data, that would otherwise be missed. 
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ANTECEDENTES: El diagnóstico genético se recomienda en todos los pacientes con  
feocromocitoma (FEO) y paraganglioma (PGL), (FPGL), ya que el 65-80% se explican por una 
mutación en uno de los 34 genes descritos. Se han propuesto distintos algoritmos de diagnóstico 
genético, pero suelen excluir los FPGL esporádicos (FPGL-E) y ninguno incluye el estudio de 
mutaciones somáticas (MS). Además, como la lista de genes relacionados con FPGL no para de 
crecer cada año, el diagnóstico genético implica cada vez más tiempo, y los paneles de genes 
mediante secuenciación masiva (PG-NGS) emergen como una herramienta rentable y efectiva. 
OBJETIVOS: Nuestro objetivo fue aclarar la heterogeneidad genética en el desarrollo de los FPGL 
mediante el estudio genético sistemático. El estudio se realizó en dos partes sucesivas.  
MATERIAL Y MÉTODOS: La parte I incluyó 329 propósitus y se centró en la caracterización 
genética de pacientes con FPGL-E mediante la secuenciación por Sanger (SS) y las grandes 
deleciones de los principales genes relacionados con FPGL. Noventa y nueve tumores de los 
pacientes sin mutación germinal (MG) se incluyeron en el estudio de MS en RET, VHL, HRAS, 
EPAS1, MAX y SDHB. En la parte II el estudio genético se realizó de forma “ciega” utilizando 2 PG-
NGS. Uno permitía el estudio en ADN germinal y de tumor congelado y el segundo fue 
específicamente diseñado para DNA extraído de tumor parafinado. En el segundo estudio se 
incluyeron 453 pacientes con FPGL (30 de ellos controles con mutaciones patogénicas conocidas 
y 275 habían sido parcialmente estudiados mediante SS (WTPS)).  
RESULTADOS: Parte I: se encontraron MGs en 46 pacientes (14%), siendo más frecuentes en PGLs 
(28.7%) que en FEOs (4,5%) (p=6.62×10-10). Los PGLs de cabeza y cuello (CC-PGLs) y los torácicos 
(T-PGLs), más comúnmente presentaban MGs (p=2.0×10-4 y p=0.027, respectivamente), pero no 
los abdominales (A-PGLs). Se encontraron MSs en el 43% de los tumores estudiados, y fueron más 
frecuentes en FEOs (48,5%) que en PGLs (32.3%) (p=0.13). Cinco casos metastásicos y un cuarto 
de los FPGL-E presentaban una MS, independientemente de la edad. Parte II: el abordaje con NGS 
mostró una sensibilidad ≥99.4%, independientemente del tipo de ADN. Se identificaron 45 
variantes de significado desconocido y 89 mutaciones, siendo MGs 29 (7,2%) y MSs 58 (31,7%) en 
los 183 tumores estudiados (37 se encontraron en los casos WTPS).  
CONCLUSIONES: Recomendamos priorizar el estudio de MG en los pacientes con un único CC-PGL 
y T PGL, y de MS en FEO. El fenotipo catecolaminérgico y la IHC-SDHB deberían guiar el estudio 
genético, principalmente en A-PGLs únicos. Los casos pediátricos y metastásicos no deberían 
excluirse del estudio somático. Ambos PG-NGS son una alternativa eficiente y precisa a la SS, que 
facilita el estudio de genes “minoritarios” de FPGL y el diagnóstico genético en pacientes con datos 
clínicos incongruentes o ausentes, que de otra manera no serían diagnosticados. 
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1.1 DISEASE DEFINITION AND ANATOMY 
Pheochromocytomas (PCCs) and paragangliomas (PGLs), together referred as PPGL, are 
neuroendocrine tumors (NETs) derived from the chromaffin cells of the embryonic neural crest 
that develops into sympathetic and parasympathetic paraganglia. Neoplasias derived from 
sympathetic paraganglia tend to be catecholamine-secreting tumors and can be located either 
in the adrenal medulla (PCC) or at the thoracic (T-PGL) and/or abdominal (A-PGL) region, 
whereas tumors derived from parasympathetic paraganglia are mainly non-secreting tumors 
mostly located in the head and neck area (HN-PGLs), and in minor percentage in the thorax1.  
Thoracic-abdominal PGLs (TA-PGLs) most commonly arise around the inferior mesenteric artery 
(the organ of Zuckerkandl), the aortic bifurcation, and less frequently in chest and pelvis. HN-
PGLs arise preferentially from vascular regions (the jugular bulb, and the carotid body) or along 
the glossopharyngeal and/or the vagus nerves2–5 (Figure 1).  
 
 
 
 
 
 
 
 
 
 
Figure 1. Location of PPGL. Normal paraganglia is colored in green, and tumors in orange.   
 
1.2 EPIDEMIOLOGY  
The prevalence of PPGL has been estimated to be between 1:4500 and 1:17003, being the 
prevalence in patients with arterial hypertension 0.2-0.6% (1.7% in children). Up to 20% of PPGL 
are diagnosed during childhood6, being PCC the most frequently diagnosed endocrine tumor in 
children7. Diagnosis of PPGL may be missed during life, as PCC are diagnosed as incidentally 
discovered adrenal masses during imaging studies for other reasons in 5% of patients, and 
autopsy studies have demonstrated undiagnosed tumors in 0.05-0.1%8. Annual incidences of 
PPGL (cases per million) in the general population3 and in children6 are 3–8 and 0.3, respectively. 
The only statistics in Spanish population dates from 1994 and reported an incidence of 2.06 in 
the South of Galicia9.  
Pheochromocytoma  
 Head and neck PGL 
heochromocytoma  
 Thoracic PGL  
 Abdominal PGL  
 Organ of Zuckerkandl   
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PPGL can occur at any age, but the peak incidence occurs in the third to fifth decades of life. The 
average age at first PPGL diagnosis is 24 years in hereditary cases and 43 years in sporadic cases1, 
with an equal incidence between males and females, except under the age of 10 in which there 
is a slight predominance in males3,6. The only environmental risk factor described is chronic 
hypoxia, which, in populations living at high altitude, leads to an increased incidence of HN- 
PGLs1,6. Combining two large series of 693 unselected PPGL patients the type of tumor was PCC 
in 69%, TA-PGL in 15%, and HN-PGLs in 22% (some patients having combinations of tumors)5,10,11. 
1.3 PROGNOSIS  
The metastases rate of PPGL ranges from less than 1 % to more than 60 %, depending on tumor 
location, size and genetic background2. Although features such as size (larger than 5 cm), 
extraadrenal location of primary tumors5,12, a high “Pheochromocytoma of the Adrenal gland 
Scales Score” (PASS), or increases in plasma 3-methoxytyramine (3-MT, a dopamine-DOPA 
metabolite)13,14 provide useful information to assess the likelihood of metastatic disease, the 
finding of mutations in SDHB is the only criterion strongly associated with an increased risk of 
metastases at diagnosis or during follow-up: 30% (range 20-70)4,15–17. However, for patients with 
apparently benign primary tumors, the mean incidence of metastatic recurrences and new 
tumors during follow-up is 11.3 % and 6.2%, respectively, being those patients harboring a 
germline mutation the ones with a higher probability of both18. Prognosis of metastatic PPGL is 
poor, with a 5-year mortality rate greater than 50%19,20.  
Nowadays metastatic PPGL remain a diagnostic challenge, as currently there are no reliable 
cytological, histological, immunohistochemical, or molecular criteria for malignancy21, and the 
diagnosis remains strictly based on the finding of metastases where chromaffin cells are not 
usually present22. Metastases have been reported to be located in lymph nodes in around 80%, 
bones in 71%, and lungs and liver in 50% of metastatic cases4,22–24. The diagnosis is usually 
obtained from imaging studies, as histological confirmation is rarely available25. Consequently, 
metastases in PPGL can only be defined in advanced stages, and the inability to predict tumor 
behavior does not allow an optimal therapeutic planning24. 
Recently, different studies have attempted to predict metastatic potential through different 
measurements such as the presence of tumor necrosis, high Ki-67 index (>4%)/mitotic count, or 
pS100 absence26 in pathological study, overexpression of HIF-α and its target genes27,28, 
extremely high mRNA copy numbers of a variant of carboxypeptidase E29, overexpression of the 
microRNA (miRNA) 183 (miR-183) in tumors30,31, or the hypermethylation of the negative 
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elongation factor complex member E gene32 among others, but further studies are needed to 
confirm the predictive value of these markers, especially during diagnosis procedures.  
1.4 PPGL-ASSOCIATED SYNDROMES  
PPGL can develop in an apparently sporadic presentation, or as part of several tumor syndromes 
associated with alterations in distinct genes. While initially it was thought that only 10% of cases 
were caused by germline mutations, after discovering an increasing list of PPGL-related genes, 
nowadays PPGL show the highest degree of heritability of all human tumors33. Thus, currently it 
is recognized that a genetic germline mutation explain at least 40% of patients, including cases 
with features suggesting inheritability (such as early age at onset, multiple and/or metastatic 
tumors and/or family history of PPGL or other syndrome-associated tumors), and 8-12% of 
apparently sporadic PPGL11,33–40. In pediatric cases up to 70-80% harbor a germline mutation, 
regardless of their family history41,42.  
Approximately 40% of PPGL develop primarily in the context of three familial tumor syndromes: 
von Hippel-Lindau disease (VHL) caused by VHL mutations, multiple endocrine neoplasia type 2 
(MEN2) caused by RET mutations, and familial PPGL: 1) hereditary PGLs, caused by mutations in 
succinate dehydrogenase (SDH), fumarate hydratase (FH) and malate dehydrogenase type 2 
(MDH2) genes; and 2) familial PCCs, caused by mutations in the transmembrane protein 127 
(TMEM127) or the MYC associated factor X (MAX) genes. A small fraction of PPGL are associated 
with other syndromes: the Carney triad (CTd) defined by the coexistence of PGL, gastrointestinal 
stromal tumor (GIST), plus pulmonary chondroma, and the Carney-Stratakis syndrome (CSS) 
characterized by PGL and GIST43. Both CTd and CSS have been related to SDH genes mutations, 
but whereas CSS is almost always caused by mutations in SDH genes, they appear rarely in CTd. 
However, epigenetic SDHC promoter mutations have been recently linked to CTd43–45. The 
presence of PPGL in two syndromes classically related with PPGL, multiple endocrine neoplasia 
type 1 (MEN1) and neurofibromatosis type 1 (NF1), has been finally found to be rare: <1%5 and 
0.1-5.7%46, respectively. Latterly, two additional syndromes have been linked to PPGL: the 
Pacak-Zhuang syndrome and syndromes associated with leiomyomatosis, being related to 
mutations in the endothelial PAS domain-containing protein 1 EPAS1/HIF2A (EPAS1) gene47 and 
FH48, respectively. To note, each syndrome presents a set of signs and tumors with overlap 
between them, and they are detailed in Table 1.  
Hereditary cases mainly follow an autosomal dominant mode of transmission. Exceptions to this 
rule are the inheritance linked to SDHD49, SDHAF2/SDH5 (SDHAF2)50 and MAX51mutations. In 
these cases, only those carriers that inherit the mutation from their fathers will develop the  
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Table 1. Summary of phenotypic and genetic features associated with the described PPGL related genes.   
 
Gene 
 
Driver 
or 2nd 
hit  
Chr. 
Location 
Type 
of 
gene 
Cluster Inheritance 
 
Mean 
age 
 
Germ.  
 
Som.  Mos. GD 
Risk of 
malignancy 
Predominant 
tumor location 
Number of 
tumors 
BC 
Related syndrome  
Associated tumors/features 
FH Driver 1q42.1 TSG C1A (AD)  NR 
<1-5 
(0.8%) 
<1 (1) NR 
Yes52  
 
High 
(60%)53 
PCC+TA>HN Multiple (NA) 
PGL8; Reed syndrome or Hereditary Leiomyomatosis and 
Renal Cell Cancer (HLRCC); multiple cutaneous and uterine 
leiomyomatosis (MCUL); cutaneous and uterine leiomyomas; 
type 2 papillary renal carcinoma54 
IDH1 Driver 2q34 TSG  C1A ? NR NR <1 (1) NR NR ? HN Single (NA) None reported 55 
MDH2 Driver 7q11.23 TSG C1A (AD)  NR <1% (1) NR NR NR ? TA Multiple (NA) Early-Onset Severe Encephalopathy56 
SDHA Driver 5p15.33 TSG C1A (AD)  40 <1-5 <1 (1) NR NR 
Mod. 
(<10%) 
TA>>PCC Single (NA) 
PGL6; Leigh syndrome (homozygous patients, but no PPGL 
described); CCRC; GIST; pituitary adenoma.  
SDHAF2 
/SDH5 
Driver 11q12.2 TSG C1A 
AD, 
paternal  
 
30-40 <0.1-1 0 NR NR Low HN>>PCC 
Multiple 
(87%)5 
(NA) PGL2 
SDHB Driver 1p36.13 TSG C1A AD  30 10 <1 NR Yes 
High  
(30-70%) 
TA>HN>PCC 
Multiple 
(21%)5 
NA, 
DA 
Carney-Stratakis syndrome; PGL4; CCRC; GIST; pituitary 
adenoma; thyroid carcinoma. 
SDHC Driver 1q23.3 TSG C1A AD  40-50 <1-5 0 
Yes 
 
NR Low  HN>TA>PCC 
Multiple 
(17%)5 
(NA) 
Carney-Stratakis syndrome; PGL3; CCRC; GIST; pituitary 
adenoma. 
SDHD Driver 11q23.1 TSG C1A 
AD, 
paternal  
35 9-10 <1 NR  NR 
Low  
(<5%) 
HN>TA>PCC  
Multiple 
(56%)5 
NA,
DA 
Carney-Stratakis syndrome; PGL1; renal cell carcinoma; GIST; 
pituitary adenoma; thyroid carcinoma; NET (?)57  
EGLN1/ 
PHD2 
Driver 
1q42.1 
 
TSG C1B ? NR <1 (2)  NR NR NR ? TA>PCC Multiple (NA) Hereditary polycythemia; polycythemia58. 
EGLN2/ 
PHD1 
Driver 19q13.2 TSG C1B ? NR <1 (1) NR NR NR ? TA>PCC Multiple  (NA) Hereditary polycythemia; polycythemia58. 
EPAS1/ 
HIF2A 
Driver 2p21 O C1B ? NR 
<1-5 
(1) 
5-7 Yes NR ? TA>PCC Multiple NA 
Familial erythrocytosis type 4; Pacak-Zhuang; polycythemia; 
somatostatinoma. 
VHL Driver 3p25.3 TSG C1B 
AD  
 
30 7-10 10 Yes Yes 
Low  
(<5%) 
PCC (Bil PCC 
50%)>>>TA, HN 
30-55% PPGL as 
the first 
manifestation 
of VHL 
Multiple 
NA> 
DA 
von Hippel Lindau (I 1/36 000): 10-25% present PPGL 
CCRC, hemangioblastomas of CNS/retina/kidney and 
pancreas, pancreatic NET and cysts, endolymphatic sac 
tumors of the middle ear, papillary cystadenomas of the 
epididymis and/or broad ligament.  
Autosomal recessive congenital polycythemia (also known as 
familial erythrocytosis type 2. 
ATRX 
Driver 
and 
2nd hit 
Xq21.1 TSG C2A ? NR NR 12.6 NR NR ? PCC, PGL (Single) ? 
X-linked alpha thalassemia mental retardation syndrome 
(germline mutation); gliomas, neuroblastomas, 
medulloblastomas and NET (?). 
HRAS Driver 11p15.5 O C2A ? NR NR 10 NR NR Low  PCC>PGL Single (A) Costello syndrome (germline).  
H3F3A ? 1q42.12 O C2A ? NR NR NR 
Yes 
(7%) 
NR ? PCC, A-PGL  ? (A) Giant cell carcinoma of bone (?); Glioma (?).  
KIF1B Driver 1p36.22 TSG C2A (AD) NR <1 (2) <1 (2) NR NR ? PCC (Bil?) ? (A) 
Neuroblastoma (?), ganglioneuroma (?), leiomyosarcoma (?); 
Lung adenocarcinoma (?); Colorectal carcinoma (?)59. 
MAX Driver 14q23.3 TSG C2A 
AD, 
paternal   
32 
<1-5 
(1.1%) 
<5 NR Yes60 
Mod. 
(10%) 
PCC (Bil PCC 
68%)>PGL 
Single 
A> 
NA 
PGL7/FPCC2; renal oncocytoma (?)60. 
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or 2nd 
hit  
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Location 
Type 
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gene 
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age 
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Som.  Mos. GD 
Risk of 
malignancy 
Predominant 
tumor location 
Number of 
tumors 
BC 
Related syndrome  
Associated tumors/features 
NF1 Driver 17q11.2 TSG C2A 
AD  
 
42 <3-5 20-40 Yes Yes 
Mod. 
(12%) 
PCC 95% (Bil 
PCC 16%)>TA 
Single 
A 
+NA 
von Recklinghausen’s disease (I 1 : 2500–3000): 0.1-5.7% 
present PPGL, 3.3-13% based on autopsy studies35. 
Café-au-lait spots, neurofibromas, axillary and inguinal 
freckling, Lisch nodules (iris hamartomas), bony 
abnormalities, optic/CNS gliomas, malignant peripheral 
nerve sheath tumors, macrocephaly, and cognitive defects.  
RET Driver 10q11.21 O C2A 
AD  
 
30-40 5-10 10 NR NR 
Low  
(<5%) 
PCC (Bil PCC 50-
80%)>>>TA, HN 
12-25% PPGL as 
the first 
manifestation 
of  MEN25 
Multiple 
A 
+NA 
MEN2 (I 1/30000-40000): 50% present PPGL 
Medullary thyroid carcinoma (95% MEN2A, 100% MEN2B). 
Parathyroid adenomas (15-30%), notalgia or cutaneous 
lichen amyloidosis, Hirschsprung disease (MEN2A or Sipple 
syndrome) 
Marfanoid habitus, mucocutaneous neuromas, myelinated 
corneal nerves, gastrointestinal ganglioneuromatosis 
(MEN2B, MEN3 or Gorlin syndrome). 
TMEM127 Driver 2q11.2 TSG C2A AD  43 
<1-5 
(0.9%) 
0 NR NR Low (<5%) 
PCC (Bil PCC 33-
39%)> TA, HN 
Single 
A 
+NA 
PGL5/FPCC1; renal cell carcinoma (?).  
 
MET 
Driver 
and 
2nd hit 
7q31 O C2B ? NR <1 (1) 2.5 (5) NR NR ? PCC ? (A) Papillary renal cancer30,61. 
BAP1 ? 3p21.1 TSG ? (AD) NR <1 (1) NR NR NR ? PGL ? ? Uveal/cutaneous melanoma; mesothelioma; CCRC (?)62. 
BRAF ? 7q34 O ? (C2?) ? NR NR 1,2 (1) NR NR ? PCC (Single) ? Melanoma (?); colorectal cancer (?). 
EZH2 ? 7q36.1 TSG ? ? NR 2 (1) NR NR NR ? (PCC)  ? ? Lymphoma; myeloid malignancies. 
FGFR1 ? 8p11.23 O ? (C2?) NR NR 2 (1) NR NR NR ? PCC (Single) ? Glioblastoma. 
JMJD1C ? 10q21.3 TSG ? ? NR ?  NR NR ? (PCC) ? ?  
KDM2B ? 12q24.31 ? ? NR  NR NR 2 (1) NR NR ? (PGL) ? ?  
KMT2B/ 
MLL4 
? 19q13.12 ? ? ? NR 2 (1) NR NR NR ? PGL  (Multiple) ?  
KMT2D/ 
MLL2 
? 12q13.12 O ? ? NR (2) (12) NR NR ? PCC (Single) ? 
Kabuki syndrome; gliomas, neuroblastomas, 
medulloblastomas and NET30,63. 
MEN1 Driver 
 
11q13 
 
TSG ? AD NR <1  NR NR Yes64  ? PCC Single  ? 
MEN1 syndrome (I 1/30000) :  <1% present PPGL.  
Primary hyperparathyroidism; pituitary adenoma; 
gastroenteropancreatic NET; adrenal cortical tumors, 
carcinoid tumors, facial angiofibromas, collagenomas, and 
lipomas.  
MERTK ? 2q13 O ? ? NR 2 (2) NR NR NR ? PCC, PGL ? ? Medullary thyroid carcinoma (?). 
MITF  ? 3p13 O ? AD NR NR NR NR NR ? PCC>> TA, HN Single ? Melanoma; renal cell carcinoma; pancreatic carcinoma63,65. 
SETD2 ? 3p21.31 TSG ? ? NR 2 (1) NR NR NR ? (PCC) ? ? Renal cancer; leukemia.  
TERT 
promoter 
? 5p15.33 O ? ? NR NR 11.1 (2) NR NR ? A>PCC Single ?  
TP53 ? 17p13.1 TSG ? ? NR NR 2.35 (2) NR NR ? PCC (Single) ? 
Li Fraumeni-like syndrome; adrenal cortical carcinoma, 
breast cancer, choroid plexus carcinoma, and osteosarcoma. 
 
 
Chr: chromosome; ?: unknown; TSG: tumor suppressor gene; O: oncogene; (): it is not clear; AD: autosomal dominant; NR: not reported; Germ.: germline mutations - percentage (number of cases described); Som.: somatic mutations – percentage 
(number of cases described); Mos.: mosaicism; GD: gross deletions; Mod.: moderate; PGL: paraganglioma; PCC: pheochromocytoma; A: abdominal PGL; TA: thoracic-abdominal PGL; HN: head and neck PGL; Bil: Bilateral; BC: Biochemical predominant 
secretion; NA: noradrenergic (predominant secretion of noradrenaline/normetanephrine); A: adrenergic (predominant secretion of adrenaline/metanephrine); DA: dopaminergic (secretion of dopamine/3-methoxytyramine); I: incidence66; GIST: 
gastrointestinal stromal tumor; CNS: central nervous system; CCRC: clear cell renal carcinoma; NET: neuroendocrine tumor.    
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disease, although the underlying mechanism is not totally clear. Despite initially it was though 
that SDHD and SDHAF2 presented maternal imprinting, exceptions of maternal transmission 
have been reported67,68, and further research is needed to elucidate the real mechanism. In 
addition, an incomplete penetrance has been shown for SDHA, SDHC69, SDHB70, TMEM12771, 
FH53, and MDH272. However, only data for SDHB have been reported, being 30% (95% confidence 
interval (CI) 17–41%) the average of the penetrance of tumors at age 80 of all SDHB carriers70.  
The genetic scenario of sporadic PPGL changed in 2011 when it was reported that 14% of PPGL 
could be explained by somatic mutations in RET and VHL73. One year later NF1 was found to be 
somatically involved in an additional 24-41% of PPGL74,75. Other genes explaining heritable 
susceptibility have been also found to be somatically mutated (SDHB76, SDHD77, SDHA (TCGA 
data), MAX78); however their somatic involvement is scarce. In addition, new key players were 
discovered in the sporadic presentation, such as HRAS79 and EPAS180. Interestingly, EPAS1 was 
firstly described to cause PPGL through somatic mosaicism47,81, a mechanism that had been 
previously described at least for NF182 and VHL83 mutations. Consequently, nowadays it is clear 
that somatic mutations play an important role in PPGL as they have been described in up to 40% 
of tumors1,84.  
1.5 ELUCIDATING THE GENETIC SCENARIO OF PPGL  
The first genes with mutations described as cause of PPGL were those responsible of specific 
syndromes, such as NF1 (NF1), MEN2A (RET), VHL (VHL), and MEN1 (MEN1), as some patients 
affected by these diseases developed PPGL (especially PCCs). In 2000, targeted mutational 
analysis in families affected by HN-PGLs lead to the discovery of SDHD49, a component of the 
succinate dehydrogenase mitochondrial complex II (SDH), being the first human tumor model 
found to carry an inherited mutation in a gene encoding a metabolic enzyme33. Later, the other 
members of the complex were found to be involved in PPGL pathogenesis as well: SDHC85, 
SDHB86, SDHAF250, and finally SDHA87.  
Combining data from gene expression profiles performed in 2004 by Eisenhofer et al.88 and in 
2005 by Dahia et al.89 it was possible to know that tumors with mutation in VHL, SDHB and SDHD 
presented an overexpression of angiogenesis/hypoxia pathways related-genes (cluster 1), in 
comparison with RET- and NF1-tumors, which showed overexpression of genes related to the 
RAS/RAF/MAPK and PI3K/AKT/mTOR kinase signaling pathway (cluster 2). In addition, it was 
already established that cluster 1 tumors shared a noradrenergic secretion, while cluster 2 was 
enriched with tumors producing both adrenaline and noradrenaline. Further methylation 
studies showed that the noradrenergic secretory phenotype of cluster 1 tumors was caused by 
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low expression of phenylethanolamine N-methyltransferase (PNMT), the enzyme that converts 
norepinephrine to epinephrine, through the hypermethylation of the PNMT promoter. Posterior 
studies performed by Favier et al.90 and our group91 distinguished two subclusters in cluster 1 
based on the activation of distinct pseudo-hypoxic pathways, and finally, a DNA methylation 
profiling uncovered that one of these subtypes in cluster 1 showed an hypermethylator 
phenotype (cluster 1A)48.  
The use of Next Generation Sequencing (NGS) tools has been a key point to elucidate new 
players in the genetic scenario of PPGL. Due to the relatively high cost and the ethical concerns 
regarding incidental findings, whole-exome sequencing (WES) has been mainly used in research 
settings48,51,72,79,92,93, while targeted gene panels (TGPs) have shown a greater applicability as a 
diagnostic tool, being faster, cheaper and more sensitive, even in cases with mosaicism47,81–83, 
than the classically used Sanger sequencing94–99. In addition, TGPs enable the screening of genes 
systematically excluded in Sanger sequencing study due to their large size or rarity of their 
mutations, and facilitate patient selection for the screening of new genes, large rearrangements 
or the use of ‘omic platforms (e.g. to detect mutations beyond coding regions)30. 
Using Sanger sequencing of a candidate region, and combining ‘omic data with NGS and/or copy 
number alteration (CNA) data for tumors without known mutations attributed to cluster 1 or 2, 
new genes were discovered. TMEM127100, MAX51, and HRAS79 were described as driver genes 
for cluster 2 tumors, and FH48, EPAS1101, and MDH272 for cluster 1. In addition, other genes have 
been described in the last years, but they seem to play a minor role in PPGL (“minor” genes) 
since the mutations have been described in isolated families (KIF1B, BAP1, EGLN1/PHD2 
(EGLN1)33, and EGLN2/PHD1 (EGLN2)58); in few sporadic cases (isocitrate dehydrogenase type 1 
(IDH1)55, MERTK, H3F3A, SETD2, EZH2, FGFR193 and BRAF95); or mainly reported in patients with 
mutations in recognized PPGL driver genes, suggesting a secondary role (ATRX102, TP5395, 
JMJD1C, KDM2B93, KMT2D/MLL2, and MET30). Finally, germline MITF mutations65 and mutations 
outside the exonic region have been recently described, such as promoter alterations in TERT103 
or epi-mutations in SDHC104. Some clinical features have been related to mutations in these 
genes, but the limited number of cases described needs further studies before establishing a 
real association (Table 1).  
Despite this heterogenic genetic background, integrative genomic studies have provided 
evidence for strong concordance between genetic status and multi-omics data (transcriptomic 
gene expression, CNA, metabolomics signature, miRNA profiles and DNA methylation), allowing 
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to classify PPGL tumors into two main clusters and five molecular subgroups, each one displaying 
a specific set of genomic alterations and related clinical characteristics30,31,35,51,84,105(Figure 2).   
 
Figure 2. Molecular signatures of PPGL subtypes.  
PNMT: phenylethanolamine N-methyltransferase; EMT:  epithelial-to-mesenchymal transition; LOH: loss 
of heterozygosity. *Related to metastatic cases31. Adapted from30,31,35,51,84,105. 
 
1.5.1 CLUSTER 1: Pseudo-hypoxia cluster 
Altered genes related to this cluster cause the so called pseudo-hypoxic response by stabilizing 
hypoxia-inducible factors (HIFs) under normoxic conditions84.  
Under normal oxygen tension, the degradation of α subunits of HIF (HIF1α, 2α, and 3α) is 
initiated through its hydroxylation by prolyl hydroxylase domain (PHD) proteins: PHD1, PHD2, 
and PHD3 (encoded by EGLN2, EGLN1, and EGLN3 genes, respectively). Under normoxia 
conditions, PHDs use oxygen and α-ketoglutarate to hydroxylate HIF prolyl residues. The 
hydroxylated HIFα is then targeted by the von Hippel-Lindau protein (pVHL), a component of the 
E3 ubiquitin ligase complex, which modifies HIFs for their degradation in proteasomes. On the 
other hand, under hypoxia conditions, HIFα is stabilized and binds to the HIFβ subunit to form 
an active transcription factor that regulates expression of a large repertory of genes involved in 
angiogenesis, cell survival, polycythemia, and tumor progression.   
· CLUSTER 1A: Krebs cycle cluster and familial PGLs 
This subcluster is characterized by the Krebs cycle reprogramming and with oncometabolite 
accumulation or depletion. It contains tumors with mutations in SDH genes, FH, MDH2, and 
IDH1.  
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SDH genes encode SDH, a mitochondrial enzyme responsible for reactions in the tricarboxylic 
acid (TCA) cycle, where it catalyzes the oxidation of succinate to fumarate, and in the respiratory 
electron transfer chain (complex II of the mitochondrial respiratory chain), where it transfers 
electrons to coenzyme Q. SDH is a heterotetramer composed of four proteins: two catalytic 
(SDHA and SDHB), and two structural (SDHC and SDHD) that anchor the complex to the 
mitochondrial inner membrane. An associated protein, SDHAF2, is a highly conserved cofactor 
of flavin adenine dinucleotide which is implicated in the flavination of SDHA and is essential for 
SDH function106. Otherwise, FH, MDH2, and IDH1 encode other TCA cycle enzymes involved in 
the reversible hydration/dehydration of fumarate to malate, the reversible conversion of malate 
to oxaloacetate with the concurrent reduction of NAD to NADH, and the oxidative 
decarboxylation of isocitrate to α-ketoglutarate, respectively.  
Mutations in SDH, FH, and MDH2 TCA-cycle-related genes lead to the accumulation of its 
substrates which act as oncometabolites: succinate, fumarate, and malate, respectively. In 
addition, mutated IDH1 adquire a neomorphic enzyme activity that converts alpha-
ketoglutarate to 2-hydroxyglutarate, another oncometabolite. These metabolites cause 
hypermethylation by inhibiting 2-oxoglutarate-dependent dioxygenases, such as PHD and 
histone and DNA demethylases. Thus, on the one hand they act as a competitive inhibitor in the 
process to hydroxylate HIF prolyl residues, stabilizing HIFα and, mediated by the pVHL, activating 
genes that facilitate angiogenesis, anaerobic metabolism, and a pseudo-hypoxic state84,106–108. 
On the other hand, due to histone and DNA demethylases inhibition, tumors with mutations in 
these genes show a similar CpG island methylator phenotype (CIMP) characterized by DNA 
hypermethylation32,48,72.  
· CLUSTER 1B: von Hippel–Lindau and PGL–polycythemia syndromes 
Cluster 1B is characterized, similarly to cluster 1A tumors, by the activation of the pseudo-
hypoxia signaling pathway through the stabilization of HIF transcription factor proteins with 
increased angiogenesis as well as cell proliferation, invasiveness, and migration. However, they 
do not present the hypermethylation seen in cluster 1A tumors. This cluster contains tumors 
with mutations in VHL, EGLN1, EGLN2, and EPAS1. Mosaic (at least in VHL and EPAS1) and 
germline mutations in these genes can be associated to the presence of polycythemia.  
Mutations in VHL, as well as in EGLN1/EGLN2, disrupt the process of HIFα degradation, leading 
to its stabilization, whereas gain of function mutations at EPAS1 hydroxylation sites disrupt the 
recognition of EPAS1 by members of the PHD family, as well as its hydroxylation and the 
consequent degradation by pVHL. To note, PPGL became the first tumors known to carry 
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activating mutations of EPAS1, which had long been implicated in multiple human cancers, but 
had never been genetically proved to function as a bona fide oncogene33.  
1.5.2 CLUSTER 2: Kinase signaling cluster  
As mentioned before, cluster 2 is characterized by the activation of RAS/RAF/MAPK and 
PI3K/AKT/mTOR signaling pathways and protein translocation, causing a pro-mitogenic and anti-
apoptotic state. This cluster contains tumors with mutations at least in NF1, RET88,89, 
TMEM127100, MAX51, HRAS79, and two genes with a rare involvement: KIF1B59 and MET30.  
-. Neurofibromin (NF1) suppresses cell proliferation by promoting the conversion of RAS into its 
inactive form, thereby inhibiting the oncogenic RAS/RAF/MAPK signaling cascade, and also 
inhibits the PI3K/AKT/mTOR pathway via suppression of RAS. Thus, NF1 mutations lead to the 
activation of both pathways. To note, NF1 has one of the highest rates of spontaneous mutation 
of any gene in the human genome5. This in part explains why between 30 and 50% of patients 
have de novo mutations5, and is the gene with the highest rate of somatic mutations73,96.  
-. RET encodes a transmembrane tyrosine kinase receptor (RTK) for members of the glial cell 
line-derived neutropic factor. It activates multiple intracellular pathways involved in cell growth 
and differentiation. Oncogenic activation of RET activates both RAS/RAF/MAPK  and 
PI3K/AKT/mTOR -dependent cell signaling genome5. Interestingly, gain of function mutations 
are related with PCC and medullary thyroid carcinoma (MTC), and inactivating mutations are 
related to Hirschsprung’s disease (HD), but some overlap has been described between MEN2 
and HD. 
-. TMEM127 encodes a transmembrane protein which acts as a negative regulator of mTOR. 
Thus, mutations in TMEM127 results in reduced inhibition of the mTOR pathway in a 
RAS/RAF/MAPK and PI3K/AKT independent manner5. 
-. MAX encodes a transcription factor, MAX, that belongs to the basic helix–loop–helix leucine 
zipper family and plays an important role in regulation of cell proliferation, cell differentiation 
and apoptosis, as a part of the MYC/MAX/MXD1 network. Heterodimerization of MAX with MYC 
family members results in sequence-specific DNA-binding complexes that act as transcriptional 
activators. In contrast, heterodimers of MAX with MXD1 family members repress transcription 
of the same target genes by binding to the same consensus sequence, and thus antagonize MYC–
MAX function. Mutated MAX causes deregulation of the MYC–MAX–MXD1 pathway that leads 
to altered transcription and signaling in the NRAS–PIK3CA–AKT1–mTOR pathway. MAX-mutated 
tumors have a unique transcriptomic signature, supported by their intermediate expression of 
PNMT, and consequently a subsequent lower production of epinephrine51,84.   
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-. HRAS gene encodes a small GTP-binding protein that affects multiple downstream pathways 
related to cell growth and homeostasis.  
-. KIF1B and MET are kinesin related genes. While one of the splice variants of KIF1B, KIF1Bb, 
functions as a tumor suppressor that is necessary for neuronal apoptosis, MET is a member of 
the RTK family, but their specific role need further studies. 
1.5.3 OTHER GENES  
Other genes encoding kinases (FGFR1)93, chromatin remodeling proteins (ATRX102,109, H3F3A, 
KMT2D, SETD2, JMJD1C, KMT2B, or EZH293), and related with multiple type of human neoplasia 
(promoter region of TERT, or somatic mutations in TP53 and BRAF) have been also involved in 
PPGL pathogenesis, but their specific roles have also to be clarified in larger series.   
1.6 GENETIC DIAGNOSIS   
On the whole, hereditary and somatic mutations explain at least 60-80% of PPGL cases and are 
found in a mutually exclusive manner33. Exceptions to this rule are mutations described in the 
“new” PPGL-related genes (e.g. ATRX), as they have been mainly described in cases with 
mutations in classical PPGL driver genes, and double somatic mutations described at least in 
NF174and EPAS198,110, or somatic mutations in NF1 in tumors carrying a somatic mutation in RET 
or VHL74. However, these second variants seem to act as modifiers and their role should be 
resolved by large-scale sequencing analyses33. 
Therefore, current guidelines indicate consideration of genetic testing in all patients with PPGLs, 
but for cases with indicators of low heritability (unilateral PCC without syndromic features, 
metastatic presentation, or family history of PPGL), the decision to perform germline genetic 
testing should be balanced between the cost of testing and the psychological impact on the 
patient and their family of not having a test that might explain why they have the disease8.  
However, as the genetic spectrum increases with newly described genes having low prevalence 
(<1% of cases) and no distinctive clinical features, systematic genetic screening of all PPGL-
related genes has become a time- and resource-consuming process. The decision of which gene 
to test is made on the basis of clinical presentation (age at onset, location and number of tumors, 
syndromic features, family history, and metastases), biochemical secretory phenotype, and 
immunohistochemical tumor characterization1,111. In this regard, many different algorithms have 
been proposed35,38,111–116. In addition, some specific algorithms focused on sporadic 
PPGL10,11,36,38–40 have been also proposed, as these cases tend to be excluded from 
comprehensive genetic screening beyond SDHB mutations, and even SDHB study is not always 
performed, being genetic data about sporadic cases still scarce. Importantly, none of the 
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algorithms proposed contemplate testing for somatic mutations, despite they have been also 
related to metastatic73,74,96, and pediatric cases73, as well as PPGL cases diagnosed before 40 
years old73,78,79,97,117. 
1.7 CLINICAL PRESENTATION  
In the case of sympathetic tumors (PCCs, TA-PGLs) the clinical presentation is related to the 
hypersecretion of one or more catecholamines: epinephrine and/or norepinephrine. Later, the 
enlargement of the tumor can cause mass-effect symptoms in adjacent tissues and organs (e.g. 
hydroureteronephrosis or renal hypertension)5. On the other hand, parasympathetic tumors 
(HN-PGLs) rarely produce significant amounts of catecholamine (<5%), and commonly present 
as slow-growing painless cellular masses, being the initial clinical presentations symptoms of 
cervical mass and/or compression or infiltration of adjacent structures (e.g. hearing loss, 
tinnitus, cervical mass, dysphagia, cranial nerve palsies)2,4,5,8.  
The classic triad of PPGL symptoms described is headache, sweating, and palpitations, but it only 
occurs in 40% of the patients. Many patients present arterial hypertension (85-90%), which may 
be sustained (50-60%) or paroxystic (50%). Peculiarly, hypertensive crises could come up due to 
incidental tumor manipulation during diagnostic procedures, after using certain drugs, ingestion 
of foods or beverages containing tyramine, and especially common in children are exercise-
induced crises7. Other symptoms include pallor (30-60%), feelings of anxiety or panic (20%), 
fever (66%), or nausea and vomiting (26-43%).  
PPGL symptoms and signs are non-specific and can mimic many other conditions, and can vary 
greatly from one patient to another, even within the same family. PPGL diagnosis is challenging 
and critical, as un- or miss-diagnosed patients can suffer severe consequences of hypertensive 
crises, including heart attacks, strokes, and even death3,66.  
1.8 DIAGNOSIS 
1.8.1 BIOCHEMICAL STUDIES 
Diagnosis of PPGL relies on biochemical evidence of catecholamine tumor secretion. 
Biochemical testing should be performed in symptomatic patients, patients with an adrenal 
mass incidentally found during imaging studies or surgery for other reasons, and those who have 
hereditary predisposition or syndromic features suggesting hereditary PPGL.  
Catecholamines are metabolized within chromaffin cells to metanephrines (norepinephrine to 
normetanephrine, and epinephrine to metanephrine, respectively) and this intra-tumor process 
occurs continuously and independently of the exocytotic catecholamine release, providing and 
advantage for measurement of metanephrines during diagnosis of tumors that only release 
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catecholamines episodically or in low amounts. Measurement of metanephrines in urine and/or 
plasma has a superior diagnostic sensitivity (97% and 99%, respectively) over measurement of 
the parent catecholamines. Consequently, metanephrines’ measurement remains 
recommended as the initial screening test (Figure 3).  
Secretion is so rare in HN-PGLs (<5%), 
that if a HN-PGL presents 
hypersecretion it is recommended to 
discard a concurrent PCC and/or TA-
PGL. However, 3-MT, previously 
mentioned as related with metastatic 
PPGL, has been shown to be elevated in 
almost one third of patients with HN-
PGLs, and its determination is a useful 
diagnostic test4,118.                                                                                       
Therefore, current recommendations are that initial screening test for PPGL must include 
measurements of fractionated metanephrines (metanephrine, normetanephrine, and 3-MT) 
measured separately in plasma, urine, or both, as available, using liquid chromatography with 
tandem mass spectrometric or electrochemical/fluorometric detection methods, being 
immunoassays methods a secondary measurement option. To minimize false-positive results, 
blood sampling should be performed at a supine position (collected after 30 min of supine rest), 
and overnight fast only when measurements include plasma free 3-MT118,119. Despite the plasma 
test offers sensitivity advantages over the urine test, it is rarely implemented correctly, 
rendering the urine test preferable for mainstream use118. 
The clonidine suppression test can be useful to distinguish true-from false-positive borderline 
elevations of plasma normetanephrine, but it has not been validated in any prospective study. 
In the case of mild elevations, wait-and-retest or proceed directly to imaging studies to localize 
PPGL could be considered8.  
Test results within reference intervals for plasma free metanephrines exclude almost all cases 
of PPGL. Exceptions include microscopic recurrences or small tumors (<1 cm) found incidentally 
or during screening because of a hereditary predisposition to PPGLs or history of the disease, 
HN-PGLs and rare phenotypically immature A-PGLs that despite having large size are non-
secreting tumors (silent A-PGLs). According to this latter one, despite not having defects in the 
mechanisms of storage or secretion of catecholamines, show absence of the tyrosine 
Tyrosine  
↓ Tyrosine hydroxylase 
DOPA 
↓                           COMT 
Dopamine                                     3-Methoxytyramine 
↓                           COMT 
Norepinephrine                           Normetanephrine 
↓ PNMT                 COMT   
Epinephrine                                  Metanephrine 
 
CATHECOLAMINES                     METANEPHRINES  
Figure 3. Cathecolamine synthesis and O-
methylation.  
COMT, catechol-O-methyl-trans-ferase; PNMT, 
phenyl-ethanolamine-N-methyl-transferase.  
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hydroxylase and do not synthesize catecholamines120. However, plasma concentrations of 
chromogranin A (CgA, a biomarker of NETs) are consistently elevated, indicating that CgA can be 
used as an alternative biochemical parameter in the setting of silent PGLs120.  
Metanephrines measurement provides high accuracy for diagnosis of PPGL, but can also be 
useful for clinical decision-making about imaging studies during the primary diagnosis and the 
follow-up. Metanephrine alone, or in combination with normetanephrine, almost always 
indicate an adrenal location or reflect recurrence of a previous adrenal tumor121. Solitary 
increases of normetanephrine cannot be used to predict tumor location, however the elevation 
of 3-MT points extraadrenal location122 and the possibility of metastases13,14. Although not 
offering sufficient power to identify all metastatic patients, plasma 3-MT shows a diagnostic 
sensitivity of 86% and specificity of 96%, but its measurement is not yet widely available14,23,36,118. 
In addition, as mentioned before, biochemical phenotype can be used to guide genetic testing. 
For instance, SDHB mutation testing has no utility among patients with adrenaline-producing 
metastatic PPGLs123, but should be considered in the case of 3-MT secreting tumors118 or in silent 
PGLs120.  
1.8.2 IMAGING STUDIES 
After confirming a PPGL biochemically, anatomical and functional imaging studies are critical for 
a) primary tumor localization; b) the detection of multiple primary tumors; and c) the detection 
of metastases. The knowledge of these three points are important to make the optimal 
treatment decision between curative surgery and palliative treatment options124,125. In the case 
of HN-PGLs, imaging studies are essential to perform the diagnosis in the majority of the cases.   
There is not ‘gold-standard’ imaging technique for all patients with (suspected) PPGL. A tailor-
made approach is clearly warranted to assess disease extension at the time of the discovery of 
the primary tumor and during the follow-up23, relying on the decision on many factors: 1) clinical 
parameters, including age, known hereditary syndrome, renal function (to avoid contrast 
nephropathy), and the anticipated radiation burden; 2) results of previous imaging (tumor size 
and location, suspicion of metastases); 3) biochemical findings; 4) preference of the patient; 5) 
the knowledge of the genetic status; and finally 5) the local availability of scanning systems and 
insurance issues125.  
1.8.2.1 ANATOMICAL IMAGING STUDIES 
First line anatomical imaging modalities include computed tomography (CT) and/or magnetic 
resonance imaging (MRI), as provide a high sensitivity and allow precise tumor delineation, 
which is critical for pre-surgical evaluation125.  
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CT is the first-choice imaging modality, as it shows an excellent spatial resolution for thorax, 
abdomen, and pelvis, with a sensitivity between 88 and 100%, being able to detect tumors 5 
mm or larger. However, MRI should be considered in the case of HN-PGLs, paracardiac PGLs, 
and metastatic/residual/recurrent PPGL, as some studies showed that CT-sensitivity was lower 
than MRI. In addition, MRI is recommended in patients with surgical clips, allergy to CT contrast, 
and in whom radiation exposure should be limited (children, pregnant/lactating women, and 
asymptomatic carriers of a germline mutation)4,8,125. Despite having high sensitivity, these 
techniques show a low specificity, making appropriated to complete localization diagnostic 
procedures with functional imaging studies2,125. The combination of anatomical and functional 
imaging in one time shows the highest sensitivity for the staging of PPGL, but are expensive and 
not yet widely available techniques.  
1.8.2.2 FUNCTIONAL IMAGING STUDIES  
The use of functional imaging techniques is recommended in all PPGL, except in the case of PCCs 
smaller than 5 cm, PPGL associated with adrenergic phenotype and non-SDHB2,25,125. Different 
approaches have been described consecutively: planar scintigraphy, single-photon emission 
computed tomography (SPECT) and positron emission tomography (PET). Each one represents 
an improvement of the sensitivity and spatial resolution, implying higher price and 
consequently, a lower availability. To note, PET is also a quantitative imaging technique, as the 
“Standardized Uptake Value” of the radiotracer can be used to estimate the degree of tracer 
concentration in a defined region allowing the detection of subcentimetric lesions125.  
The radiotracers used in these techniques are taken up by the tumor cells through different 
mechanisms that should be known by the physician to decide which type of imaging study 
should be the more appropriated based on the clinical PPGL scenario.  
· NOREPINEPHRINE TRANSPORTER VIA THE CELL MEMBRANE: Metaiodobenzylguanidine 
(MIBG) is structurally similar to norepinephrine. MIBG is commercially available labeled with 
123I or 131I. 123I-MIBG in comparison with 131I-MIBG scintigraphy provides images of higher 
quality, higher sensitivity, and lower radiation exposure. In addition SPECT can be more feasibly 
performed with 123I-MIBG, and there is less time between injection and imaging (24h versus 
48–72h)25,125. Thus, 131I is preferable used for targeted radionuclide therapy and 123I for 
diagnosis and when planning targeted radionuclide 131I-MIBG therapy25, as besides confirming 
uptake, it helps achieve personalized dosimetric25,125. In the case of PCC, as a diagnostic tool, 
123I-MIBG shows a sensitivity (S) and specificity of 85-88% and 70-100%, respectively. However, 
the sensitivity has been shown to be decreased in PGLs (56-75%), especially in HN-PGLs (18-
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50%)25, and necrotic, metastatic (56-83%), recurrent (<75%), and/or SDHB-related PPGLs 
(<50%)111,125. Regarding PET radiotracers, 18F-fluorodopamine (18F-FDA)-PET/CT has the highest 
sensitivity and specificity across genetically different PGLs (tumors with unknown genotype, 
SDHB, and non-SDHB), and it is the preferred technique for the localization of the primary PGL 
(S 77–100%) and to rule out metastases (S 77-90%), except in HN-PGLs. 11C-epinephrine126and 
11C-hydroxyephedrine (11C-HED)127 are, as FDA, very sensitive and specific radiotracers, but all 
of them suffer from their limited availability25,111,125. 
· SOMATOSTATIN RECEPTORS (SSTR): Overexpression of SSTR-2A and SSTR-3 was recently 
shown in PPGL with SDH deficiency128, and different radiolabelled peptides for SSTR have been 
used not only for the diagnosis, but also when targeted radionuclide therapy with somatostatin 
analogues (177Lu-DOTATATE) is planned4,25,125. 111In-DTPA-Pentetreotide (111In-DTPA-
P)/Octreotide (Octreoscan, Covidien) are mainly used in planar scintigraphy, showing lower 
sensitivity than 123I-MIBG, except in HN-PGLs (S 89-100%)8,25,125. 68Ga-labeled somatostatin 
analogues (68Ga-DOTA-SSTa): 68Ga-DOTA-Tyr3-octreotide (68Ga-DOTA-TOC), -Nal3-octreotide 
(68Ga-DOTA-NOC), and (Tyr3)-octreotate (68Ga-DOTA-TATE) are used with PET/CT and show 
sensitivities approaching 100%129. They have shown excellent preliminary results in localizing 
HNPGLs4, and aggressive and dedifferentiated PPGL25. To note, [68Ga]-DOTATATE PET/CT has 
shown a significantly superior detection rate to all other functional and anatomical imaging 
modalities in the evaluation of SDHB metastatic PPGL130.  
· GLUCOSE MEMBRANE TRANSPORTER: [18F]-fluoro-2-deoxy-D-glucose (18F-FDG) accumulates 
in proportion to the glycolytic cellular rate, providing an index of intracellular glucose 
metabolism25,125. In comparison with other NET that usually exhibit high 18F-FDG uptake in the 
later stages of the disease, 18F-FDG-PET positivity is almost a constant feature in PPGL (S 74-
100%)125. It shows a higher performance for metastatic PPGL, and is mainly influenced by the 
genetic status (e.g. S 83% in SDHB versus 62% in non-SDHB mutation carriers, being as low as 
40% in MEN2-related PCCs)2,8,22,25,131–133. 
· AMINO ACID TRANSPORTER SYSTEM: Dihydroxyphenylalanine (DOPA) is the precursor of all 
endogenous catecholamines, and PPGL cells can take it up through the amino acid transporter 
system. 18F-FDOPA-PET/CT is an excellent first-line imaging tool, and has a high sensitivity for 
the localization of non-metastatic PPGL (81-100%), especially in HN-PGLs (100%)8,25,125,131,134. In 
metastatic disease, 18F-FDOPA PET presented higher sensitivity in SDHB-negative patients (93%) 
than in SDHB-positive patients (20%)25,131. A special advantage in the screening of hereditary 
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cases is that 18F-FDOPA PET shows lack of significant uptake in normal adrenal glands, very 
useful for instance in the screening of MEN2 cases25.  
1.8.2.3 OTHER TECHNIQUES  
In vivo detection of succinate using pulsed proton magnetic resonance spectroscopy has been 
reported recently as a highly specific and sensitive hallmark of SDHx mutations, being this 
technique useful to stratify patients or classifying variants of unknown significance (VUS) with 
no need of tissue sampling. Thus, it may help for the characterization of inoperable tumors and 
suspicious lesions and serve as a surrogate biomarker in the assessment of tumor response to 
specific treatments135,136.   
1.8.3 IMMUNOHISTOCHEMICAL TUMOR CHARACTERIZATION  
PPGL are positive for CgA, the most reliable marker for discriminating them from adrenal cortical 
tumors and metastatic tumors that are not NET. PCC may be discriminated from other 
metastatic NET to the adrenal by staining for tyrosine hydroxylase. Other neural markers such 
as synaptophysin and neuron specific enolase are typically positive.  
Immunohistochemistry (IHC) study could help not only to guide the genetic study, but also to 
classify VUS identified in the genetic screening. However, they have been only optimized to be 
used in formalin-fixed paraffin embedded (FFPE) tissue. SDHB-IHC and SDHA-IHC are the most 
widely used and available techniques, and detect SDHx mutations with a high sensitivity and 
specificity. SDHB, SDHC, SDHD and SDHAF2-mutated tumors are negative at SDHB-IHC and 
positive at SDHA-IHC, while SDHA-mutated tumors are negative at IHC for both137,138. Other used 
IHC have been optimized for identifying truncating MAX mutations (MAX-IHC), and S-(2-
Succinyl)cysteine (2SC) staining for FH mutated tumors. On the other hand, tumors with 
mutations in TCA genes show almost undetectable nuclear staining of 5-hydroxymethylcytosine 
(5-hmC), as the accumulation of intermediates associated with their mutations lead to impaired 
5-mC hydroxylation48,55,72.  
1.9 TREATMENT  
1.9.1 SYMPTOMATIC TREATMENT 
An adequate α- and β-adrenergic blockade is needed in PPGL patients at least 2 weeks prior to 
the surgery, and to control blood pressure and alleviate symptoms related with the 
catecholamine hypersecretion in those inoperable cases, although they have no effect on tumor 
size.  
Regarding α -adrenergic blockade, phenoxybenzamine is the most commonly used agent, as is a 
long-acting, nonselective (α1 and α2), and noncompetitive blocker. Doxazosin, prazosin, and 
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terazosin are specific, cheap, competitive and therefore short-acting α1-adrenergic blockers, but 
have the potential for severe postural hypotension immediately after the first dose. β-
adrenergic blockade using agents such as propranolol, atenolol or metoprolol can be used if the 
patient present clinical manifestations caused by β-adrenoreceptor stimulations (e.g. 
tachycardia, arrhythmia, angina, or nervousness). They should be instituted after the α-
adrenergic blockade has been optimized (e.g. once the patient develops reflex tachycardia or 
orthostatic hypotension) as due to the loss of β-adrenoceptor-mediated vasodilatation, an 
exacerbation of epinephrine-induced vasoconstriction and a resultant serious and life-
threatening elevation of blood pressure could occur3. Alternative treatments include calcium 
channel antagonists (e.g. nifedipine and amlodipine), angiotensin receptor blockers, and 
angiotensin-converting enzyme inhibitors.  
On the other hand, α-methyl-para-tyrosine inhibits catecholamine synthesis, but is frequently 
associated with overwhelming side effects (e.g. anxiety, depression, fatigue, and diarrhea), it is 
expensive and difficult to obtain. Thus, this medication may be only recommended for selected 
adults with metastatic PPGL in whom other medications are not able to normalize blood 
pressure and other symptoms of catecholamine excess8,23. 
1.9.2 SURGERY 
The only curative treatment for PPGL is surgery. A minimally invasive procedure using 
laparoscopic resection is recommended for most PCCs and TA-PGLs if the tumor is small, non-
invasive and surgically favorable located. In the remaining cases, open approach should be 
carried out to ensure complete tumor resection, prevent tumor rupture, and avoid local 
recurrence. Partial adrenalectomy sparing adrenal cortex could be considered in patients with 
bilateral PCC or PCC associated with hereditary disease, and those patients with small tumors 
who have already undergone a contralateral complete adrenalectomy to prevent permanent 
hypocortisolism2,111.   
Even in cases with advanced disease surgery should be considered, as palliative surgery could 
release tumor pressure on surrounding tissues or decrease tumor mass (surgical debulking). 
Despite a survival advantage is not proven, it could also lead to a significant decrease in 
biochemical secretion, and therefore to decrease α- and β blockade doses to prevent 
catecholamine release, which can also facilitate subsequent radiotherapy or chemotherapy2,111.  
In the case of HN-PGLs, wait and see may be considered in asymptomatic cases with a low risk 
of metastases, while active treatment (surgery, radiosurgery or conventionally fractionated 
53 
 
 
 
                                                                                                                                                                  I. Introduction                                                    
 
external radiotherapy) is considered in symptomatic cases, in progressive disease, and in cases 
at higher risk of metastases4.  
Despite there is a vast interest and effort to develop new therapeutic approaches to treat 
metastatic PPGL, data are either limited or still at an experimental level, as PPGL are tumors 
characterized by their rarity and heterogeneity139. So far, the treatments are basically palliative, 
and metastatic PPGL is an orphan disease for which therapeutic options are very limited.  
1.9.3 INTERNAL TARGETED RADIOTHERAPY 
Treatment with 131I-MIBG has been employed to treat metastatic PPGL since 1984 in patients 
showing positive 123I-MIBG scintigraphy140. Although reported therapy effects varied 
considerably, stable disease could be achieved in 52% and a partial hormonal response in 40%. 
Reported 5-year survival rate was 45-64% and mean time of progression-free survival 23.1-28.5 
months, being hematologic toxicity the most frequent side effect2,23,141,142.  The use of histone 
deacetylase inhibitors (e.g. romidepsin and trichostatin A) in vitro and in vivo showed an 
upregulation of the norepinephrine transporter system, increasing the uptake of 123I-MIBG, 
that could enhance the therapeutic efficacy of 131I-MIBG treatment143. 90Y-DOTATOC, 177Lu-
DOTATOC, and 177Lu-DOTATATE treatments have been only used in limited number of patients 
with positive SSTR-imaging tumors, and more studies should be carried out23,114,141,144–148. 
1.9.4 CHEMOTHERAPY 
Combination chemotherapy with cyclophosphamide, vincristine and dacarbazine (CVD) for the 
treatment of metastatic PPGL was introduced in 1985149. CVD is preferred in patients with 
negative 123I-MIBG scintigraphy and in patients with rapidly growing tumors, even if lesions 
show positive 123I-MIBG scintigraphy, or extensive organ tumor burden (especially in the 
liver)2,23,150. Partial response could be achieved on tumor volume and hormonal response in 37% 
and 40%, respectively, but complete response on tumor volume could be achieved in only 4% of 
patients2,23,150. Anecdotally, cyclophosphamide alone achieved a long-term clinical benefit after 
progression or toxicity with Sunitinib in two frail and symptomatic patients151.  
1.9.5 FOCUSED TREATMENT OF ORGAN METASTATIC LESIONS 
External-beam irradiation of bone metastases, especially those that are rapidly growing, or 
embolization, radiofrequency ablation and cryoablation may provide additional treatment 
alternatives, not possible if metastases are numerous or very small2. 
1.9.6 MOLECULAR TARGETED THERAPIES 
Molecular targeted therapies are promising strategies, but favorable results are still lacking:  
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-. Everolimus, an inhibitor of mTOR pathway, showed relatively disappointing results in series 
with few patients152. Later, a phase II study reported a modest efficacy, as five of seven patients 
achieved stable disease153. 
-. Temozolamide and thalidomide, both acting as antiangiogenic agents, in a phase 2 study 
including only three patients showed an objective biochemical (CgA) and radiological response 
rate of 40% and 33%, respectively154. In a series of 15 cases using temozolamide partial 
responses were observed in four of 10 patients with SDHB mutations and in none of the five 
patients with sporadic PPGL155. 
-. Imatinib, a selective inhibitor of the ABL, platelet derived growth factor receptor and stem cell 
ligand RTK exhibited no response in two cases156.  
-. Sunitinib, a RTK inhibitor targeting antiangiogenic factors, has been used in few cases with 
objective responses and manageable toxicity157–159. In a retrospective review of a series of 17 
patients, eight experienced benefit according to the “Response Evaluation Criteria In Solid 
Tumors” (RECIST 1.1) criteria, being the response partial in three and stable in five. In addition, 
of the 14 patients with hypertension, six became normotensive and two could discontinue 
antihypertensive treatment. The median overall survival from the time sunitinib was initiated 
was 26.7 months with a progression-free survival of 4.1 months (95% CI 1.4-11.0). To note, most 
patients who experienced a clinical benefit were carriers of SDHB mutations160. Several phase II 
trials are currently ongoing using RTK inhibitors which endpoints are objective response rate 
(sunitinib, pazopanib, axitinib, and dovitinib) and progression-free survival (FIRSTMAPP-
Sunitinib Trial, www.ClinicalTrials.Gov)21.  
- Somatostatin analogues: octreotide and lanreotide bind with high affinity to SSTR2 and SSTR5 
subtypes, and individual reports of octreotide treatment in patients with HN-PGLs have been 
published130. Pasireotide (SOM230), which is active on SSTR 1-3 and 5, showed a more significant 
inhibition of cell growth, as well as a significantly higher induction of apoptosis in primary PCC 
cell cultures than octreotide161. As SOM230, other treatments have achieved promising results 
in cellular and animal models, but have no still been used in vivo in humans.  
In recognition of the distinct genotype-phenotype presentations of hereditary PPGLs, and the 
relevance of knowing the gene underlying the PPGL development,  a personalized approach to 
patient management, regarding biochemical testing, imaging, surgery, and follow-up has been 
recommended8. Thus, nowadays it is increasingly evident that successful PPGL management 
requires a multidisciplinary team approach, and an exquisite genetic characterization of every 
patient. 
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The main objective of this thesis was to elucidate the genetic heterogeneity of PPGL 
development in PPGL patients through a systematic genetic screening study. Genetic data were 
analyzed taking into account clinical parameters, such as number of tumors, age at presentation, 
and location of the primary tumor, or the presence of metastases among others, to be able to 
translate this information to useful recommendations for the management of these patients in 
the clinical setting.   
To accomplish this, the study was carried out in two consecutive phases with three objectives 
each one, respectively:  
 
2.1 PART I:  
Genetic characterization of apparently sporadic PPGL (S-PPGL) using Sanger sequencing 
2.1.1 To assess the prevalence of somatic and germline mutations in the PPGL “major” 
genes in patients with S-PPGL using Sanger sequencing in DNA samples from blood, 
FFPE and frozen tumors.   
2.1.2 To evaluate features classically used to guide the genetic diagnosis in S-PPGL: 
location of the primary tumor, age at presentation, biochemical secretion 
phenotype, and presence of metastases.  
2.1.3 To propose a genetic testing algorithm specifically designed for patients with S-
PPGL.  
 
2.2 PART II:  
Genetic characterization of PPGL patients using targeted gene panels – Next generation 
sequencing (TGPs).  
2.2.1 To perform the genetic screening of “major” and “minor” PPGL genes using two 
customized TGPs in different types of DNA samples (obtained from blood, saliva, 
FFPE and frozen tumor) from PPGL index patients. 
2.2.2 To evaluate genetic results with singular clinical features. 
2.2.3 To optimize and validate the two TGPs results to be used in the clinical setting.  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                      
                                                                                III. MATERIAL AND METHODS 
61 
 
 
 
                                                                                                                                                  III. Material and methods.                                                    
 
3.1  PART I: Genetic characterization of apparently S-PPGL using Sanger sequencing 
3.1.1 PATIENTS   
The inclusion criteria for patients with S-PPGL included the coexistence of four points: (1) the 
presence of a single PPGL (focal and unilateral); (2) the absence of syndromic features of NF1, 
MEN1, MEN2, and VHL syndrome in the patient and their relatives; (3) the absence of family 
history of PPGL, and (4) no known genetic mutation (WT). The diagnosis was based on 
pathological study and plasma or urine catecholamines and/or metanephrines assessment, as 
well as imaging tests.  
A total of 329 unrelated Spanish index cases with S-PPGLs were recruited between 1997 and 
2014 at Spanish public hospitals. All patients provided informed consent for genetic diagnosis. 
3.1.2 CLINICAL DATA   
A complete clinical questionnaire was requested from each patient, and included the following 
information: gender, age at diagnosis, clinical presentation (referring to the context in which the 
first suspicion of PPGL arose, classified as incidentaloma if after an imaging study or from a 
surgical procedure, and symptomatic if adrenergic or due to local mass symptoms), personal or 
familial history of signs or tumors of PPGL-related genetic diseases (MTC, primary 
hyperparathyroidism (PHP), gastro-entero-pancreatic tumors, cutaneous or uterine 
leiomyomas, renal cancer), findings from physical examination (weight, height, arterial tension, 
Marfanoid habitus, café-au-lait spots, neurofibromas, freckling), biochemistry studies 
(hemoglobin, hematocrit, calcium, phosphorus, urine calcium, 25-OH-D vitamin, thyrocalcitonin, 
CgA, predominant biochemical secretion measured either by liquid chromatography with 
electrochemical detection or tandem mass spectrometry, depending on the center), results 
from imaging studies performed (including if optic fundus had been performed, and other signs 
found in image studies like hemangioblastomas, or visceral cysts), tumor location, number of 
tumors, and metastatic behavior. The time from the initial diagnosis or resection of the primary 
tumor used to classify metastases was six months, being ≤ six months for synchronous and > six 
months for metachronous metastases24. Distant metastases were documented by imaging tests 
and pathological examination when possible24. The questionnaire also collected data about 
surgical and nonsurgical treatments, follow-up visits with the results of the monitoring of 
biochemical and imaging tests. The family pedigree was also drawn. Spanish version of the 
clinical questionnaire sent to the corresponding physicians is available in Supplementary data.  
Among the 329 S-PPGL index patients included: 60.8% were PCCs and 39.2% were PGLs. Among 
PGLS, 47.3% were HN-PGLs, 10.1% were T-PGLs, 41.9% were A-PGLs, and the location of one 
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PGL was not specified. The median age at onset was 46 (Interquartile range (IQR): 35–59) years 
and 58% were women.  
3.1.3 SAMPLES  
Blood sample to perform germline genetic study was obtained from each patient. Physicians 
were re-contacted to request tumor sample (frozen and/or FFPE) from patients with negative 
germline genetic screening. Of 99 tumor samples collected, 75 were FFPE and were studied for 
SDHB-IHC, and SDHA-IHC on tumors testing negative on SDHB-IHC, as previously described45,138.  
3.1.4 DNA EXTRACTION  
DNA was extracted from blood following a standard method and from frozen/FFPE tissue using 
the DNeasy kit (Qiagen Inc.), following the manufacturer’s instructions162. 
3.1.5 MUTATION TESTING: SANGER SEQUENCING  
Germline DNA from each patient was tested by Sanger sequencing for mutations in RET (exons 
10, 11, 13–16), VHL (all exons, plus the promoter region), SDHA, SDHB, SDHC, SDHD, SDHAF2, 
TMEM127, MAX and FH (all exons). Testing for gross deletions in VHL, SDH genes, TMEM127, 
MAX and FH was done by MLPA (MRC-Holland) or multiplex PCR, as previously described51,163,164. 
The study of somatic mutations in RET (exons 10, 11, and 16), VHL (promoter region plus exons 
1–3), EPAS1 (exon 12), HRAS (exons 2–3), MAX, SDHB, SDHC and SDHD (all exons) was carried 
out based on biochemical secretion and SDHB-IHC result. Hence, tumors with positive SDHB-IHC 
were studied for RET in adrenergic-secreting tumors, and VHL in noradrenergic secreting 
tumors. As the predominant secretion pattern was not been clearly established for EPAS1 and 
HRAS, and because MAX-mutated cases present both types of secretion, all tumors (except one 
with negative SDHB-IHC) were studied for somatic mutations in these three genes. SDHB was 
studied if SDHB-IHC showed negative, and SDHC and SDHD were only tested if SDHB-IHC was 
negative and SDHA-IHC was positive. Finally, we studied somatic mutations in NF1 (using the 
primers previously described165) in adrenergic PPGL in which frozen tumor sample was available 
(five tumors).  
NF1 was not tested in FFPE samples, as this gene spans 58 exons, and DNA from FFPE tumor 
samples suffers from low quality and presence of artifacts, such as C>T base substitutions caused 
by deamination, and strand-breaks. NF1 was analyzed in one of the tumors by NGS as part of 
another study (data not shown). Somatic nature of the mutations was confirmed ruling out their 
presence in germline DNA. Details summarizing the steps of the study are shown in Figure 4. 
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           ↓ 
     SDHB somatic study 
                 ↓ 
     Negative  
 SDHA-IHC                           SDHC and SDHD study 
329 S-PPGLs 
46 with germline mutations 283 negative for germline mutations 
99 tumor samples available 184 with no tumor sample 
56 FFPE  19 FFPE and frozen  24 frozen 
75 FFPE available to test SDHB-IHC 
1 negative staining  71 positive staining  
Predominant secretion 
18 adrenergic   39 noradrenergic  41 not known or no secretion 
43 Somatic mutations 56 WT 
3 could not be evaluated 
Figure 4. Details summarizing the steps of the genetic workflow study. S-PPGL: sporadic pheochromocytoma/paraganglioma; IHC: immunohistochemistry; FFPE: formalin fixed 
paraffined embedded.  
 
 HRAS, EPAS1 and MAX somatic study N = 98 (18 adrenergic plus 39 noradrenergic plus 41 not available/no secretion) 
 RET somatic study N = 59 (18 adrenergic plus 41 not available/no secretion)  
 VHL study N = 80 (39 noradrenergic plus 41 not available/no secretion)  
 SDHB study N = 23 (1 tumor with negative SDHB-IHC plus 3 FFPE tumors with SDHB-IHC not evaluable plus 19 frozen tumors without adrenergic secretion).  
 SDHC and SDHD study N = 1  
Negative Positive 
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3.1.6 VARIANT INTERPRETATION 
Genetic variants found were classified as mutations or VUS according to information available 
in public databases. Their presence was checked in the Exome Aggregation Consortium (ExAC; 
http://exac.broadinstitute.org/); Catalogue of Somatic Mutations in Cancer (COSMIC; 
http://cancer.sanger.ac.uk/cosmic), the Single Nucleotide Polymorphism database (dbSNP;      
http://www.ncbi.nlm.nih.gov/SNP/), Leiden Open source Variation Database (LOVD; 
http://chromium.lovd.nl/LOVD2/), and the Universal Mutations Database for VHL mutations 
(UMD-VHL mutations; http://umd.be/VHL/). In silico analysis was performed using Sorting 
Intolerant From Tolerant (SIFT), Mutation Taster, Polymorphism Phenotyping v2 (Polyphen2), as 
well as tools able to predict splicing changes. Whether or not the variants had been previously 
reported was also taken into account. 
3.1.7 STATISTICAL ANALYSIS 
We used Pearson’s χ2 test, or Fisher’s exact test when necessary, to compare proportions. Two-
sided p values<0.05 were considered statistically significant. Statistical analyses were performed 
using IBM SPSS statistics V.17.0 (IBM, Armonk, New York, USA) and R software V.2.7.2 
(http://www.r-project.org/) was used to generate Figure 5.
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3.2 PART II: Genetic characterization using TGPs specifically designed for the study of PPGL 
patients  
3.2.1 PATIENTS  
The inclusion criteria were patients affected by PPGL. The diagnosis of PPGL, as Part I, was based 
on pathological study and biochemical secretion of cathecolamines and/or metanephrines, plus 
imaging tests.   
A total of 453 unrelated index patients affected by PPGL were recruited between 1997 and 2016 
from 11 PPGL referral centers from Bethesda (USA-Section on Medical Neuroendocrinology, 
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), 
National Institutes of Health) and the European Network for the Study of Adrenal Tumors-
ENS@T. Participating ENS@T referral centers were located in Madrid (Hereditary Endocrine 
Cancer Group, Spanish National Cancer Research Centre), Florence (Department of 
Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence and Istituto 
Toscano Tumori), Padova (Endocrinology Unit, Department of Medical and Surgical Sciences 
University of Padova), Rotterdam (Department of Pathology, Erasmus University Medical 
Center), Delft (Department of Pathology, Reinier de Graaf Hospital), Liège (Department of 
Endocrinology, Centre Hospitalier Universitaire de Liège), Dresden (Institute of Clinical 
Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Medical Faculty Carl 
Gustav Carus, Technische Universitat Dresden), Lübeck (1st Department of Medicine, University 
Medical Center Schleswig-Holstein, Campus Lübeck), Munich (Department of Internal Medicine 
IV Campus Innenstadt, University-Hospital, Ludwig-Maximilians-University of Munich), and 
Würzburg (Department of Internal Medicine I, University Hospital Würzburg). 
Amongst included patients, 30 carried pathogenic mutations previously detected by Sanger 
sequencing (being 13 found in part I), and were used as controls to validate the NGS assay. The 
remaining cases consisted of 423 unrelated index patients without a known mutation, wild type 
(WT). In 305 (72%) WT patients, genetic screening by Sanger sequencing had already been 
partially performed following different algorithms proposed35,38,111–116 and the genetic workflow 
study detailed in part I in S-PPGLs (Figure 4). The remaining 118 (28%) patients had no previous 
genetic studies. Clinical characteristics of the 423 WT PPGL patients are summarized in Table 2. 
All patients provided informed consent for genetic testing. In addition, tumor tissues from the 
Erasmus MC, Rotterdam, the Netherlands, were used according the code of conduct: “Proper 
Secondary Use of Human Tissue” established by the Dutch Federation of Medical Scientific 
Societies. 
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Table 2. Clinical characteristics of the 423 PPGL patients without a known mutation included in the study.  
Composite tumor: tumor with presence of neuroendocrine and other type of tumor cells. NF1, Neurofibromatosis type 1; 
MEN2A, multiple endocrine neoplasia type 2; IQR, interquartile range; PCC, pheochromocytoma; PGL, paraganglioma; HN-
PGL, head and neck paraganglioma; TA-PGL, thoracic-abdominal paraganglioma; ACTH, adrenocorticotropic hormone.  
Type of sample available  
Only germline DNA 
N = 229 (54%) 
Germline and tumor DNA  
N = 27 (6%) 
Only tumor DNA.  
N = 167 (40%) 
Classification of the 
patients based on prior 
analysis of the samples 
using Sanger sequencing  
Yes, N = 305 (72%): 
  Only germline DNA, N = 215 
  Germline and tumor DNA, N = 10 
  Only tumor DNA, N = 80 
 
No, N = 118 (28%): 
  Only germline DNA, N = 14 
  Tumor DNA available not previously studied, N = 104 
       Only tumor DNA, N=87 
       Germline and tumor DNA, N=17 
Patients with syndromic 
related tumors    
N = 13: 4 Medullary thyroid carcinomas or C cell hyperplasia: ID2, D234, ID309 and ID412; 
              3 Gastrointestinal stromal tumors: ID79, ID95 and ID450;  
              3 Patients with NF1 clinical diagnosis: ID325, ID332 and ID357;  
              3 Pituitary adenomas: ID23, ID295 and ID440. 
Family history  
N = 5: 1 Patient belonging to a MEN2A family: ID 381;  
            2 Patients with first degree relatives diagnosed with NF1: ID5 and ID91; 
            2 Patients with first degree relatives diagnosed with PPGL: ID30 and ID106. 
Sex 
Female N = 243 (59%) Male N = 168 (41%) 
*No data, N = 12 
Age at onset  Median 48 (IQR = 38-59) years Pediatric cases (<18 years), N = 13  
Number and location of 
tumor  
Single. N = 362 (88%) 
     PCC, N = 240 
     HN-PGL, N = 71 
     TA-PGL, N = 49 
     Unknown-PGL. N = 2 
Multiple. N = 49 (12%) 
     PCC (bilateral and/or multiple), N = 17 
     PCC and PGL, N = 10 
     PGL. N = 22 
 
*No data N = 12 
Predominant biochemical 
secretion  
- Adrenergic. N = 66 (34%); 
- Noradrenergic. N = 126 (65%); 
- Dopaminergic. N = 1 (0.5%): ID401; 
- Co-secretion of dopamine and noradrenaline/adrenaline. N = 10: ID24, ID107, ID109, ID192, 
ID284, ID285, ID327, ID402, ID405 and ID 446; Co-secretion of ACTH. N = 2: ID108 and ID304. 
- Secretion high, but unspecified. N = 21; No secretion. N = 56; Not done. N = 6. 
*No data. N = 147   
SDHB 
immunohistochemistry  
- Positive.  N = 117 
- Negative. N = 17 
- Not evaluable. N = 2 
*No data. N =287  
Metastasis N = 31 (7.3%)  
Singular  pathological 
features  
- Black PCC. N = 2: ID164 and ID429; 
- Composite tumor with ganglioneuroma. N = 7: ID65, ID100, ID209, ID232, ID294,       
    ID306 and ID435; Composite tumor with lymphoma, N = 1: ID248;  
- Presence of ACTH in the immunohistochemical study. N = 3: ID108, ID304 and ID451.  
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3.2.2 CLINICAL DATA  
Clinical data in Spanish hospitals were recruited as mentioned in part I with the clinical 
questionnaire (Supplementary data). Data collected for the other participating centers included 
at least: number and tumor location, biochemical phenotype, presence of metastases, 
pathological findings, personal and family history of PPGL or PPGL-related tumors.  
3.2.3 SAMPLES 
Tumor and germline DNA was requested from each patient. A total of 491 DNA samples from 
the 453 index patients were studied. DNA obtained exclusively from tumor was available for 182 
(40%) cases, matched tumor-germline DNA for 36 (8%) patients, and only germline DNA for 235 
(52%) cases. In the latter group, two patients had germline DNAs from two resources: blood and 
saliva, and blood and GenomiPhi. In only 2 cases germline DNA source was saliva. Of 218 tumor 
samples, 114 (52%) were frozen and 104 (48%) FFPE. FFPE tumor slides were evaluated for 
SDHB-IHC, if available.   
3.2.4 DNA EXTRACTION  
DNA was extracted from peripheral blood samples following a standard method (FlexiGene DNA 
Kit, Qiagen). For 7 patients, sample material amplified by the Illustra GenomiPhi HY DNA 
Amplification Kit (GE Healthcare Life Sciences) was used. DNA samples were obtained from saliva 
using the Oragene·DNA kit (DNA genotek). In tumor samples, the selection of representative 
tumor areas was performed on a FFPE slide stained with hematoxylin-eosin, if available. DNA 
from frozen tumor tissue was extracted with the DNeasy Blood & Tissue Kit (Qiagen), and from 
FFPE tumor tissue with Covaris S2 System (Covaris), according to the instructions provided by 
the manufacturer. DNA quality was assessed using the NanoDrop spectrophometer, considering 
an absorbance ratio >1.7 to be acceptable for both 260/280 and 230/260 nm measurements. 
DNA was quantified with the Quant-iT™ PicoGreen® dsDNA Assay Kit (ThermoFisher Scientific). 
The Agilent 2100 Bioanalyzer System (Agilent) was used to assess the size and quantity of DNA 
fragments in FFPE DNA samples. 
3.2.5 MUTATION TESTING: TGPs 
3.2.5.1 TGPs DESIGN  
Two TGPs were designed using the TruSeq Custom Amplicon 1.5 kit system (Illumina), one (P-I) 
to work with germline and frozen tumor DNA, and the other (P-II) was a double strand design 
specifically addressed to study DNA from FFPE tumor tissues, as lead to avoid deamination 
artefacts. Probes were designed using the online DesignStudio software (Illumina) to capture 
the coding plus 50 bp intronic flanking regions, excluding non-coding exons. Both designs 
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contained RET (exon 8 to 16), VHL (promotor to exon 3), NF1 (all exons), MAX (exon 1, and 3 to 
5), TMEM127 (exon 2 to 4), SDHA, SDHB, SDHD, SDHC, SDHAF2, MDH2, FH (all exons), EPAS1 
(exon 9 and 12), and HRAS (exon 2 and 3). P-I additionally included KIF1B, MEN1, EGLN1 (all 
exons), and EGLN2 (exon 2 to 6). As the involvement of exon 7 in RET166 was not known when 
TGPs were designed, and it was analyzed by Sanger sequencing.  
Table 3. Characteristics of the TGPs designed.  
 
 
 
 
 
 
 
           bp: base pairs; FFPE: formalin fixed paraffined embedded tumor sample.  
DNA libraries were prepared according to the manufacturer’s protocol and samples were 
sequenced using the MiSeq platform (Illumina) with a paired-end mode using MiSeq Reagent Kit 
V3 (Illumina, Spain), 500 cycles in P-I and 300 cycles in P-II. The genetic study of tumor DNA (if 
available) was prioritized to constitutional DNA. 
3.2.5.2 TGPs DATA ANALYSIS  
Sequencing reads were de-multiplexed using MiSeq Reporter (Illumina). For raw variant calling, 
we used Genome Analysis Toolkit v2 (GATK) in P-I and Somatic Variant Caller in P-II. Variant 
calling format (VCF) was annotated using the version 83 of Ensembl Variant Effect Predictor and 
assembly GRCh37/hg19 of the human reference genome. 
In P-II we doubled checked variants annotated as having a biased prevalence in one of the pools 
(pool bias), and recovered those previously filtered out due to low coverage in one of the pools 
if they were detected in at least 20 reads and in 10% of reads. In addition, short indels were 
detected considering a variation cutoff of 15% in the number of reads in consecutive 
nucleotides, as problems with these type of variants and MiSeq Reporter had been previously 
described98. We analyzed sequence data using an in-house pipeline. All filtered variants were 
validated by Sanger sequencing, and the somatic nature was confirmed using constitutional 
DNA.  
 Panel I Panel II 
Type of DNA sample Germline and frozen  FFPE 
DNA input 150 ng 250 ng 
Number of genes included 18 14 
Type of design One strand Double strand  
Read Length 2x250 bp 2x150 bp 
Amplicon Length 250 bp 150 bp 
Number of amplicons designed 344 399 (x2) 
Number samples/flow cell 96 48 
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In addition, to avoid false negatives results, exons with less than 50-fold coverage were analyzed 
by Sanger sequencing in samples without mutations found. Additionally, as gross deletions 
cannot be accurately detected by this platform94, MLPA and/or multiplex PCR were applied to 
germline DNA if no mutation was found for VHL, SDH genes, FH, MAX, TMEM127 and MDH2, as 
previously described51,52,72,94,163,164. 
3.2.6 VARIANT INTERPRETATION  
The workflow used in the filtering process of sequence data analysis, the study of low coverage 
regions and gross deletions, and the variant interpretation is depicted in Figure 6.   
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Figure 6. Workflow for next-generation sequencing-based diagnostic testing.  
*Artefactual variants are those located in GC rich regions and/or homopolymeric tracts.  IHC, immunohistochemistry; EVS, Exome Variant Server; bp, base pairs; CONDEL, CONsensus 
DELeteriousness score; ExAC, Exome Aggregation Consortium; COSMIC, Catalogue of Somatic Mutations in Cancer; LOVD, Leiden Open (source) Variation Database; UMD, Universal Mutation 
Database; ARUP, ARUP Scientific Resource for Research and Education (MEN2) RET database; ATA, American Thyroid association- Revised American Thyroid Association guidelines for the 
management of medullary thyroid carcinoma (MTC); UMD, The Universal mutation Database; VUS, Variant Unknown Significance; SS, Sanger sequencing; MLPA, Multiplex Ligation-dependent 
Probe Amplification assay (MRC-Holland); qPCR, quantitative PCR.
SS of exons with <50 fold-coverage plus MLPA/Multiplex PCR for VHL/SDH genes/FH/MAX/TMEM127/MDH2 
Mutation VUS No variants 
Validated by SS Validated by SS Not validated by SS Not validated by SS 
Evaluation of amplification quality using the amplicon coverage file  
Immunohistochemistry (MAX51, FH54and SDH genes137,209)/qPCR 
(MDH2)72/functional assays (if available) 
Filtering process: Exclusion of:  
- Polymorphisms present in >1% of the population according to public databases (dbSNP/EVS) 
- Repeated variants (>10 samples)  Integrative Genome Viewer tool (BAM file) analysis to test for 
artefactual variants*  
- Variants in SDH genes present in cases with positive SDHB-IHC 
- Variants in non-SDH genes present in cases with negative SDHB-IHC 
- Intronic variants (more than 20bp from exonic regions) 
Variants indentified in each sample  
Variants remaining after filtering: Prioritization for validation using SS based on:  
- Consequence: stop, frameshift, splice site >> missense > synonymous, intronic variant further than 3 bp from an exonic region 
- Functional impact prediction: SIFT, PolyPhen, Mutation Taster, CONDEL and Alamut  
- Database: ClinVar, Tumor Portal, ExAC, COSMIC, LOVD, UMD (MEN1, VHL), ARUP and ATA guideline for MTC (RET) 
- Previously reported (PubMed search)  
- Number/percentage of reads 
Molecular report to the physician 
Mutation VUS No variants 
Samples included in the next-generation sequencing study  
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4.1 PART I: Genetic characterization of apparently S-PPGL using Sanger sequencing 
4.1.1 CLINICAL CHARACTERIZATION  
Clinical characteristics of cases included by tumor location are detailed in Table 4. Clinical and 
genetic data from the 329 patients included in the study are shown in supplementary table S1.  
Table 4. Clinical characteristics by tumor location. 
            NS: no statistically significant differences.  
 
The clinical presentation of S-PPGLs was mainly symptomatic (71.4%). Adrenergic symptoms 
were the predominant clinical presentation in PCCs (68.1%), T-PGLs (37.5%) and A-PGLs (47.7%), 
while local mass symptoms were more common in HN-PGLs (79.4%). PCCs and A-PGLs were 
predominantly secreting tumors (96.1% and 94.6%, respectively), HN-PGLs were more often 
non-secreting tumors (80%) and T-PGLs were a more even mix of both. Although the proportion 
of the secreting HN-PGL seems to be higher than previously described167, it is important to note 
that we did not have this information for all patients. In these patients with secreting HN-PGL, 
additional PPGLs were ruled out using images techniques. Fifteen pediatric cases (diagnosed at 
or under the age of 18 years) were recruited, all derived from sympathetic lineage: seven PCCs, 
one T-PGL and seven A-PGLs, and most (83.3%) presenting with adrenergic symptoms. Twenty-
Location N 
Gender 
Age at onset 
in years 
Clinical Presentation 
Biochemical 
secretion 
Metastatic 
cases 
Male Female Median (IQR) 
Incidentaloma 
(image/ 
surgery) 
Symptomatic 
(adrenergic/ 
local mass) 
No Yes 
PCC 200 88 112 45 (36-57) 41 (36/5) 100 (96/4) 5 124 11 
P-value  
PCC vs PGL   NS  2.3x10
-12 0.0083 
PGL 129 50 79 48 (33-60) 24 (13/11) 62 (26/36) 35 47 18 
· HN-PGL 61 21 40 52 (39-61) 5 (2/3) 29 (2/27) 28 7 5 
P-value  
HN-PGL vs T-PGL   NS  NS 
0.012 
P-value 
 HN-PGL vs A-PGL   0.0057  3.6x10
-11 NS 
· T-PGL 13 3 10 50 (32-62) 4 (2/2) 4 (3/1) 5 5 5 
P-value 
T-PGL vs A-PGL   NS  0.0028 
0.046 
· A-PGL 54 26 28 44 (24-59) 15 (9/6) 29 (21/8) 2 35 7 
· Un-located 
PGL 1  1 62 unknown unknown 
1 
Total cases 329 138 191 46 (35-59) 65 (49/16) 162 (122/40) 40 171 29 
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nine cases had developed metastases, which were more common in PGLs (14.0%) than in PCCs 
(5.5%; p=0.008), and in T-PGLs (38.5%) than in HN-PGLs (8.2%) or A-PGLs (13.0%) (p=0.012 and 
p=0.046, respectively). 
4.1.2 GENETIC CHARACTERIZATION  
Genetic analysis revealed mutations in 89 (27.1%) of 329 S-PPGLs; 46 were germline (14%) and 
43 were somatic (43.4% of the 99 tumors tested). A summary of the assessment of each variant 
found (mutation vs VUS) is shown in supplementary table S2. Germline mutations were more 
prevalent in PGLs (37/129, 28.7%) than in PCCs (9/200, 4.5%) (p=6.62×10−10). The most 
frequently germline mutated gene in S-PPGLs was SDHB (29/46, 63.0%). This result was expected 
due to the existence of founder effects affecting this gene in the Spanish population10. The 
number of mutations in other genes was six for SDHD, two for SDHC, two for RET and one for 
VHL. Moreover, as previously published, the contribution of mutations in “new” PPGL-genes was 
minor: three in SDHA (0.9%), one in SDHAF2 (0.3%), two in TMEM127 (0.6%), and no FH and 
MAX mutations were found35,53,78,94,96–98,168–170. 
Among the 99 tumor samples, 68 were PCCs and 31 PGLs. Among the 75 FFPE samples, all except 
one showed positive SDHB-IHC. Somatic mutations were more prevalent in PCCs (48.5%) than 
in PGLs (32.3%; p=0.13). HRAS was the gene most often somatically mutated (15.3% of the 98 
tumors tested), followed by VHL (11/80, 13.8%), RET (8/59, 13.6%), EPAS1 (6/98, 6.1%), SDHB 
(1/23, 4.3%), NF1, and SDHD (one case each, but only 5 and 1 tumor were studied, respectively). 
Figure 7 summarizes results of genetic testing.  
4.1.3 RELATION TO TUMOR LOCATION  
To make a recommendation about which type of sample (germline versus tumor DNA) should 
be prioritized for genetic screening of the known PPGL-related genes, and to avoid an 
overestimation of the frequency of patients with somatic mutations, not only the 99 germline 
negative cases with tumor material available were included in the analysis, but also the 46 
germline-positive patients, together referred as bona fide patients. The remaining 184 germline-
negative cases were excluded from this study since tumor material was not available and thus, 
a somatic mutation could not been discarded. Statistically significant differences were found 
between PCCs and PGLs regarding the proportion of somatic mutation carriers versus germline 
mutation carriers (p=6.67×10−8). In this subset of patients, somatic mutations were found in 
4.2% of HN-PGLs, 0% of T-PGLs, 24.3% of A-PGLs and 42.9% of PCCs. Among all locations, HN-
PGLs and T-PGLs were mainly associated with germline mutations (p=2.0×10−4 and p=0.027, 
respectively) (Table 5).  
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Figure 7. Results for each step of the genetic workflow.  
S-PPGL: sporadic PPGL; mut.:mutation; wt: wild type; G-DNA: germline DNA; T-DNA: tumor DNA. 
 
Table 5. Summary of genotype profile by tumor location for cases with germline and tumor DNA available. 
 
 
 
The most frequently mutated gene in PCCs was HRAS, while SDHB was the major contributor in 
PGLs regardless of their location, followed by SDHD in HN-PGLs, even though the involvement 
of this gene has been mainly related to multiple PPGLs33. In A-PGLs, SDHA, EPAS1 and HRAS were 
Location 
 
Total 
 
N = 145 
 
Germline 
mutation 
N = 46 
P-value 
Germline vs 
Somatic mutation 
 
Somatic 
mutation 
N = 43 
 
Mutated 
 
N = 89 
P-value 
Mutated vs non-
mutated 
 
Non-
mutated 
N = 56 
PCC 77 9  
6.67x10-8 
 
33 42 
NS 
35 
PGL 68 37 10 47 21 
  · HN-PGL 24 15 2.0x10-4 1 16 NS 8 
  · T-PGL 7 6 0.027 0 6 NS 1 
  · A-PGL 37 16 NS 9 25 NS 12 
  · TA-PGL 44 22 0.0078 9 31 NS 13 
S-PPGL
N=329
PCC 
N = 200
68 tumor samples 
available
33 Somatic 
mut.
158 WT: 
- 123 in G-DNA;
- 35 in G-DNA and T-
DNA.
9 
Germline 
mut.
HN-PGL 
N = 61
9 tumor samples 
available
1 Somatic 
mut. 
45 WT: 
- 37 in G-DNA;
- 8 in G-DNA and T-
DNA.
15 
Germline 
mut.
T-PGL
N= 13
1 tumor sample 
available
0 Somatic 
mut.
7 WT: 
- 6  in G-DNA;
- 1 in G-DNA and T-
DNA.
6 
Germlin
e mut.
A-PGL
N= 54  
21 tumor samples 
available
9 Somatic 
mut. 
29 WT: 
- 17  in G-DNA;
- 12 in G-DNA and T-
DNA.
16 
Germlin
e mut. 
PGL unknown 
location
N= 1
0 tumor samples 
available
0 Somatic 
mut.
1 WT: 
- 1 in G-DNA.
0 
Germlin
e mut.
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mutated with similar frequency (three cases each). Genetic results by tumor location, and 
clinical characteristics by gene mutated, are detailed in Table 6.  
    Table 6. Mutations by gene, tumor location and clinical characteristics.  
 
4.1.4 UTILITY OF PREDOMINANT SECRETION OF PPGLs TO GUIDE GENETIC SCREENING  
HRAS-mutated, RET-mutated and NF1-mutated S-PPGLs presented predominantly adrenergic 
secretion. EPAS1-mutated, VHL-mutated, SDHB-mutated and SDHA-mutated S-PPGLs had, as 
expected, noradrenergic secretion. Only two TMEM127-mutated cases were found, one with 
adrenergic and the other with noradrenergic secretion. The case in our series with a mutation 
in SDHAF2 showed mainly adrenergic secretion.  
The result from an assessment of genes mutated by location, for adrenergic and noradrenergic 
secreting tumors, suggested that in case of noradrenergic secreting tumors, VHL should be 
tested before SDHB (p=3.51×10−5) and SDHD (p=7.1×10−4) in PCCs, SDHD before VHL 
(p=0.0095) in HN-PGLs and SDHB before VHL (p=0.0024) in TA-PGLs. However, no statistically 
Location 
Number of cases (Number of malignant cases) 
HRAS 
N=15 
(1) 
RET 
N=10 (1) EPAS1 
N=6 
(1) 
VHL 
N=12 (1)  
SDHB 
N=30 (10)  
SDHD 
N=7 (3) SDHC 
N=2 
(1)  
SDHA 
N=3 
(1) 
SDHAF2 
N=1  
(0) 
TMEM127 
N=2 
 (0) 
 NF1 
 N=1 (0) 
Ger. 
N=2 
(0) 
Som. 
N=8 
(1) 
Ger. 
N=1 
(0) 
Som. 
N=11 
(1)  
Ger. 
N=29 
(10) 
Som. 
N=1 
(0) 
Ger.  
N=6 
(2) 
Som. 
N=1 
(1) 
Som. 
N=1 (0) 
· PCC 12 (1) 2 (0) 
     8 
(1) 
 
3 (1) 
 
1 (0)  9 (0) 4 (2) 0 0 0 0 0 0 2 (0) 1 (0) 
· HN-PGL 0 0 0 0 0 1 (1)  8 (2)  0 5 (1) 0 1 (0) 0 1 (0) 0 0 
· TA-PGL 3 (0) 0 0 3 (0) 0 1 (0) 17 (6) 1 (0) 1 (1) 1 (1) 1 (1) 3 (1) 0 0 0 
     T-PGL 0 0 0 0 0 0 5 (4) 0 0 0 1 (1)  0 0 0 0 
     A-PGL 3 (0) 0 0 3 (0) 0 1 (0)  12 (2)  1 (0) 1 (1)  1 (1)  0 3 (1) 0 0 0 
Gender:  
Male/Female 
5/10 2/0 5/3 0/6 0/1 7/4 18/11 1/0 4/2 0/1 1/1 1/2 0/1 1/1 0/1 
Age: Median 
(IQR)  
53  
(44-66) 
51 
(42-
61) 
48  
(43-
58) 
57  
(48-72) 
18 
27 
(17-
36) 
30  
(20-
42)  
56 
34  
(28-
40) 
45 
55  
(52-
57) 
26 
(21-49) 
40 
31  
(28-33) 
51 
Secretion: 
no/yes 
3/7 0/5 0/3 0/11 7/14 2/0 1/0 0/3 0/1 0/2 0/1 
Type of 
secretion* 
N (%) 
A 6 
(100%) 
A 4 
(100%) 
NAd 3 
(100%) 
NAd 9 
(100%) 
NAd 13  
(100%)  
- - 
NAd 3 
(100%) 
A 1  
(100%) 
NAd 1 
(50%) 
A 1 (50%) 
A 1 
(100%) 
PCC: pheochromocytoma; PGL: paraganglioma; HN: head and neck; T: thoracic; A: abdominal; IQR: interquartile range; Ger.: 
germline; Som.: somatic; A: predominantly adrenergic secretion; NAd. : predominantly noradrenergic secretion.  
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significant differences were found in adrenergic tumors between the proportions of HRAS-
mutated and RET-mutated cases for each location (Table 7).   
Table 7. Comparison between gene mutated and tumor location. 
PCC: pheochromocytoma; PGL: paraganglioma; HN: head and neck; TA: thoracic-abdominal; NS: differences statistically not significant 
(p>0.5). 
4.1.5 PEDIATRIC CASES   
Data on age at presentation by tumor location and genetic mutational status are summarized in 
Figure 5. The median age at onset for germline mutation carriers was lower than that for somatic 
mutation carriers and cases without a mutation.  
Driver mutations were more frequently found in pediatric than in adult cases (73.3% vs 25.2%, 
p=0.00020). Germline mutations were found in 53.3% of children, involving SDHB in six cases 
(75%) and SDHA and VHL in one case each. In addition, three somatic mutations were found in 
the five tumors available from the pediatric cases with negative germline screening (60%), all of 
them in VHL. Proportionally less adult cases (12.5%) presented germline mutations (p=0.00030), 
while somatic mutations were found in a similar percentage (41.9%) to that for pediatric patients 
(p=0.65).  
Considering only those cases with bona fide diagnosis (patients with germline mutation and 
those with negative germline screening and tumor available), 3 (23.1%) pediatric S-PPGL 
presented a somatic mutation, similar to the 39 (29.8%) somatic mutations found in adult S-
PPGL (p=0.15). Similarly, if only pediatric and adult cases with a bona fide diagnosis were taken 
into account, no statistically significant differences in the proportion of cases with a driver 
mutation were identified, 11 (84.6%) and 77 (58.7%), respectively (p=0.068).  
Location 
Number of cases 
HRAS 
N=15 
p-
value 
HRAS 
VS RET 
RET 
N=10 
EPAS1 
N=6 
p-
value  
EPAS1 
VS 
VHL 
p-
value  
EPAS1 
VS 
SDHB 
p-
value 
EPAS1 
VS 
SDHD 
VHL 
N=12 
p-
value 
VHL 
VS 
SDHB 
p-
value 
VHL 
VS 
SDHD 
SDHB 
N=30 
p-
value  
SDHB 
VS 
SDHD 
SDHD 
N=7 
PCC 12 NS 10 3 NS NS NS 10 
3.51x 
10-5 
7.14x 
10-4 
4 NS 0 
HN-PGL 0  0 0 NS NS 0.021 1 NS 0.0095 8 NS 5 
TA-PGL 3 NS 0 3 NS NS NS 1 0.0024 NS 18 NS 2 
     T-PGL 0  0 0  NS  0 NS  5 NS 0 
     A-PGL 3 NS 0 3 NS NS NS 1 0.036 NS 13 NS 2 
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          Figure 5. Age at diagnosis by tumor location and genetic mutation status.  
WT: wild type; G-DNA: germline DNA; T-DNA: tumor DNA; PCC: pheochromocytoma; HN-PGL: head and neck         
paraganglioma; T-PGL: thoracic-paraganglioma; A-PGL: Abdominal paraganglioma. 
 
 
74 40 (31-45) 54 (43-63) 
22 (16-32) 53 (45-62) 48 (34-61) 34 (25-47) 62 (48-72) 
46 (34-59) 32 (26-46) 45 (38-56) 
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4.1.6 METASTATIC CASES   
Of the 29 metastatic cases, 19 (65.5%) harbored a driver mutation. Germline mutations were 
found in 14 (48.3%), most commonly in SDHB (71.4%), followed by SDHD (14.3%). No mutations 
were found in other genes associated with a higher rate of metastases, such as MAX78 and FH53. 
However, in one metastatic S-PPGL we found a somatic mutation in HRAS, a gene that has not 
previously been reported to be involved in metastatic PCCs. In addition, as previously described, 
there were metastatic cases with germline mutations in SDHA, SDHC or with somatic mutations 
in EPAS1171, RET, VHL73, and SDHD77.  
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4.2 PART II: Genetic characterization of PPGL using TGPs  
4.2.1 TECHNICAL ASSESMENT AND VALIDATION OF TGPs   
Good amplification quality was obtained for 466 (95%) DNA samples corresponding to 428 (95%) 
patients (WT and controls). The NGS assay failed for the remaining 25 samples, despite libraries 
being generated twice. Since germline DNA was also available for 4 of the tumor samples that 
failed, they were still included in the study (ID47, ID71, ID101 and ID123). Supplementary table 
S3 details clinical characteristics of the 21 remaining patients.     
The sensitivity of NGS P-I and P-II was assessed based on polymorphic and pathogenic variants 
previously found by Sanger sequencing: 534 (73 unique) and 337 (56 unique) for each panel 
respectively, and reached 99.6% (P-I) and 99.4% (P-II). The only 4 variants not detected by TGPs 
were located in amplicons showing low coverage (≤ 50 reads): 1 VUS in TMEM127 (exon 2) and 
1 Single nucleotide polymorphism (SNP) in MDH2 (exon 1) in P-I, and 2 SNPs in exon 1 of MDH2 
in P-II. The assay was still informative in low coverage regions, as 17 SNPs located there were 
validated (Supplementary tables S4 and S5).   
Considering both panels, 7% of exons included in the design (16/224 of P-I and 11/157 in P-II) 
showed low coverage, 38% affecting exon 1 of different genes, and the remaining were located 
in regions with high GC content, as previously reported98,172. Sanger sequencing of low-coverage 
regions did not detect any variant. 
In addition, cross-amplification of SDHA and NF1 pseudogenes was ruled out in both panels since 
29 SDHA and 3 NF1 previously known variants were validated by P-I, and 25 SDHA variants by P-
II. Similarly, 19 NF1 variants were found using P-II and validated by Sanger sequencing.  
The longest duplication detected was 6bp in length (SDHB: c.424-19_424-14dupTTCTTC) in both 
panels. The largest deletions identified by P-I and P-II spanned 6bp (SDHB: c.424-19_424-
14delTTCTTC) and 22 bp (NF1: c.2364_2385delAAAGCTAATCCTTAACTATCCA) in length, 
respectively. SDHB gross deletions were not detected by the NGS assay in a positive control and 
a new positive case (ID 152).  
4.2.2 GENETIC CHARACTERIZATION  
4.2.2.1 DETECTION OF VARIANTS IN WT PATIENTS                                                                       
NGS analysis of the properly amplified 403 WT patients revealed 89 pathogenic mutations (71 
unique), 29 germline mutations, 58 somatic mutations, and 2 mutations in tumor DNA of 
patients without germline DNA available. Figure 8 and figure 9 detail mutated cases.    
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The most frequently germline mutated genes were SDHB (2.2%, 9/403) and SDHD (1.2%, 5/403), 
followed by SDHC, FH, NF1 (0.7%; 3 mutations in each gene), SDHA (0.5%, 2/403), and finally 
SDHAF2, VHL, RET and MAX (0.25%; 1 mutation in each gene).  
Among the 183 tumor samples of WT patients with properly amplified, NF1 was the gene most 
frequently mutated (14%). Somatic mutations in VHL, HRAS and RET were found in a similar 
percentage (6.6%, 5.5% and 4.4% respectively), and EPAS1 was involved in 3 (1.6%) cases. Of 
note, one germline DNA and 5 tumors apparently negative by Sanger sequencing showed 
mutations with low percentage of reads (<15%) by NGS. A review of the chromatograms and/or 
second tumor selection confirmed the NGS findings by Sanger sequencing (Figure 10).  
ID 100: Somatic mutation VHL: c.494T>G; p.Val165Gly: 58/1240 reads (4.68%) 
FFPE tumor DNA                                        FFPE tumor DNA                                   Germline DNA                  
                                                                     (2nd tumor selection)                            (blood)    
  
  
 
 
 
ID 274: Somatic mutation VHL: c.464T>G; p.Val155Gly:  ID 376: Somatic mutation HRAS: c.182A>G; p.Gln61Arg: 
Frozen tumor DNA: 25/179 reads (14%)                             Frozen tumor DNA: 25/210 reads (11.9%)  
 
 
 
 
 
ID 296: Germline mosaicism: SDHD: c.443G>A; p.Gly148Asp:  
   Blood DNA: 198/1055 reads (18.8%)    Saliva DNA: 201/1042 reads (19.3%)      
                                                                                                                                            
 
 
 
  Figure 10. Sanger sequencing chromatograms of pathogenic variants found in low percentage of reads. 
Germline mutations were more prevalent in cluster 1 genes (83%), while somatic mutations 
predominantly affected cluster 2 genes (74%). 
In addition, 45 VUS (42 unique) were found, 35 germline and 10 in tumor DNA (2 of them somatic 
82 
 
 
3
3
4
3
3
1
3
2
9
1
4
9
4
4
1
1
6
2
2 1
5
2
3
7
1
1
2
4
3
6
8
5
0
2
9
6
1
4
7
3
2
8
3
3
6
6
7
1
0
6
1
4
1
1
4
5
1
1
4
2
4
7
3
5
8
3
7
4
1
0
0
1
2
5
1
9
0
1
4
8
1
5
3
1
8
2
2
7
4
3
2
3
3
2
6
3
2
7
3
5
3
2
9
1
3
7
2
3
5
5
1
5
4
58 23 27 17 17 45 65 11 ? 53 59 29 47 47 49 45 46 22 52 52 34 44 42 61 45 30 17 25 14 48 68 50 44 24 72 43 ? ? 56
C1A SDHB
SDHA
SDHD
SDHC
SDHAF2
FH
C1B VHL
EPAS1 VUS VUS
3
2
2
2
7
5
Patient ID
Blood studied
Tumor studied
Previously studied
Tumor
Family PPGL 
62 39
Female 
Age (years)
Metastasis 
Secretion 
SDHB-IHC
Type of mutation
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Cluster 1 mutations.  
PPGL, pheochromocytoma and/or paraganglioma; IHC, immunohistochemistry; VUS, variant of unknown significance; HN-PGL, Head and neck paraganglioma; TA-PGL, thoracic-abdominal 
paraganglioma; PCC, pheochromocytoma; Neg., Negative; Pos., Positive; Adrenergic sec., predominantly adrenergic predominant secretion; Noradrenergic sec., predominantly noradrenergic 
secretion; mut., mutation; Cases categorized as probably germline or somatic, are represented as germline and somatic mutations, respectively.   
Yes                                  HN-PGL                         PCC                               Neg. SDHB-IHC          Adrenergic sec.            Germline mut.             Missense                      Synonymous 
No                                   TA-PGL                          Multiple                       Pos. SDHB-IHC          Noradrenergic              Somatic mut.               Frameshift                    Gross deletion 
Blood studied,              No data                         PGL unknown                                                 sec.                                  Mut. in tumor,             Splice region                Stop                                                                              
(but not tumor)                                                                                                                                                                      (blood not available) 
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Germline mutation
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Mutation i  tumor, no blood
Frameshift 
splice region
gross deletion 
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Figure 9. Cluster 2 mutations.  
PPGL, pheochromocytoma and/or paraganglioma; IHC, immunohistochemistry; VUS, variant of unknown significance; HN-PGL, head and neck paraganglioma; TA-PGL, thoracic-abdominal 
paraganglioma; PCC, pheochromocytoma; Neg., negative; Pos., positive; Adrenergic sec., predominantly adrenergic secretion; Noradrenergic sec., predominantly noradrenergic secretion; Mut., 
mutation; *This VUS in MAX had been previously reported and functional assays found that it was not pathogenic.
Yes                                  HN-PGL                         PCC                               Neg. SDHB-IHC          Adrenergic sec.            Germline mut.             Missense                      Synonymous 
No                                   TA-PGL                          Multiple                       Pos. SDHB-IHC          Noradrenergic              Somatic mut.               Frameshift                    Gross deletion 
Blood studied,              No data                         PGL unknown                                                 sec.                                  Mut. in tumor,             Splice region                Stop                                                                              
(but not tumor)                                                                                                                                                                      (blood not available) 
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mutations). Three VUS were found in patients carrying pathogenic mutations. Twelve VUS 
involved SDH genes, but SDHB-IHC could only be performed in two, strongly arguing against 
pathogenicity, as SDHB-immunostaining was positive. Other VUS involved NF1 (7), FH (5), MEN1 
(2) and RET (1); but none of these patients presented with syndromic features. VUS were also 
found in EPAS1 (4), MDH2 (6), KIF1B (3) and TMEM127 (2). A summary of mutations and VUS is 
shown in Supplementary table S6.  
To note, among VUS validated by Sanger, five might be pathogenic: a SDHB missense variant 
predicted by in-silico tools to be deleterious and possibly damaging, not previously described 
and, in which we did not have available FFPE tumor sample to perform SDHB-IHC; a FH missense 
variant associated with positive SDHB-IHC and negative 5-hmC IHC, in which we requested more 
FFPE slides to perform 2SC-IHC study; a RET synonymous variant described to affect splicing173; 
two candidate second hit EPAS1 variants, located close to the hydroxylation site in patients 
carrying known pathogenic EPAS1 mutations. Thus, further functional assays are required to 
determine their pathogenicity. 
Twenty-four variants reported by NGS were not validated by Sanger sequencing; two were 
located in homopolymeric tracts in KIF1B, and 22 showed low coverage of the variant (<12% and 
<13 reads of the altered variant), suggesting they were artefacts (Supplementary table S7). For 
272 patients no variants were found; tumor DNA was available for 90 (33%) of these.   
4.2.2.2 DETECTION OF VARIANTS ACCORDING TO PREVIOUS SANGER SEQUENCING       
The sample set (properly amplified) was divided in two groups: 1) cases previously partially 
studied by Sanger sequencing according to genetic testing algorithms (WTps; N=289); and 2) 
patients not previously studied (WTnotps; N=114). The distribution of the variants in each group 
is represented in figure 11 (mutations) and figure 12 (VUS).  
As expected, driver mutations were more frequently found in WTnotps (52/114, 46%) than in WTps 
(37/289, 13%). While WTnotps had more germline mutations (14%, 16/114) than WTps (4.5%, 
13/289), the percentage of somatic mutations was similar: 34 (34%) of the 100 tumors available 
in WTnotps and 24 (29%) of the 83 WTps tumors.   
Three FH mutations (3/289, 1%), two mutations in each of SDHB, SDHD and SDHC (2/289, 0.7%), 
and one mutation in each of SDHA, RET and VHL (1/289, 0.35%) were found among the WTps. 
Among WTnotps SDH genes were the major players.  
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All NF1 germline mutations were found in NF1 syndromic patients, and somatic NF1 mutations 
were found in a similar percentage in WTps (15 %) and WTnotps (13%), as NF1 was not previously 
studied by Sanger sequencing.  
4.2.3 VARIANTS FOUND IN CASES WITH SINGULAR FEATURES    
Among the 4 non-RET cases with MTC or C cell hyperplasia, only one had a SDHB germline 
mutation (ID2). No mutations were found in patients with GIST nor pituitary adenomas.  
A SDHC-germline mutation was identified in one (ID30) of the 2 PPGL familial cases. In the 2 
patients with NF1-affected relatives, no NF1 germline mutations were found, suggesting they 
might be phenocopies. We could not assess this hypothesis, because tumor DNA was not 
available. Patient ID381, from a MEN2A family, appeared to be a phenocopy due to a NF1 
somatic mutation.   
One somatic mutation in VHL (ID327) was found among the eleven dopamine-secreting cases, 
and in one out of the 8 composite tumors (ID100). The two black PCCs harbored RET mutations, 
one (ID164) a RET p.Met918Thr somatic mutation and the other (ID429) a germline VUS. No 
mutations were found in the 3 ACTH-immunostaining positive cases.  
4.2.4 MULTIPLE CASES  
In the 47 cases with multiple tumors and properly amplified, mutations were identified in 13% 
(6/47): 1 NF1 germline mutation in a clinically diagnosed NF1 case, 3 SDHD and 1 SDHAF2 
germline mutations in patients with multiple HN-PGLs, and 1 NF1 somatic mutation in a reported 
“double” PCC (out of 15 available tumors).  
 
7.2.5 PEDIATRIC CASES  
Regarding pediatric cases, a driver mutation was found in 41.7% (5/12): 3 SDHB germline 
mutations and 2 VHL somatic mutations (out of the 7 with tumors available, 28.6%). Only one 
case did not show properly amplified.  
 
7.2.6 METASTATIC CASES   
Finally, a driver mutation was detected in 30% (9/30) of metastatic cases well-amplified. Six 
harbored germline mutations in SDHA (2), SDHB, SDHD, MAX or VHL (1). Three out of the 16 
available tumors (18.8%) harbored somatic mutation in NF1 (2) and HRAS (1). No mutations 
were found in MDH2 or FH. 
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Figure 11. Comparison of the distribution of mutations depending on if the 
samples had been previously studied (partially) using Sanger sequencing or not. 
SS: Sanger sequencing; WT: Wild Type; VUS: Variant of Unknown Significance; MUT. 
Mutation. Reason of having not considered the study of the gene found mutated in the cases 
previously studied using SS: ʘ: No predominant biochemical secretion data available; ∞: 
Opposite biochemical secretion data; □: No blood available previously to perform gross 
deletions, only frozen tumor; ¥: Data from secretion received between SS-MiSeq.; ×: No data 
received*: Syndromic features; ˭: Not previously studied using SS.  
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Figure 12. Comparison of the distribution of VUS depending on if the samples 
had been previously studied (partially) using Sanger sequencing or not.   
SS: Sanger sequencing; WT: Wild Type; VUS: Variant of Unknown Significance; MUT. 
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5.1 DRIVER GERMLINE AND SOMATIC MUTATIONS  
5.1.1 GERMLINE MUTATIONS  
Since 2002, several reports have been published on genetic screening in S-PPGLs, with the 
estimated prevalence of hereditary cases ranging from 11.3% to 24%36–40,115,174. However, it is 
difficult to compare these findings because the criteria used to define S-PPGLs varied between 
studies; some included cases with multifocal40 or bilateral36,40 tumors, or cases with family 
history40, while others focused on benign tumors39 or secreting tumors36,40, or included cases 
diagnosed within a specific age range174. Further, only germline mutations involving the PPGL-
related genes known at the time (RET, VHL, SDHB, SDHD and SDHC) were considered.  
That said, in our 2009 study, we found germline mutations in 19 (14%) of the 135 cases studied38, 
and part I of this thesis shows the same percentage of hereditary cases (N=46, 14%), despite 
having increased the sample size to 329 patients and five additional genes having been included 
in the analysis (SDHA, SDHAF2, TMEM127, MAX, and FH), but these results were expected, as 
these “new” genes have a limited contribution in PPGL susceptibility. In fact, only were involved 
in three cases for SDHA (0.9%), one in SDHAF2 (0.3%), two in TMEM127 (0.6%), and no MAX or 
FH mutations were found.  
TGPs detected germline mutations in 29 (7.2%) PPGL cases, despite we included six more PPGL-
related genes in the germline genetic screening (NF1, MEN1, KIF1B, EGLN1, EGLN2, and MDH2). 
This proportion was the expected, since 95% of the patients included in part II were not 
syndromic and had no family history, and similarly to part I, germline mutations involving the 
“minor” genes was similar to that reported (<1%)33,35: three in FH (0.7%), two in SDHA (0.5%), 
and one in MAX and SDHAF2 (0.25%), with no mutations found in TMEM127, EGLN1, EGLN2, 
KIF1B, MDH2, and MEN1. The 3 germline mutations in NF1 were found in patients with 
previously known clinical features of NF1 syndrome (ID325, ID332 and ID357), as anticipated.  
Moreover, if we consider the patients included in part II that accomplish with the criteria used 
in part I for S-PPGL (single tumors without syndromic features and absence of a family history 
of PPGL), we analyzed 335 S-PPGL using TGPs in part II. Among them, 18 germline mutations 
were found (5.4 %): 8 in WTps (3%) and 10 in WTnotps (11.1%), being the rate in WTnotps similar to 
that previously reported in non-syndromic cases175 and part I.  
These results confirm that all S-PPGL should be included in the study of germline mutations, as 
S-PPGL showed in both parts of this study a rate of germline mutation higher than 10%, the rate 
stablished by the American Society of Clinical Oncology (ASCO) to consider genetic screening.  
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In addition, our results confirm the limited contribution reported for “novel” PPGL-genes: SDHA 
(<1%)33, SDHAF2 (<1%)170, TMEM127 (0.9%)169, MAX (1.1%)78 and FH (0.83%)53,94,97,98. 
Furthermore, cases related to the remaining relatively “new” genes can be considered 
anecdotic, as very few patients have been associated so far with germline mutations in them: 
EGLN1 (N=2), EGLN2 (N=1)58, KIF1B (N=2)59, and MDH2 (N=1)72, and we did not discover any 
other case. To note, MEN1 mutations have not been identified in S-PPGL98.   
However, despite mutations in these 10 “minor” genes are rare, genetic screening of them 
(comprising 89 exons) plus NF1 (comprising 58 exons) by conventional methods would have 
delayed the diagnosis, which is especially critical for NF174,176, MAX78, FH54, SDHA, SDHC177,178, 
and MDH272 mutation carriers, as mutations in these genes have been associated with 
metastases and poor prognosis. Thus, these genes should not be excluded from a 
comprehensive genetic screening in PPGL cases.  
5.1.2 SOMATIC MUTATIONS  
In recent years, somatic mutations in S-PPGLs have also been reported, highlighting the 
importance of working with tumor samples to provide a genetic diagnosis73,74,78–80,95,96,98,99,117. 
In part I of this study, somatic mutations were found in 43.4% of the 99 tumors tested, showing 
a higher frequency of somatic mutations than the previously reported rate 36%74, probably 
because we included the study of HRAS and EPAS1, which seems to be relevant to S-PPGL. A 
higher frequency of mutations was seen for RET (13.6%), VHL (13.8%) and HRAS (15.3%); as the 
previously reported prevalences were 5–5.1%, 8.5–9.2% and 6.9–10%, respectively73,74,79,95,117. 
On the other hand, our study found a similar frequency of EPAS1 mutations (6.1%) to that 
previously reported 7.9%80.  
Remarkably, although germline mutations in the HRAS and EPAS1 genes have been reported to 
be associated with the ‘Costello syndrome’ and ‘familial erythrocytosis type 4’, respectively, no 
case with PPGL has been reported in families with those syndromes33,79,117,168. However, elevated 
urine catecholamine metabolites have been described in some patients with Costello 
syndrome179 and EPAS1 mutations have been found as a mosaic in germline DNA extracted from 
leucocytes and buccal cells in two patients with polycythemia and PPGLs180,181. Although we did 
not ruled out the presence of these mutations in germline DNA in part I, none of the cases with 
somatic mutations in EPAS1 or HRAS showed any of the associated syndromic features. 
Despite somatic mutations in SDH genes have been reported very rarely77,182–186, we found a 
somatic mutation in SDHB and another one in SDHD in 2 S-PPGL.  
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In 2012, two independent studies found somatic NF1 mutations in 24% and 41% of PPGL 
patients, predominantly in PCCs and one A-PGL74,96. For three of the cases, the mutation was 
found to be in the germline, all had mild features and none had previously been identified as a 
syndromic NF1 patient74. We found one somatic mutation in NF1 among the five adrenergic 
frozen tumors available (20%). This lower percentage is probably due to the limited number of 
tumors analyzed for somatic NF1 mutations, but studying NF1 using Sanger sequencing is 
difficult due to large size, the absence of identified hot spots, and the high cost and time of 
delivery.  
When using TGPs, somatic mutations were detected in 32% of the 183 tumors studied. If we 
consider the tumors without germline mutations in part II (N=167), as done in part I, we detected 
somatic mutations in 35%: 31% of WTps (25/82) and 39% of WTnotps (33/85).   
To note, despite being NF1 the gene most frequently somatically mutated74,96, the use of TGPs 
revealed a relatively lower prevalence of somatic mutations in NF1 (14%), as well as in the other 
genes somatically involved: VHL (6.6%), HRAS (5.5%), RET (4.4 %), and EPAS1 (1.6%), in 
comparison with previously published data: 24-41% in NF174,96, 8.5–9.2% in VHL73,74,95, 6.9–10% 
in HRAS79,117, 5–5.1% in RET73,74,95, and 7.9% in EPAS180. Although tumors from WTnotps showed a 
more similar percentages to previously reported (Figure 11), the lower percentages in general 
are probably caused by the fact that in previous studies, part I, and WTps of part II, somatic study 
was carried out in selected cases using different parameters (e.g. biochemical 
secretion)73,79,117,176. 
Finally, MAX was not somatically involved in our series, which is consistent with previous reports 
(1.65–2.5% frequency with only three cases reported previously)78.  
5.2 VARIANTS OF UNKNOWN SIGNIFICANCE  
One of the main problems of NGS is the amount of data derived of their use, being the finding 
of numerous VUS a challenge for clinical diagnosis. In comparison with part I, in which only 6 
different VUS were found (only one in a case with a pathogenic mutation (ID619)), TGPs 
elucidated 45 VUS (39 different VUS, being only three present in cases with pathogenic 
mutations (ID322, ID275, ID166)).  
Among the 5 patients in which the only finding in part I was a VUS, four were included in part II 
(ID130, ID218, ID382, and ID395). ID382-patient presented a VUS in MAX in part I (p.Ser142Leu), 
that afterward was proven to be not pathogenic by our group through functional studies187, and 
the inclusion in part II revealed a NF1 pathogenic somatic mutation. No other mutations were 
found in the remaining cases, although only one tumor sample could be obtained. The fifth 
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patient of part I that was not included in part II, presented a missense SDHB variant in a highly 
conserved residue (ID163: p.Asp74Gly) and we requested a slide of FFPE tumor sample to 
perform SDHB-IHC to assess the pathogenicity of the variant to the corresponding physician. 
Other IHC previously mentioned can be further used to assess the pathogenicity of the VUS 
found, such as SDHA-IHC for SDHA VUS138, 5-hmc and 2SC for FH VUS54, MAX-IHC for novel MAX 
truncating variants51,78 among others.  
Thus, to further characterize the pathogenicity of VUS, an optimal communication with treating 
physicians is required to obtain updated clinical information and/or tumor sample, as shown by 
the study of Burnichon et al. in which the re-examination and review of family history led to the 
classification of NF1 germline variants as pathogenic74. In other cases, the knowledge of the 
catecholamine phenotype can help to assess the pathogenicity of the genetic variant found88. 
Current knowledge suggests that mutations in driver genes in PPGL are mutually exclusive. Thus, 
multiplexing different genes in parallel in TGPs aids VUS classification94, as shown by the finding 
of a NF1 somatic mutation (ID166) in a case in which we simultaneously found a germline VUS 
in MEN1 (c.-10G>A), suggesting the latter is not pathogenic.  
Other VUS could be more challenging to classify, as shown previously with co-occurring NF174 
and EPAS198,110 variants. In our series, one patient harbored a double somatic mutation in NF1 
(ID434) and 2 cases double EPAS1 variants (ID275: p.Pro531Thr and p.Leu400Pro; ID322: 
p.Asp539His and p.Gly537Gly). It is worthy to note that we only studied exon 9 of EPAS1 in part 
II, but it seems that variants in exon 9 may be acting as modifier rather than causative of 
PPGL110,181.  It was not possible to rule out that these second variants were acting as modifiers 
through appropriated functional assays, as previously performed with other EPAS192 or MAX187.  
In conclusion, VUS classification is a resource- and time-demanding task, and an international 
cooperative effort is required to update existing databases188.  
5.3 GENETIC STUDY AND CLINICAL DATA  
5.3.1 GUIDED GENETIC STUDY USING CLINICAL DATA (PART I)  
In part I, similarly to the COMETE cohort study, where somatic genetic assessment was guided 
by findings from genome-wide expression studies73,74, our somatic study was, in part, guided by 
the fractionated biochemical profile observed for each tumor, highlighting the importance of 
having access to secretion data. 
In addition to the predominant secretion, our study highlights the utility of differentiating tumor 
location to select not only the most appropriate DNA sample (germline or tumor), but also the 
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genes to be studied. Our analysis enabled us to conclude that the study of germline DNA should 
be prioritized in single HN-PGLs and T-PGLs, while the study of tumor DNA should be 
recommended in patients with single PCCs. Despite not finding statistically significant 
differences between the frequencies of somatic and germline mutations in A-PGLs, SDH genes 
were involved in 72% of mutated cases (being only two somatic mutations). In addition, 20% 
(3/15) of HRAS-mutated cases in this series were A-PGLs, compared with the 4.2% (1/24) 
previously reported79,95,117, highlighting the relevance of HRAS somatic testing in tumors located 
outside the adrenal glands. Consequently, for A-PGLs, it seems appropriate to recommend a 
germline study (starting with the SDH genes) in cases with tumors negative or without SDHB-
IHC and somatic screening (excluding the SDH genes) in those with positive SDHB-IHC staining. 
5.3.2 “BLINDED” GENETIC STUDY USING TGPs (PART II)  
TGPs genetic results made evident that some pitfalls could occur relying too much in clinical data 
to guide genetic testing.  
Inevitably, the mutation detection rate in part II is dependent on the extent of previous 
conventional genetic screening using algorithms based on available clinical data. In a study by 
Rattenberry et al. NGS was shown to successfully detect mutations in previously unstudied 
cases94; our data additionally demonstrates that TGPs can detect mutations in genes that have 
been previously disregarded due to discordant or missing clinical data. Driver mutations were 
found in 37 of the 289 Wtps (13%): germline mutations 13/289 (4.5%), and somatic mutations 24 
of the 83 WTps tumors (29%). This finding highlights the risk of relying excessively on phenotypic 
features to guide mutation testing.  
For instance, two patients older than 60 years with a single PCC were found to be carriers of a 
germline mutation in VHL (ID374; p.Arg200Trp) or RET (ID283; p.Phe776Leu). These mutations 
would probably had been overlooked if methods other than TGPs had been applied. These 
results are crucial for the management of both index cases and their relatives, as theses specific 
mutations have been related to polycythemia189 and MTC190, respectively. This approach also 
allowed us to detect NF1 somatic mutation in 2 TA-PGL cases, despite this gene being mainly 
associated with PCCs73,176.  
Another confounding factor could be the biochemical secretion. In this regard, these data will 
help to guide screening, but there are incongruous values due to variation in sample collection 
procedures or interfering drugs or foods118. Of note, in this study 1 VHL and 1 FH mutation were 
detected in adrenergic-secreting tumors, and 3 RET-mutated cases were noradrenergic. 
Furthermore, 9 cases with a NF1 somatic mutations presented noradrenergic secretion. While 
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NF1 has been classically associated with an adrenergic secretion,  the heterogeneous profile of 
NF1 tumors had been pointed out before75.   
A remarkable finding was a NF1 somatic mutation in a patient with multiple PCC (ID357). After 
reviewing the pathological report, the tumor was reclassified as a single multi-lobulated PCC.  
5.4 AGE AT ONSET  
Although there is no agreement on the upper age limit to apply for genetic testing8,11,36–38,42,191, 
45 years resulted in a better identification of mutation-positive cases in the study of Erlic et al., 
where various clinical parameters were assessed using multiple logistic regression192.  
Taking into account this limit of age in part I (Figure 5), we analyzed the possible consequences 
of limiting genetic studies depending on the age at presentation.  
Thus, if germline screening had not been performed in index cases older than 45 years in our 
series, we would have missed 11.1% hereditary cases of HN-PGLs, 25% of T-PGLs, 8% of A-PGLs 
and 3.2% of PCCs. Conversely, younger patients tend to be excluded from somatic studies. Thus, 
if the somatic screening had not been performed in index cases younger than 45 years, we would 
have missed the genetic diagnosis of 42.9% A-PGLs, and even more importantly, 53.3% of PCCs. 
Therefore, we recommend that a germline and somatic genetic diagnosis be carried out for all 
S-PPGLs, regardless of the age of diagnosis. 
Historically, pediatric age has been considered a predictor of the presence of germline mutations 
in PPGL-related genes. In fact, previous pediatric series have shown rates of germline mutation 
of around 80%41. The results from part I in bona fide cases showed that at least half of pediatric 
S-PPGL presented a germline mutation, and a quarter of S-PPGLs could be explained by a somatic 
mutation.  
In part II, 12 out 13 pediatric patients included in the study show enough amplified to be 
evaluated, being able to detect a germline mutation in 25% and a somatic mutation in 29%. 
Among them, 7 (58%) had been previously studied using Sanger, and a somatic mutation in VHL 
(ID153) and a gross deletion in SDHB (ID152) could be detected.  
In conclusion, both parts of this thesis highlight that it is also important to study somatic 
mutations in young patients, being VHL the main player (100% of somatic were located in this 
gene in both parts of this thesis). On the other hand, SDHB represented 75% and 100% of the 
germline mutations found in pediatric patients in part I and part II, supporting that this gene 
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should be the first one to be studied if NGS is not available, not only for the prevalence, but also 
for the metastatic rate associated to this gene4,15–17.   
Moreover, pediatric cases with somatic mutations should be assessed with caution, as it is 
especially important to rule out the presence of mosaicism. In this regard, NGS has been proven 
useful as a diagnostic tool to accurately quantify the level of mosaicism through the study of 
different embryological lineage cells180. To note, VHL somatic mutations in part II were detected 
using TGPs in a frequency of reads of the altered variant around 28% and 29% in tumor DNA 
from patient ID190 and ID153, respectively, which could be an indicator of the presence of 
mosaicism, among other factors previously mentioned (e.g. normal tissue contamination). Thus, 
if a somatic mutation is found in a pediatric case, a search for the mutation in multiple tissues is 
encouraged to better evaluate the extension of the disease, as well as to improve the 
management and follow-up of the patient and their offspring180. 
5.5 METASTATIC BEHAVIOUR   
As expected, SDHB was the main gene involved in metastatic S-PPGLs, even in cases with PCC 
(40% of metastatic PCC with a driver mutations identified). It was the most commonly mutated 
gene among metastatic T-PGLs (80%). Somatic mutations in VHL, RET, EPAS1, HRAS and SDHD 
were detected in one case each. Thus, because knowing the driver mutation is especially 
important in the determination of the most appropriate therapeutic intervention35, metastatic 
cases should not be excluded from comprehensive testing for somatic mutations. 
NGS allowed us to detect mutations in SDHA, VHL, NF1 and HRAS among metastatic cases in 
which SDHB involvement had been ruled out, as 20 (67%) had been previously studied using 
Sanger sequencing. These genes would likely had been ignored and the diagnosis delayed due 
to the low prevalence of metastatic cases reported with mutations in these genes, as well as the 
large size of some of them. Of note, we found the second malignant case related to a HRAS 
mutation (ID376). 
5.6 SINGULAR FEATURES IN CLINICAL DATA  
Surprisingly, despite black PPGL being rare, the two cases in our series were related to RET 
variants. Patient ID164 has been reported193 and case ID429 harbored a germline synonymous 
RET variant in exon 11 previously demonstrated to alter the splicing of the gene in HD173. The 
co-occurrence of MEN2 and HD is intriguing, since the latter is caused by RET inactivating 
mutations, and MEN2 to activating ones. However, MTC incidence among HD patients varies 
between 2.5 and 5%, with all activating mutations located in exon 10194. As it was not possible 
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to perform functional studies to assess the pathogenicity of this specific variant, it was classified 
as a VUS and the recommendation for this case would be to follow it as a potential MEN2 case. 
5.7 SEQUENCING APPROACHES  
Nowadays TGPs are broadly used due to its cost-effectiveness and ease of management. Several 
groups have already used this technology for PPGL genetic testing94,98,195,196. While it is difficult 
to compare these studies, mainly due to their different design196, it is clear that an optimal and 
uniform multiplexing of all regions of interest is yet to be established.   
Rattenberry et al. suggested near equal quality of TGPs to Sanger sequencing in PPGL, and a 
significant reduction in both cost and time consumption94. Similar performance of diagnostic 
TGPs has been reported by an accumulating number of observations in other diseases using 
different enrichment assays and sequencing platforms94,197–200. However, current guidelines for 
the diagnostic use of NGS state that the validity of the selected bioinformatic software needs to 
be ensured by the local investigator before clinical application201. Thus, the local laboratory 
should select, validate and maintain a robust bioinformatics pipeline, a process that will require 
trained and experienced personnel. These investments and the running costs of bioinformatic 
processing will inevitably increase cost of TGPs202.  
The momentum of NGS in a clinical setting was recently strengthened by demonstrating equal 
quality of generated results compared to Sanger sequencing203. In a study of Crona et al. in PPGL 
tumor samples, Targeted NGS was performed using Truseq custom amplicon enrichment 
sequenced with a double strand design (such as panel II of part II of this Thesis) on an Illumina 
MiSeq instrument. Results were analysed in parallel using 3 bioinformatics pipelines 
(Commercially available MiSeq Reporter 2.1.43 (MSR), CLC GenomicsWorkbench 5.51 (CLC) and 
the in-house custom pipeline (ICP), and compared to results from traditional Sanger sequencing. 
Compared to Sanger sequencing, variant calling revealed a sensitivity ranging from 83 to 100% 
and a specificity of 99.9-100%, demonstrating that TGPs show equal performance and 
comparable quality to Sanger Sequencing in PPGL. To note, only MiSeq reporter identified all 
pathogenic variants in both sequencing runs detected by Sanger Sequencing204, this is the main 
reason why we used it in part II.  
Herein, we designed a comprehensive TGPs for PPGL, including for the first time EGLN1/PHD2, 
EGLN2/PHD1, MEN1 and MDH2, and screened a large international multicenter series of 
patients using germline and tumor DNA. In addition, we performed a stringent process of 
validation and a multi-step workflow analysis to confirm this platform as an efficient and 
accurate alternative to conventional sequencing in the diagnosis setting. We used MiSeq 
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reporter, and our pipeline allowed us to rescue pool biased variants, as well as indels such as 
the NF1 frameshift variant (c.7269_7270delCA) in ID445, as troubles regarding these types of 
variants had been previously reported with Illumina's platform98,204. Consistent with previous 
reports94,98,195,196, the sensitivity of the TGPs was extremely high (99.5%).  
As this platform is not able to multiplex all the regions designed with a well coverage and it is 
not able to detect gross deletions, the workflow of this study included in a second step the 
conventional sequencing of the regions with low coverage and the study of gross deletions. In 
this regard, even applying a stringent threshold of 50-fold coverage, we did not find any 
additional variants in the Sanger sequencing of these regions, suggesting that the 30-fold 
coverage threshold used in the study of Rattenberry et al. is appropriated94. The MLPA/Multiplex 
analysis of TGPs negative patients diagnosed an additional case (0.3%, 1/291 germline DNA 
available), highlighting that gross deletions are rare events (<1%)35. Further, performing an 
MLPA/Multiplex study on selected cases as a second step reduces cost and processing time, and 
the protocol can be even more focused using SDHB, 2SC, and MAX- IHC54,60,177. 
In comparison with previous TGPs studies, we used the variant filtering threshold to prioritize 
variants for validation, instead of using it for filtering them out. Applying fixed thresholds can 
significantly reduce the detection sensitivity for heterozygous variants due to normal tissue 
contamination30, intra-tumor heterogeneity139 and mosaicism47,81–83. Three cases showed 
potential mosaicism, as the variants were detected in around 20% of reads, 2 affecting VHL in 
pediatric cases previously mentioned (ID153 and ID190), and 1 involving SDHD (ID296), the latter 
not previously described.  
5.8 DNA SAMPLES  
5.8.1 FFPE TUMOR SAMPLES  
The prevalence of mutations in the SDH genes in A-PGLs, metastatic cases, as well as pediatric 
S-PPGLs cases stresses the importance of using SDHB-IHC as a filter to optimize genetic screening 
in part I, and therefore highlights the importance of having access to FFPE tumor material35,137. 
A good example of utility of performing IHC to guide the genetic study using Sanger sequencing 
was the case with a somatic mutation in SDHD, as SDH genes mutations are scarce and rarely 
analyzed.  
When FFPE tumor material is unavailable, at a minimum SDHB germline mutations should be 
tested for, given the higher associated risk of developing metastases15, and the presence of a 
founder effect, at least in the Spanish population37. 
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In part II, FFPE tumor samples to perform IHC studies was used in the filtering process to select 
the genetic variants that should be validated by Sanger sequencing, but also to test the 
pathogenicity of VUS found in these genes94,95,97.  
5.8.2 SOURCE AND QUALITY OF DNA SAMPLES  
Frozen and blood DNA samples have optimal quality for molecular diagnosis. However, their use 
is not always feasible, as saliva, GenomiPhi or FFPE tumor samples are sometimes the only 
available DNA source.  
In part I we used germline DNA derived from blood and tumor DNA from FFPE and frozen 
samples. In part II, we tried to analyze all the patients with the available DNA source, 
independently of the type of sample. Saliva DNA samples performed well, as the germline 
mosaicism in SDHD was detected in a similar percentage of reads to that in the blood DNA of 
the same patient (ID296). Additionally, samples amplified by GenomiPhi were found to be useful 
for diagnostic purpose as our panel detected all SNPs previously identified by Sanger 
sequencing.  
A common problem with FFPE samples is the high number of false-positive variants resulting 
from deamination (C:G>T:A); this was the main reason why NF1 was not tested in FFPE samples 
in part I of this thesis. In part II, this circumstance was resolved by applying doubled stranded-
TGP. In addition, the use of Covaris system in part II improved the DNA extraction efficiency and 
the percentage of cases diagnosed, in comparison with part I in which we used Qiagen 
extraction, since the FFPE samples in which DNA was extracted with the Covaris system showed 
a higher number of reads/amplicon. In fact, the amplification failed in less FFPE samples than in 
blood or frozen tissue DNA. Thus, in part II we were able to study all types of DNA samples with 
similar performance.  
We therefore consider critical the access to the tumor sample for a complete PPGL genetic 
screening and diagnosis. The study of DNA from tumor sample as the first step allows “to kill 
three birds with one stone”, as allows the detection of germline, somatic and mosaic mutations.  
In our series, the frequency of somatic mutations (43.4% and 32%, in part I and II, respectively) 
was in agreement with previous reports, even in cases highly likely to carry a germline mutation. 
Thus, a somatic was found in 60% and 28.6% of pediatric cases, 29% and 19% of malignant in 
part I and II, respectively, and 7% of multiple tumor cases studied in part II. Furthermore, 
studying the tumor DNA of apparently familial cases can reveal phenocopies.  
5.9 FUTURE OUTCOMES  
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Despite using TGPs, a comprehensive clinical record is still useful when performing genetic 
diagnosis, as demonstrated by findings for case ID79. This patient was diagnosed with a GIST 
and multiple noradrenergic PGLs. The tumor showed negative SDHB-IHC, TGPs did not detect 
any SDH variant and gross deletions were also ruled out. Our workflow allowed us to select this 
case to be further studied using multi-omics platforms, to finally detect a functional epi-
mutation in SDHC, which is an event recently described as causing the disease 104.  
As the list of new PPGL genes is growing constantly, their inclusion to already designed panels is 
not a cost-effective process, as it requires the generation of new libraries and their validation. 
Our workflow allowed us to select the specific cases that would benefit from further genetic 
screening. Examples of this point are the implementation of the study of MERTK58 and exon 7 of 
RET163 in patients with PCC and MTC, despite no mutation being found, or the selection of WT 
composite tumors to further study ATRX (35 exons), which has not only been related to 
composite PCC, but also to metastatic PPGL106.  
5.10  REASONS TO CONSIDER GENETIC SCREENING IN ALL PPGL CASES  
Genetic screening is expensive and time-consuming, especially if NGS is not available, but there 
are important implications of having a genetic diagnosis in S-PPGLs. According to the American 
Society of Clinical Oncology (ASCO)’s general recommendations for genetic screening, all 
patients with a risk of at least 10% of carrying a genetic mutation should be offered genetic 
testing, especially when the results would aid in diagnosis or influence the management of the 
patient or family members at hereditary risk of cancer116,205. 
The identification of germline or mosaic mutations allow the early diagnosis of multiple tumors 
or additional syndromic neoplasias in the proband, as well as in relatives at risk. On the other 
hand, the identification of a somatic mutation benefits: (1) family screening, as it frees relatives 
from the need for genetic screening and clinical follow-up (more caution has to be taken in the 
case of ‘somatic mutations’ in pediatric cases since the possibility of a germline mosaicism 
cannot be excluded); (2) diagnosis, making unjustified the exhaustive follow-up required for 
patients harboring germline mutations associated with a high risk of developing multiple tumors 
and different cancer types; (3) prognosis, as it is known that mutations in some genes have a 
well-known high risk of metastatic behavior, and; (4) therapeutic opportunities, since the 
identification of the mutated gene and the corresponding pathway opens up the possibility of 
new therapeutic approaches if surgery is not curative. Regarding this latter point, it has been 
proposed that mutations involving cluster 1 genes could be targeted using an antiangiogenic 
approach, mutations in cluster 2 genes could be treated by targeting the mTOR and the RAS–
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RAF pathway and, specifically, for FH-related and SDH-related malignant PPGLs, drugs targeting 
epigenetic pathways could be an option1,24,35,84.  
Finally, the identification of a somatic mutation avoids additional germline genetic screening as 
new susceptibility genes are discovered, which is associated with considerable anxiety and 
psychological ill health, especially in relatives of pediatric and metastatic cases33,35,97,206,207. 
In conclusion, the results of this study should bring to an end years of controversy and debate, 
as it brings new evidence that highlights the need to recommend genetic testing for all patients 
with PPGL, regardless of the apparent sporadic presentation, or the age at first PPGL diagnosis.  
In summary, Sanger sequencing of the appropriated gene in syndromic cases, as well as SDHB in 
pediatric, multiple and metastatic cases is still an effective first step approach, with TGPs as the 
most reasonable second step. In the case of S-PPGL, for laboratories where TGPs is not available 
or not optimized, we propose a genetic testing algorithm based on tumor location for sporadic 
single PPGL based on the present and previous findings5,35,94–99,112,116,208 (Figure 13). Where NGS 
can be used, the sample type that should be tested is tumor DNA for PCCs and germline DNA for 
HN-PGLs and T-PGLs. For A-PGLs, it seems crucial to have a FFPE tumor sample available in order 
to perform SDHB-IHC, the findings from which can be used to determine the ideal source of DNA 
sample to study.  
On the other hand, before applying TGPs in clinical setting, it is critical to ensure: adequate 
library preparation; high accuracy; and avoidance of false positive and negative results through 
the implementation of alternative techniques. Thus, this technology should be performed in 
specialized and accredited laboratories with expertise in PPGL8. 
Here, we have demonstrated the effectiveness and feasibility of this diagnostic tool, able to 
detect low-coverage, pool biased and indel variants. We conclude that our TGPs workflow 
enables the study of the main driver PPGL genes in different DNA sources, and improves the 
clinical management of index cases and their relatives at risk. In addition, TGPs is the optimal 
method to select cases that will benefit from further investigation in a research setting, as the 
etiology of one third of PPGL cases remains in the darkness.
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Figure 13. Proposed genetic testing algorithm for patients with sporadic-pheochromocytoma and paraganglioma (S-PPGL) based on SDHB-
immunohistochemistry (IHC) in formalin-fixed paraffin-embedded tissue (if available) and biochemical phenotype.  
This algorithm has been elaborated considering previous reports’ findings5,35,94–99,112,116,208 and the current series. (g), germline DNA; HN-PGL, head and neck-paraganglioma; 
PCC, pheochromocytoma; PGL, paraganglioma; (t), tumour DNA; TA-PGL, thoracic plus abdominal-paraganglioma. *Test if possible. 
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6.1 The results of this study bring new evidence regarding the need to recommend genetic 
testing for all patients with PPGL, regardless of the apparent sporadic presentation, or the 
age at diagnosis.  
6.2 It is also important to study somatic mutations in young patients, metastatic, and multiple 
cases. Furthermore, studying the tumor DNA of apparently familial cases can reveal 
phenocopies. Identifying a somatic mutation not only benefits family screening, diagnosis, 
prognosis, therapeutic opportunities, but also avoids additional germline genetic screening 
as new susceptibility genes are discovered, which is associated with considerable anxiety and 
psychological ill health. 
6.3 In S-PPGL, in addition to the predominant secretion and SDHB-IHC staining, our study 
highlights the utility of differentiating tumor location to select not only the most appropriate 
DNA sample (germline or tumor), but also the genes to be studied. For laboratories where 
TGPs are not available or not optimized, we have proposed a genetic testing algorithm using 
Sanger sequencing. Where NGS is available, the study of germline DNA should be prioritized 
in HN-PGLs and T-PGLs, while the study of tumor DNA should be recommended in PCCs. For 
A-PGLs, it seems appropriate to recommend germline study (starting with the SDH genes) in 
cases with tumors negative or without SDHB-IHC, and somatic screening (excluding the SDH 
genes) in those with positive SDHB-IHC staining.  
6.4 Sanger sequencing of the appropriated gene in syndromic cases, as well as SDHB in pediatric, 
multiple and metastatic cases is still an effective first step approach, being TGPs the most 
reasonable second step in the genetic diagnosis of PPGL.  
6.5 We have demonstrated the effectiveness and feasibility of two TGPs as diagnostic tools in 
the clinical setting, able to detect low-coverage, pool biased and indel variants. In addition, 
our TGPs-workflow enables the study of the main driver PPGL genes in different DNA sources 
with similar performance, and improves the clinical management of index cases and their 
relatives at risk. Furthermore, TGPs are the optimal methods to select cases that will benefit 
from further investigation in a research setting, as the etiology of one third of PPGL cases 
remains unknown.  
6.6 The access to the tumor sample is critical for a complete PPGL genetic screening and 
diagnosis. The study of tumor DNA as the first step allows “to kill three birds with one stone”, 
as allows the detection of germline, somatic and mosaic mutations. To note, FFPE tumor 
sample is very useful, as SDHB-IHC is not only used to guide the genetic study using Sanger 
108 
 
 
 
VI. Conclusions                                                                                                                                                                 .                                                    
 
sequencing in S-PPGL, but also in TGPs in the filtering process, as well as to test the 
pathogenicity of VUS.
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6.1 Los resultados de este estudio aportan nuevas evidencias sobre la necesidad de recomendar 
el estudio genético en todos los pacientes con feocromocitomas y paragangliomas (FPGL), 
independientemente de si la presentación es aparentemente esporádica (FPGL-E) o la edad 
en el momento del diagnóstico.  
6.2 Es importante estudiar la presencia de mutaciones somáticas en los pacientes jóvenes y/o 
con tumores metastásicos y/o múltiples. Además, el estudio del ADN tumoral de casos 
aparentemente familiares puede revelar la presencia de fenocopias. La identificación de una 
mutación somática, no sólo beneficia el consejo familiar, el diagnóstico, seguimiento y el 
planteamiento de las posible opciones terapéuticas, sino que también evita continuar 
insistiendo en el estudios genéticos del ADN germinal a medida que se descubren nuevos 
genes de susceptibilidad, que se asocia a la presencia de ansiedad considerable e 
inestabilidad emocional.  
6.3 Nuestro estudio pone de relieve que en los FPGL-E, además de la secreción predominante y 
el resultado de la inmunohistoquímica de SDHB (IHC-SDHB), es útil tener en cuenta la 
localización del tumor primario no sólo para determinar la muestra de ADN más apropiada 
(germinal o tumoral), sino también los genes a estudiar. En los laboratorios en los que los 
paneles de genes no están disponibles o no se han puesto a punto, hemos propuesto un 
algoritmo de diagnóstico genético utilizando la secuenciación por Sanger. En los laboratorios 
en los que los paneles de genes están disponibles, el estudio del ADN germinal debe ser 
priorizado en el caso de paragangliomas de cabeza, cuello y torácicos, y el estudio del ADN 
tumoral en el caso de feocromocitomas. En el caso de paragangliomas abdominales, 
recomendamos el estudio del ADN germinal (empezando por los genes SDH) en caso de 
tumores con el resultado de la IHC-SDHB negativo o no disponible, y el estudio del ADN 
tumoral (excluyendo el estudio de los genes SDH) en los casos con IHC-SDHB positiva.  
6.4 El primer paso más eficaz en el diagnóstico genético es el estudio mediante secuenciación 
por Sanger del gen apropiado en los casos sindrómicos, así como el de SDHB en los pacientes 
pediátricos y en aquellos con tumores múltiples y/o metastásicos, siendo los paneles de 
genes el segundo paso más razonable.  
6.5 Hemos demostrado la eficacia y viabilidad de dos paneles de genes como una herramienta 
de diagnóstico genético útil en la práctica clínica, capaces de detectar variantes con baja 
cobertura, variantes con sesgo de cobertura entre los dos diseños de amplicones y variantes 
de inserción y/o deleción. Además, nuestro algoritmo de trabajo basado en el uso de los 
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paneles de genes permite el estudio de los principales genes de FPGL en ADN de distinto 
origen con un rendimiento similar y mejora el manejo clínico de los casos índice y sus 
familiares. Además, los paneles de genes son el método óptimo para seleccionar los casos 
que se beneficiarán de ser incluidos en proyectos de investigación, dado que la causa de un 
tercio de los FPGL aún es desconocida.  
6.6 La accesibilidad a la muestra tumoral es fundamental para completar el cribado genético y 
diagnóstico de los FPGL. El estudio primario del ADN tumoral permite “matar tres pájaros de 
un tiro”, ya que permite la detección de mutaciones germinales, somáticas y de mosaico. Lo 
óptimo es disponer de la muestra tumoral parafinada. El resultado de la IHC-SDHB se puede 
utilizar no sólo para orientar el estudio genético mediante secuenciación por Sanger en FPGL 
esporádicos, sino también cuando se utilizan paneles de genes durante el proceso de filtrado 
de las variantes y para estudiar la patogenicidad de las variantes de significado desconocido 
encontradas.  
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VIII. APPENDIX I: SUPPLEMENTAL MATERIAL  
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CUESTIONARIO CLÍNICO 
 
Hospital:  
Médico responsable:                                                             Servicio:  
Email de contacto:                                                                  Teléfono contacto:  
Fecha registro (día/mes/año): 
PACIENTE  
 
Nombre y apellidos:  
Fecha nacimiento (día/mes/año):  
Sexo: Hombre  Mujer            Lugar de nacimiento:                                  
Etnia: Caucásica     Africana     Oriental     Sud-Americana  
Peso:  kg    Talla:   cm  (en la cita en la que se firma consentimiento) 
ANTECEDENTES PERSONALES 
 
Sospecha diagnóstica inicial: Incidentaloma      Síntomas      Screening*                                                               
*Screening por diagnóstico de CMT, por ser portador de mutación 
Diabetes mellitus: Si     No ; Año de diagnóstico de DM:  
Tensión arterial (TA):  
1. Normotensión     Hipotensión     HTA   
2. En caso de HTA:  persistente     paroxística  persistente con paroxismos  
3. Año de diagnóstico de HTA:  
4. TA en momento consentimiento(mmHg): Sistólica  Diastólica                                                                                                                               
REMITENTE 
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Otros síntomas de presentación: Marcar en caso afirmativo: 
        Palpitaciones     Cefalea     Sudoración     Dolor abdominal     Dolor lumbar 
 
        Otro:  
 
Enfermedad genética o síndrome: En caso afirmativo, indicar cuál:  
          MEN 2     VHL     NF 1     FEO/PGL familiar     Otro:  
          Mutación:  
Historia de tumores diferentes a feocromocitoma o paraganglioma: Si     No  
          Año de diagnóstico, localización y tipo:  
 
ANTECEDENTES FAMILIARES 
 
En caso afirmativo: Edad de diagnóstico, número, tipo y localización 
 FEO/PGL: 
 Otro tumor diferente a FEO/PGL:  
DIAGNÓSTICO 
 
Año de diagnóstico del primer feocromocitoma/paraganglioma:  
Número de tumores:  Metástasis: Si  No    
Múltiples tumores primarios: Si   No   
SI 1 TUMOR O EL QUE PROPICIA EL DIAGNÓSTICO:  
LOCALIZACIÓN:   
Adrenal izda    dcha    Torácica    Abdominal    Cervical    cuerpo carotídeo 
  glomus timpánico    glomus supraaórtico    glomus yugular/vagal   Otra:     
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Comentario:  
TAMAÑO (mm):  
BIOPSIA: Si      No      FECHA (día/mes/año):  
EMBOLIZACIÓN PREVIA:  Si      No      FECHA (día/mes/año):  
CIRUGÍA:  Si      No      FECHA (día/mes/año):  
Vía: Abierta      Laparoscópica     Reconversión*  
Descripción cirugía:  
- Invasión loco-regional: Si     No  
- Múltiples primarios: Si     No   En caso de respuesta afirmativa: Rellenar apartado Si 
> 1 tumor. 
- Metástasis: Si     No   En caso de respuesta afirmativa: Localización y número:  
- Resultado: Resección completa     Tejido residual    
- En caso de tejido residual, especificar: Microscópico   Macroscópico  
- Comentario:  
Complicaciones intra-operatorias:  Si     No   En caso de respuesta afirmativa: 
Hipotensión     Crisis HTA     Hipoglucemia     Arritmia     Otra:  
Complicaciones post-operatorias:  
INFORME ANATOMO-PATOLÓGICO:  
Diámetro máximo: X      Y      Z   mm 
Ki67 (%):                                                                                         Índice de proliferación:  
Número de mitosis por 10 campos de gran aumento:          Número de células contadas:  
Necrosis:  Si  No    
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Invasión: Capsular: Si   No     Adiposa: Si   No    
                 Vascular: Si   No     Órganos adyacentes: Si    No  
 
SI > 1 TUMOR:  
Método diagnóstico:   
Fecha diagnóstico:  
LOCALIZACIÓN:   
Adrenal izda    dcha    Torácica    Abdominal    Cervical    glomus carotídeo 
  glomus timpánico    glomus supraaórtico    glomus yugular/vagal   Otra: 
TAMAÑO (cm): 
BIOPSIA: Si      No      FECHA (día/mes/año):  
EMBOLIZACIÓN PREVIA:  Si      No      FECHA (día/mes/año):  
CIRUGÍA:  Si      No      FECHA (día/mes/año):  
Vía: Abierta      Laparoscópica     Reconversión*  
Descripción cirugía:  
- Invasión loco-regional: Si     No  
- Múltiples primarios: Si     No   En caso de respuesta afirmativa: Localización: 
- Metástasis: Si     No   En caso de respuesta afirmativa: Localización: 
- Resultado: Resección completa     Tejido residual    
- En caso de tejido residual, especificar: Microscópico   Macroscópico  
- Comentario: 
Medicación utilizada para la preparación pre-quirúrgica:  
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Complicaciones intra-operatorias:  Si     No   En caso de respuesta afirmativa: 
Hipotensión     Crisis HTA     Hipoglucemia     Arritmia     Otra:  
Complicaciones post-operatorias/secuelas:  
 
INFORME ANATOMO-PATOLÓGICO:  
Diámetro máximo: X      Y      Z   mm 
Ki67 (%):                                                                                         Índice de proliferación:  
Número de mitosis por 10 campos de gran aumento:          Número de células contadas:  
Necrosis:  Si  No    
Invasión: Capsular: Si   No     Adiposa: Si   No    
                 Vascular: Si   No     Órganos adyacentes: Si    No  
 
DIAGNÓSTICO BIOQUÍMICO 
PLASMA  
Unidades plasmáticas: pg/mL                ng/L            nmol/L  
Fecha extracción 
(día/mes/año): 
   
Adrenalina  
plasmática:                            
   
Noradrenalina 
plasmática:                
   
Dopamina 
plasmática: 
   
Catecolaminas 
plasmáticas: 
totales   
fraccionadas   
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Metanefrina libre 
plasmática: 
   
Normetanefrina libre 
plasmática:                
   
Metoxitiramina libre 
plasmática:   
   
Metanefrinas 
plasmáticas:   
totales   
fraccionadas     
   
Cromogranina A 
suero: 
   
 
ORINA  
24h                  Muestra aislada   
Unidades urinarias: µg/día          mg/día           µmol/día  
Fecha extracción 
(día/mes/año): 
   
Adrenalina libre 
urinaria:                
   
Noradrenalina libre 
urinaria:    
   
Dopamina urinaria:                    
Catecolaminas 
totales urinarias: 
totales   fraccionadas 
   
Ácido 
vanilmandélico/Ácido 
homovalínico:                  
   
Metanefrina urinaria:    
Normetanefrina 
urinaria: 
   
Metanefrinas 
urinarias: totales   
fraccionadas 
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OTRAS DETERMINACIONES REALIZADAS (Indicar unidades y rango) 
 Cortisol                                           ACTH 
 Andrógenos 
 Calcitonina 
 Ca plasmático                               Fósforo plasmático                              Calciuria  
               PTH                                                 vitamina D 
 Hematíes                                        hemoglobina                                        EPO  
 
DIAGNÓSTICO DE IMAGEN/EXTENSIÓN  
 Ecografía:              Positiva      Negativa               Metástasis: Si     No   
Fecha (día/mes/año): 
 TAC:                        Positiva      Negativa               Metástasis: Si     No   
Fecha (día/mes/año):  
                                       Positiva      Negativa               Metástasis: Si     No   
Fecha (día/mes/año): 
                                       Positiva      Negativa               Metástasis: Si     No   
Fecha (día/mes/año): 
 RMN:                      Positiva      Negativa               Metástasis: Si     No   
Fecha (día/mes/año): 
                                       Positiva      Negativa               Metástasis: Si     No   
Fecha (día/mes/año): 
                                       Positiva      Negativa               Metástasis: Si     No   
Fecha (día/mes/año): 
 MIBG:                     Positiva      Negativa               Metástasis: Si     No   
Fecha (día/mes/año):  
 Octreoscan:             Positivo      Negativo              Metástasis: Si     No   
Fecha (día/mes/año): 
 FDG-PET:                Positiva      Negativa               Metástasis: Si     No   
Fecha (día/mes/año):  
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 18F-DOPA-PET:         Positiva      Negativa               Metástasis: Si     No   
Fecha (día/mes/año): 
 Arteriografía:        Positiva      Negativa        
Fecha (día/mes/año): 
 Ecocardiograma:                       Positiva      Negativa        
Fecha (día/mes/año):   
 Otra:                       Positiva      Negativa        
Fecha (día/mes/año):   
 
TRATAMIENTOS NO QUIRÚRGICOS: Marcar en caso afirmativo   
 MIBG:                                                                                         Dosis: 
5. Ciclos recibidos:  
6. Fecha (día/mes/año) inicio-final: 
 Quimioterapia: Agente/s utilizados:                                     Dosis: 
7. Ciclos recibidos:  
8. Fecha (día/mes/año) inicio-final: 
 Ablación por radiofrecuencia: 
9. Fecha (día/mes/año) inicio-final: 
10. Localización:  
 Radioterapia externa:                                                             Dosis: 
11. Ciclos recibidos:  
12. Fecha (día/mes/año) inicio-final: 
13. Localización:  
 Radionúclidos: Agente utilizado:                                          Dosis: 
 Ciclos recibidos:  
 Fecha (día/mes/año) inicio-final: 
 Localización:  
 Quimioembolización: Agente utilizado:  
14. Fecha (día/mes/año): 
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15. Localización: 
 Tratamiento molecular: Agente utilizado:                          Dosis:  
16. Fecha (día/mes/año) inicio-final: 
 
SEGUIMIENTO 
Fecha última revisión (día/mes/año):  
Estado actual: 
 Fallecimiento: Fecha (día/mes/año):  
                                 Causa:  
 Vivo con enfermedad residual    
 Vivo libre de enfermedad 
Comentario:  
  
 
 
MUESTRA REMITIDA 
 TUMOR: Congelado     En parafina     DNA tisular  
Fecha extracción (día/mes/año): 
 TEJIDO NORMAL: Congelado  En parafina  DNA tisular  
Fecha extracción (día/mes/año): 
 SANGRE: ENTERA      SUERO    PLASMA      
En caso de plasma, especificar si: PLASMA EDTA     PLASMA HEPARINIZADO       
Fecha extracción (día/mes/año): 
 DNA leucocitos 
Fecha extracción (día/mes/año): 
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Supplementary table S1. Clinical and genetic data from the 329 patients included in the study.  
Nº ID 
Se
x 
Age Tumor 
Behaviou
r 
Diagnosis 
BC 
secretio
n  
Tumor 
sampl
e 
SDHB-IHC  Mutation  Gene  Mutation  
Date 
ressection 
primary tumor 
(or diagnosis if 
no ressection)  
Last 
follow-
up date 
Last 
follow-
up 
status  
Met. 
locatio
n 
Met.  
time  
Met.  
diagnosis  
1 3 M 59 HN-PGL  Benign  
sympt. 
(local mass) 
NS  
Froze
n and 
FFPE 
ND Germline  SDHC ∆ 
c.253_255du
pTTT, 
p.Phe85dup 
09/2003 04/2006 
Alive, 
disease 
free  
      
2 62 M 64 PCC Benign  
sympt. 
(adrenergic
) 
No sec.  FFPE  Positive  Somatic  HRAS 
c.37G>C, 
p.Gly13Arg 
01/1995 02/2014 
Alive, 
disease 
free 
      
3 78 M 11 PCC Benign  
sympt. 
(adrenergic
) 
Nad. FFPE  
Not 
available 
No      06/1999 02/2006 
Alive, 
disease 
free 
      
4 91 F 52 PCC Benign  
sympt. 
(adrenergic
) 
Nad. FFPE  Positive No      12/2002 03/2014 
Alive, 
disease 
free 
      
5 
11
8†  
F 64 PCC Benign  
inc. 
(surgery) 
NS  FFPE  Positive Somatic  HRAS 
c.182A>G, 
p.Gln61Arg 
01/2004 
(necropsy) 
01/2004 
Decease
d 
(necrops
y after 
cardiova
scular 
shock) 
      
6 
13
0 
M 74 PCC Benign  
sympt. 
(adrenergic
) 
Nad. FFPE  Positive No      10/2006 02/2014 
Alive, 
disease 
free 
      
7 
16
7 
M 51 PCC Benign  
sympt. 
(adrenergic
) 
A FFPE  Positive Somatic  HRAS 
c.181C>A, 
p.Gln61Lys 
06/2002 01/2012 
Alive, 
disease 
free 
      
8 
17
8 
F 22 PCC Benign  
sympt. 
(adrenergic
) 
Nad. FFPE  Positive No      03/1997 01/2014 
Alive, 
disease 
free 
      
9 
66
†  
F 19 A-PGL  
Malignan
t  
sympt. 
(adrenergic
) 
Nad. FFPE  ND Germline  
SDHB-
GD ∆ 
exon 1 gross 
deletion 
04/1997 01/2002 
Decease
d (no 
respons
e to 
chemot
herapy) 
Bone, 
liver 
and 
pituitar
y 
Metac.
, 15 
month
s after 
first 
 
 
Image (MR, 
MIBG) and 
BC study. 
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surger
y 
 
10 
23
5 
M 76 PCC Benign  
inc. 
(surgery) 
No sec.  FFPE  Positive No      01/2004 02/2014 
Alive, 
disease 
free 
      
11 
28
7 
F 68 HN-PGL  Benign  
sympt. 
(local mass) 
NS  FFPE  
Not 
available 
No      02/2006 02/2006 
Alive, 
post-
surgery 
      
12 
29
9 
F 32 A-PGL  
Malignan
t  
sympt. 
(adrenergic
) 
Nad. FFPE  Positive No      04/2006 02/2013 
Alive, 
disease 
free 
Local 
lymph 
node  
Sync.  AP study  
13 
33
5 
F 62 A-PGL  Benign  inc. (image) Nad. FFPE  Positive Somatic  EPAS1  
c.1592C>T, 
p.Pro531Leu 
04/2008 05/2011 
Alive, 
disease 
free 
      
14 
34
4 
F 52 PCC 
Malignan
t  
NS NS  FFPE  Positive Somatic  EPAS1  
c.1606C>A, 
p.Asp536Tyr 
08/2001 05/2009 
Alive, 
met.  
Local 
lymph 
node 
Metac. 
, 36 
month
s after 
first 
surger
y  
Image 
(MIBG) 
15 
37
9 
F 51 A-PGL  Benign  
inc. 
(surgery) 
NS  FFPE  Positive Somatic  HRAS 
c.181C>A, 
p.Gln61Lys  
04/2005 11/2009 
Alive, 
disease 
free 
      
16 
39
6 
F 53 A-PGL  Benign  
sympt. 
(local mass) 
No sec.  FFPE  Positive Somatic  HRAS 
c.37G>C, 
p.Gly13Arg 
05/2010 11/2010 
Alive, 
disease 
free 
      
17 
41
9 
F 59 HN-PGL  Benign  NS NS  FFPE  Positive  No      11/2006 11/2006 
Alive, 
post-
surgery  
      
18 
45
0 
F 51 HN-PGL  Benign  
sympt. 
(adrenergic
) 
No sec.  FFPE  Positive No      11/2011 05/2014 
Alive, 
disease 
free 
      
19 
45
2 
F 50 A-PGL  Benign  
sympt. 
(adrenergic
) 
Nad. FFPE  Positive No      01/2011 01/2013 
Alive, 
disease 
free 
      
20 
46
0 
F 62 PCC 
Malignan
t  
sympt. 
(adrenergic
) 
A FFPE  Positive  Somatic  HRAS 
c.182A>G, 
p.Gln61Arg 
05/2009 01/2013 
Alive, 
disease 
free 
Local 
lymph 
node 
Sync.  AP study  
21 
10
3 
M 70 PCC Benign  NS NS  
Froze
n  
ND Somatic  RET 
c.1900T>C, 
p.Cys634Arg 
01/2000 06/2003 
Alive, 
disease 
free 
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22 
47
0 
M 51 PCC Benign  inc. (image) Nad. FFPE  Positive No      11/2011 07/2012 
Alive, 
disease 
free 
      
23 
47
8 
M 47 A-PGL  Benign  inc. (image) Nad. FFPE  Positive No      06/2012 06/2012 
Alive, 
post-
surgery 
      
24 
48
2 
F 76 T-PGL  Benign  NS NS  FFPE  Positive No      06/2011 06/2014 
Alive, 
disease 
free 
      
25 
48
4 
M 45 A-PGL  Benign  NS Nad. FFPE  Positive No      07/2012 01/2013 
Alive, 
disease 
free 
      
26 
49
3 
M 52 HN-PGL  Benign  
sympt. 
(local mass) 
No sec.  FFPE  Positive No      10/2012 10/2012 
Alive, 
post-
surgery 
      
27 
50
7 
F 70 PCC 
Malignan
t  
sympt. 
(adrenergic
) 
NS  FFPE  Positive No      08/2011 02/2013 
Alive, 
met.  
Bone 
and 
liver 
Sync.   
Image (CT, 
MR, 
Octreoscan) 
and BC 
study  
28 
50
8 
F 62 HN-PGL  
Malignan
t  
sympt. 
(local mass) 
Nad. FFPE  Positive No      01/2014 02/2014 
Alive, 
post-
surgery 
Local 
lymph 
node 
Sync.  AP study  
29 
51
2 
F 46 PCC Benign  inc. (image) Nad. FFPE  Positive No      10/2009 01/2014 
Alive, 
disease 
free 
      
30 
24
2 
M 25 PCC Benign  
sympt. 
(adrenergic
) 
Nad. 
Froze
n and 
FFPE 
Positive Somatic  VHL 
c.250G>C, 
p.Val84Leu  
12/2002 01/2006 
Alive, 
disease 
free 
      
31 
58
7†  
M 81 A-PGL  Benign  
sympt. 
(adrenergic
) 
A FFPE  Positive Somatic  HRAS 
c.181C>A, 
p.Gln61Lys 
05/2007 01/2012 
Decease
d (heart 
attack, 
disease 
free) 
      
32 
59
1 
F 26 PCC Benign  
sympt. 
(adrenergic
) 
Nad. FFPE  Positive No      04/2007 02/2013 
Alive, 
disease 
free 
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33 
59
4 
F 45 PCC Benign  
sympt. 
(adrenergic
) 
Nad. FFPE  Positive No      08/2006 06/2013 
Alive, 
disease 
free 
      
34 
59
9 
M 74 PCC Benign  inc. (image) Nad. FFPE  Positive No      02/2007 06/2012 
Alive, 
disease 
free 
      
35 
60
0 
F 47 PCC Benign  
sympt. 
(adrenergic
) 
Nad. FFPE  Positive No      03/2007 11/2011 
Alive, 
disease 
free 
      
36 
61
2 
M 56 PCC Benign  inc. (image) Nad. FFPE  Positive No      06/2007 02/2014 
Alive, 
disease 
free 
      
37 
62
1 
M 29 PCC Benign  inc. (image) A FFPE  Positive  No      04/2009 01/2014 
Alive, 
disease 
free 
      
38 
63
0 
M 42 PCC Benign  
sympt. 
(adrenergic
) 
A FFPE  Positive No      04/2010 12/2012 
Alive, 
disease 
free 
      
39 
63
6 
M 42 PCC Benign  inc. (image) NS  FFPE  Positive Somatic  HRAS 
c.182A>G, 
p.Gln61Arg 
07/1996 07/2010 
Alive, 
disease 
free 
      
40 
63
7 
F 9 PCC Benign  
sympt. 
(adrenergic
) 
Nad. FFPE  Positive No      10/2009 01/2013 
Alive, 
disease 
free 
      
41 
64
1 
M 57 PCC Benign  
sympt. 
(adrenergic
) 
Nad. FFPE  Positive No      03/2008 
04/2001
4 
Alive, 
disease 
free 
      
42 
15
7 
M 30 A-PGL  Benign  
sympt. 
(adrenergic
) 
Nad. No  ND Germline  
SDHB-
GD ∆ 
exon 1 gross 
deletion 
02/2001 07/2001 
Alive, 
disease 
free 
      
43 
64
7 
F 28 PCC Benign  
sympt. 
(adrenergic
) 
A FFPE  Positive Somatic  HRAS 
c.182A>G, 
p.Gln61Arg 
01/2001 11/2010 
Alive, 
disease 
free 
      
44 
64
9 
M 14 PCC Benign  
sympt. 
(adrenergic
) 
Nad. FFPE  Positive Somatic  VHL 
c.260T>C, 
p.Val87Ala   
07/2011 03/2013 
Alive, 
disease 
free 
      
45 
65
3 
M NS PCC Benign  NS NS  FFPE  Positive Somatic  RET 
c.2753T>C, 
p.Met918Thr  
01/2013 01/2013 
Alive, 
post-
surgery 
      
46 
65
7†  
F 75 PCC Benign  
sympt. 
(adrenergic
) 
Nad. FFPE  Positive Somatic  EPAS1  
c.1592C>T, 
p.Pro531Leu 
11/1996 09/2013 
Decease
d 
(unknow
n cause, 
but 
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PPGL 
free 
47 
17
5 
F 36 T-PGL  
Malignan
t  
inc. 
(surgery) 
Nad. FFPE  ND Germline  SDHB ∆ 
c.278G>A, 
p.Cys93Tyr 
01/2001 
(palliative 
surgery) 
05/2013 
Alive, 
met. 
(palliativ
e 
surgery) 
Bone 
and 
lung  
Metac. 
, 24 
month
s after 
palliati
ve 
surger
y 
Image (MR, 
MIBG) and 
BC study  
48 
65
8†  
F 75 PCC Benign  NS NS  FFPE  Positive Somatic  HRAS ◊ 
c.182A>G, 
p.Gln61Arg 
01/1998 03/1999 
Decease
d 
(unknow
n) 
      
49 
65
9 
F 27 PCC Benign  
sympt. 
(adrenergic
) 
A FFPE  Positive Somatic  HRAS 
c.182A>G, 
p.Gln61Arg 
02/1999 01/2003 
Alive, 
disease 
free 
      
50 
88
6 
M 57 PCC Benign  inc. (image) A FFPE  Positive No      02/2013 06/2013 
Alive, 
disease 
free 
      
51 
88
9 
F 43 PCC Benign  
sympt. 
(adrenergic
) 
A FFPE  Positive Somatic  RET 
c.2753T>C, 
p.Met918Thr 
04/2013 02/2014 
Alive, 
disease 
free 
      
52 
89
0 
F 49 PCC Benign  
sympt. 
(adrenergic
) 
Nad. FFPE  Positive No      01/2013 04/2013 
Alive, 
disease 
free 
      
53 
97
1 
M 20 PCC 
Malignan
t  
sympt. 
(adrenergic
) 
Nad. FFPE  Positive  No      09/2007 02/2013 
Alive, 
disease 
free 
Local 
lymph 
node, 
bona 
and 
liver 
Sync.  
(local 
lymph 
node) 
and 
Metac.  
(bone 
and 
liver, 
36 
month
s after  
the 
first 
surger
y) 
Image (MR, 
MIBG, FDG-
PET) and BC 
study 
54 
10
04 
F 45 A-PGL  
Malignan
t  
sympt. 
(local mass) 
NS  FFPE  
Negative 
and 
Somatic SDHD 
c.112C>T, 
p.Arg38* 
05/2010 06/2014 
Alive, 
met.  
Bone, 
lung 
Sync.  
(bone) 
Image (MR, 
MIBG, 
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positive 
IHC SDHA 
and 
liver 
and 
Metac.  
(lung 
and 
liver)  
Octreoscan) 
and BC 
study  
55 
10
07 
M 68 PCC Benign  NS NS  FFPE  Positive  No      01/2014 01/2014 
Alive, 
post-
surgery  
      
56 
10
10 
M 42 A-PGL  Benign  NS NS  FFPE  Positive No      11/2013 07/2014 
Alive, 
local 
residual 
disease 
      
57 
46
5 
F 15 A-PGL  Benign  
sympt. 
(local mass) 
Nad. FFPE  Positive  Somatic  VHL 
c.191G>C, 
p.Arg64Pro 
07/2011 08/2011 
Alive, 
post-
surgery  
      
58 63 F 35 PCC Benign  
sympt. 
(adrenergic
) 
NS  
Froze
n 
ND  Somatic  RET 
c.2753T>C, 
p.Met918Thr  
04/1999 04/1999 
Alive, 
post-
surgery  
      
59 
13
3 
F 38 PCC Benign  NS NS  
Froze
n 
ND Somatic  HRAS 
c.182A>G, 
p.Gln61Arg 
01/2009 10/2009 
Alive, 
disease 
free 
      
60 
14
5 
F 51 PCC Benign  
sympt. 
(local mass) 
A 
Froze
n 
ND Somatic  NF1 
c.6855C>A, 
p.Tyr2285* 
11/2010 11/2010 
Alive, 
post-
surgery 
      
61 
15
0 
M 26 PCC Benign  
sympt. 
(adrenergic
) 
A 
Froze
n 
ND  No      10/2011 01/2013 
Alive, 
disease 
free 
      
62 
17
7 
F 37 PCC Benign  
sympt. 
(adrenergic
) 
High, 
but NS  
Froze
n 
ND  No      01/2002 02/2014 
Alive, 
disease 
free 
      
63 
24
3 
M 16 A-PGL  Benign  
sympt. 
(adrenergic
) 
High, 
but NS  
FFPE  ND Germline SDHB 
c.166_170del
CCTCA, 
p.Pro56delTy
rfs*5 
06/2005 04/2013 
Alive, 
disease 
free 
      
64 
18
3 
F 48 A-PGL  Benign  
inc. 
(surgery) 
NS  
Froze
n 
ND  No      01/2002 02/2006 
Alive, 
disease 
free 
      
65 
25
1 
M 53 HN-PGL  Benign  NS NS  No  ND Germline  SDHD 
c.334_337del
ACTG, 
p.Asp113Met
fs*21 
01/2001  06/2008 
Alive, 
disease 
free 
      
66 
20
5 
F 63 PCC Benign  
sympt. 
(adrenergic
) 
Nad. 
Froze
n 
ND  No      03/2003 01/2006 
Alive, 
disease 
free 
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67 
28
6 
M 61 A-PGL  Benign  
inc. 
(surgery) 
NS  
Froze
n 
ND No      11/2005 02/2006 
Alive, 
disease 
free 
      
68 
28
8 
M 59 A-PGL  Benign  
inc. 
(surgery) 
NS  
Froze
n 
ND No      01/2003 01/2006 
Alive, 
disease 
free 
      
69 
30
5 
M 75 A-PGL  Benign  inc. (image) A 
Froze
n 
ND No      04/2007 12/2009 
Alive, 
disease 
free 
      
70 
40
3 
M 56 A-PGL  Benign  inc. (image) Nad. 
Froze
n 
ND Somatic  SDHB  
c.464C>G, 
p.Pro155Arg 
10/2010 07/2013 
Alive, 
disease 
free 
      
71 
27
8 
M 12 A-PGL  Benign  NS NS  No  ND Germline 
SDHB 
‡/∆ 
c.166_170del
CCTCA, 
p.Pro56delTy
rfs*5 
11/2005 11/2005 
Alive, 
post-
surgery  
      
72 
46
4 
F 24 A-PGL  Benign  
sympt. 
(adrenergic
) 
Nad. 
Froze
n 
ND  No      03/2012 08/2013 
Alive, 
disease 
free 
      
73 
47
5 
F 78 PCC Benign  inc. (image) 
High, 
but NS  
Froze
n 
ND  Somatic  HRAS 
c.182A>G, 
p.Gln61Arg 
06/2012 03/2013 
Alive, 
disease 
free 
      
74 
48
0 
F 51 PCC Benign  
sympt. 
(adrenergic
) 
Nad. 
Froze
n 
ND  Somatic  VHL 
c.389T>G, 
p.Val130Gly 
07/2012 11/2012 
Alive, 
disease 
free 
      
75 
60
1 
F 65 PCC Benign  
sympt. 
(adrenergic
) 
A 
Froze
n 
ND No      06/2007 09/2008 
Alive, 
unknow
n 
      
76 
51
3 
M 19 PCC Benign  inc. (image) 
High, 
but NS  
FFPE  Positive Somatic  VHL 
c.475A>G, 
p.Lys159Glu  
10/2012 05/2013 
Alive, 
disease 
free 
      
77 
62
8 
M 52 PCC Benign  
sympt. 
(adrenergic
) 
High, 
but NS  
Froze
n 
ND No      01/2010 01/2010 
Alive, 
post-
surgery 
      
78 
61
9 
M 14 PCC Benign  
sympt. 
(adrenergic
) 
Nad. 
Froze
n 
ND Somatic  VHL 
c.496G>T, 
p.Val166Phe 
03/2009 03/2009 
Alive, 
post-
surgery 
      
79 
75
1 
F 48 PCC Benign  NS NS  
Froze
n 
ND Somatic  RET 
c.2753T>C, 
p.Met918Thr  
01/2003 11/2008 
Alive, 
disease 
free 
      
80 
76
4 
F 68 PCC Benign  inc. (image) No sec.  
Froze
n 
ND Somatic  HRAS ◊ 
c.182A>G, 
p.Gln61Arg 
03/2010 05/2013 
Alive, 
disease 
free 
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81 
89
3 
F 63 PCC Benign  
sympt. 
(adrenergic
) 
A 
Froze
n 
(finish
ed) 
ND No      07/2013 09/2013 
Alive, 
disease 
free 
      
82 
28
5 
M 59 HN-PGL  Benign  NS NS  
Froze
n  
ND No      07/2005 07/2005 
Alive, 
post-
surgery 
      
83 
40
7 
F 29 HN-PGL  Benign  
sympt. 
(local mass) 
NS  
Froze
n  
ND No      10/2010 03/2012 
Alive, 
disease 
free 
      
84 
30
1 
M 27 HN-PGL  
Malignan
t  
inc. 
(surgery) 
No sec.  No  ND Germline  SDHB  
c.166_170del
CCTCA, 
p.Pro56delTy
rfs*5 
10/2001 11/2012 
Alive, 
disease 
free 
Local 
lymph 
node  
Sync.  AP study  
85 
10
0 
F 56 PCC Benign  
sympt. 
(adrenergic
) 
High, 
but NS  
Froze
n and 
FFPE 
Positive No      07/2002 02/2014 
Alive, 
disease 
free 
      
86 
13
6 
F 42 PCC Benign  
sympt. 
(adrenergic
) 
Nad. 
Froze
n and 
FFPE 
Positive No      06/2009 01/2014 
Alive, 
disease 
free 
      
87 
30
7 
M 40 HN-PGL  Benign  NS No sec.  No  ND Germline SDHD ∆ 
c.168_169del
TT, 
p.Ser57Trpfs
*11 
08/2007 
diagnosis, 
surgery 
unknown 
08/2007 
Alive, 
unknow
n 
      
88 
15
2 
F 54 PCC Benign  
inc. 
(surgery) 
A 
Froze
n and 
FFPE 
Positive No      09/2011 07/2013 
Alive, 
disease 
free 
      
89 
31
1 
F 22 A-PGL  
Malignan
t  
sympt. 
(local mass) 
No sec.  No  ND Germline  SDHD ∆ 
c.210G>T, 
p.Arg70Ser 
02/2006 09/2013 
Alive, 
met.  
Local 
lymph 
nodes 
and 
lung  
Sync.  AP study  
90 
31
2 
F 32 T-PGL  
Malignan
t  
sympt. 
(adrenergic
) 
Nad. 
Froze
n 
ND Germline  SDHB ∆ 
c.166_170del
CCTCA, 
p.Pro56delTy
rfs*5 
10/2007 11/2011 
Alive 
,met. 
Bone    Sync.  AP study  
91 
16
5 
F 69 HN-PGL  Benign  
sympt. 
(local mass) 
NS  
Froze
n and 
FFPE 
Positive No      06/2002 06/2002 
Alive, 
post-
surgery 
      
92 
32
7 
M 14 A-PGL  Benign  
sympt. 
(adrenergic
) 
NS  
Froze
n 
ND Germline  
SDHB-
GD ‡ 
exon 1 gross 
deletion 
03/2007 07/2008 
Alive, 
disease 
free 
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93 
63
1 
M 35 PCC Benign  inc. (image) Nad. 
Froze
n and 
FFPE 
Positive Somatic  VHL 
c.260T>C, 
p.Val87Ala 
01/2010 08/2010 
Alive, 
disease 
free 
      
94 
33
0 
M 40 A-PGL  Benign  
sympt. 
(local mass) 
NS  FFPE  ND Germline SDHB ∆ c.424-3C>G 04/2008 06/2008 
Alive, 
disease 
free 
      
95 
26
8 
F 53 A-PGL  Benign  
sympt. 
(adrenergic
) 
High, 
but NS  
Froze
n and 
FFPE 
Positive No      07/2004 09/2006 
Alive, 
disease 
free 
      
96 
41
8 
M 64 A-PGL  
Malignan
t  
inc. (image) Nad. 
Froze
n and 
FFPE 
Positive  No      12/2010 03/2014 
Alive, 
met.  
Local 
lymph 
node 
Sync.  AP study  
97 
53
8 
M 46 PCC Benign  
sympt. 
(adrenergic
) 
Nad. 
Froze
n and 
FFPE 
Positive No      03/2004 12/2004 
Alive, 
disease 
free 
      
98 
34
0 
F 38 HN-PGL  Benign  NS NS  No  ND Germline SDHD  
c.2T>C, 
p.Met1? 
01/2008 11/2008 
Alive, 
unknow
n 
      
99 
55
0 
M 45 PCC Benign  
sympt. 
(adrenergic
) 
A 
Froze
n and 
FFPE 
Positive Somatic  HRAS ◊ 
c.182A>G, 
p.Gln61Arg 
04/2004 07/2014 
Alive, 
disease 
free 
      
10
0 
55
3 
M 57 PCC Benign  NS NS  
Froze
n and 
FFPE 
Positive Somatic  RET 
c.2753T>C, 
p.Met918Thr  
10/2004 01/2005 
Alive, 
disease 
free  
      
10
1 
58
1 
M 36 PCC Benign  
sympt. 
(adrenergic
) 
Nad. 
Froze
n and 
FFPE 
Positive Somatic  VHL 
c.482G>A, 
p.Arg161Gln 
01/2006 02/2014 
Alive, 
disease 
free 
      
10
2 
63
5 
F 30 PCC Benign  
sympt. 
(adrenergic
) 
High, 
but NS  
Froze
n and 
FFPE 
Positive Somatic  VHL 
c.491A>G, 
p.Gln164Arg  
01/2002 01/2005 
Alive, 
disease 
free 
      
10
3 
72
8 
F 46 PCC Benign  NS NS  
Froze
n 
ND Somatic  EPAS1* 
c.1599_1604
delCCCCAT, 
p.Ile533_Pro
534del  
01/2003 10/2010 
Alive, 
disease 
free 
      
10
4 
64
3 
F 27 PCC Benign  
sympt. 
(adrenergic
) 
Nad. 
Froze
n and 
FFPE 
Positive No      02/2011 11/2011 
Alive, 
disease 
free 
      
10
5 
72
7 
F 78 A-PGL  Benign  NS NS  
Froze
n and 
FFPE 
Positive Somatic  EPAS1* 
c.1615G>T, 
p.Asp539Tyr 
07/2003 07/2003 
Alive, 
post-
surgery 
      
10
6 
75
9 
F 42 PCC Benign  
sympt. 
(adrenergic
) 
Nad. 
Froze
n and 
FFPE 
Positive No      12/2012 12/2012 
Alive, 
post-
surgery 
      
159 
 
10
7 
35
2 
F 46 A-PGL  
Malignan
t  
inc. (image) NS  No  ND Germline  SDHB  
c.725G>A, 
p.Arg242His 
No surgery, 
06/2008 (only 
biopsy) 
03/2009 
Alive, 
met. (no 
surgery)  
Liver 
and 
local 
lymph 
node 
Sync.  AP study  
10
8 
35
3 
M 32 HN-PGL  
Malignan
t  
sympt. 
(local mass) 
No sec.  No  ND Germline  SDHB  
c.269G>A, 
p.Arg90Gln 
02/2008 04/2008 
Alive, 
disease 
free 
Bone Sync.  AP study  
10
9 
76
0 
M 58 PCC Benign  NS A 
Froze
n and 
FFPE 
Positive Somatic  RET 
c.2753T>C, 
p.Met918Thr  
01/2013 01/2013 
Alive, 
post-
surgery  
      
11
0 
36
4 
F 67 HN-PGL  Benign  
sympt. 
(adrenergic
) 
No sec.  No  ND Germline  SDHB  
c.557G>A, 
p.Cys186Tyr 
No surgery, 
diagnosis 
02/2009  
09/2009 
Alive, 
stable 
disease 
(no 
surgery)  
      
11
1 
36
5 
M 25 HN-PGL  Benign  NS No sec.  No  ND Germline SDHB  
c.166_170del
CCTCA, 
p.Pro56delTy
rfs*5 
01/2009 10/2009 
Alive, 
disease 
free 
      
11
2 
36
8 
M 23 A-PGL  Benign  
sympt. 
(adrenergic
) 
Nad. No  ND Germline SDHB  
c.166_170del
CCTCA, 
p.Pro56delTy
rfs*5 
06/2006 11/2009 
Alive, 
disease 
free 
      
11
3 
96
7 
F 38 A-PGL  Benign  
sympt. 
(adrenergic
) 
Nad. 
Froze
n and 
FFPE 
Positive  Somatic  EPAS1  
c.1592C>T, 
p.Pro531Leu 
10/2013 10/2013 
Alive, 
post-
surgery  
      
11
4 
10
05 
M 65 PCC Benign  NS NS  
Froze
n and 
FFPE 
Positive  No      11/2010 11/2010 
Alive, 
post-
surgery 
      
11
5 
40
5 
F 48 HN-PGL  Benign  
sympt. 
(local mass) 
No sec.  No ND No      10/2009 10/2010 
Alive, 
local 
recurren
ce 
      
11
6 
49
8 
F 27 PCC Benign  inc. (image) Nad. FFPE  Positive Somatic VHL 
c.227T>A, 
p.Phe76Tyr 
06/2012 01/2013 
Alive, 
disease 
free 
      
11
7 
50
1 
F 78 PCC Benign  inc. (image) Nad. No ND No      07/2014 07/2014 
Alive, 
post-
surgery 
      
11
8 
10
15 
M 51 PCC Benign  inc. (image) Nad. No ND No      12/2010 03/2014 
Alive, 
disease 
free 
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11
9 
10
20 
F 53 PCC Benign  inc. (image) Nad. No ND No      05/2014 06/2014 
Alive, 
post-
surgery 
      
12
0 
10
23 
M 78 A-PGL  Benign  inc. (image) Nad. No ND No      02/2014 02/2014 
Alive, 
post-
surgery  
      
12
1 
10
24 
F 35 PCC Benign  NS Nad. No ND No      01/2012 04/2014 
Alive, 
disease 
free 
      
12
2 
5 F 56 A-PGL  Benign  
inc. 
(surgery) 
NS  No  ND No      12/2005 11/2006 
Alive, 
disease 
free  
      
12
3 
35 F 62 PCC Benign  
sympt. 
(adrenergic
) 
High, 
but NS  
No  ND No      12/1994 01/2006 
Alive, 
disease 
free 
      
12
4 
40
0 
F 42 HN-PGL  Benign  NS NS  No  ND Germline  
SDHB-
GD 
exon 1 gross 
deletion 
No surgery, 
diagnosis 
01/2010 
09/2010 
Alive, 
stable 
disease 
(no 
surgery) 
      
12
5 
56
†  
F 56 PCC Benign  
sympt. 
(adrenergic
) 
Nad. No  ND No      11/1998 01/2010 
Decease
d 
(liposarc
oma, 
but 
PPGL 
free) 
      
12
6 
64 F 34 PCC Benign  
sympt. 
(local mass) 
A No  ND No      04/1999 03/2014 
Alive, 
disease 
free 
      
12
7 
65 F 62 A-PGL  Benign  inc. (image) 
High, 
but NS  
No  ND No      07/1999 01/2013 
Alive, 
disease 
free 
      
12
8 
77 F 37 PCC Benign  
sympt. 
(adrenergic
) 
NS  No  ND No      12/1992 02/2014 
Alive, 
disease 
free 
      
12
9 
79 F 42 PCC Benign  NS NS  No  ND No      01/2000 01/2000 
Alive, 
post-
surgery  
      
13
0 
80 M 40 PCC Benign  NS NS  No  ND No      01/2000 01/2000 
Alive, 
post-
surgery  
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13
1 
82 M 23 PCC Benign  inc. (image) A No  ND No      01/1998 01/2006 
Alive, 
disease 
free 
      
13
2 
41
3 
F 44 HN-PGL  Benign  NS NS  No  ND Germline SDHB  
c.544_550del
GGGCTCT, 
p.Gly182Thrf
s*36 
12/2010 
diagnosis, 
surgery 
unknown 
12/2010 
Alive, 
unknow
n 
      
13
3 
92 F 42 PCC Benign  NS NS  No  ND No      01/2002 01/2002  
Alive, 
post-
surgery 
      
13
4 
97 F 48 PCC Benign  
inc. 
(surgery) 
NS  No  ND No      01/1997 01/2006 
Alive, 
disease 
free 
      
13
5 
98 M 31 PCC Benign  NS NS  No  ND No      11/2002 11/2002 
Alive, 
post-
surgery  
      
13
6 
99 F 59 PCC Benign  NS Nad. No  ND No      01/1987 03/2012 
Alive, 
disease 
free 
      
13
7 
10
7 
F NS PCC Benign  NS NS  No  ND No      01/2004 01/2004 
Alive, 
post-
surgery 
      
13
8 
10
8 
F 63 PCC Benign  NS NS  No  ND No      01/2004 01/2004 
Alive, 
post-
surgery 
      
13
9 
12
1 
F 39 PCC Benign  
sympt. 
(adrenergic
) 
A No  ND No      11/2004 09/2005 
Alive, 
disease 
free 
      
14
0 
42
4 
F 26 A-PGL  Benign  
sympt. 
(adrenergic
) 
Nad. FFPE  
Negative 
and 
negative 
SDHA-IHC 
Germline SDHA 
c.1754G>A, 
p.Arg585Gln 
12/2007 03/2012 
Alive, 
disease 
free 
      
14
1 
42
5 
F 53 HN-PGL  Benign  inc. (image) Nad. No  ND No      
No surgery, 
12/2009 (only 
biopsy) 
03/2012 
Alive, 
increasi
ng 
disease 
(no 
surgery) 
      
14
2 
12
3 
F 34 PCC Benign  NS NS  No  ND No      01/2007 06/2007 
Alive, 
disease 
free 
      
14
3 
12
9 
F 55 PCC Benign  NS NS  No  ND No      01/2007 02/2008 
Alive, 
disease 
free 
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14
4 
43
0 
M 37 A-PGL  Benign  NS NS  No  ND Germline  
SDHB-
GD 
exon 1 gross 
deletion 
01/2010 04/2011 
Alive, 
disease 
free 
      
14
5 
13
1 
F 21 PCC Benign  
sympt. 
(adrenergic
) 
NS  No  ND No      01/1994 04/2009 
Alive, 
disease 
free 
      
14
6 
13
4 
F 59 PCC Benign  
sympt. 
(adrenergic
) 
Nad. No  ND No      11/1994 01/2010 
Alive, 
disease 
free 
      
14
7 
43
3 
M 60 T-PGL  
Malignan
t  
inc. (image) Nad. FFPE  ND Germline  SDHB  c.287-3C>G 
No surgery, 
12/2010 (only 
biopsy) 
01/2011 
Alive, 
met. (no 
surgery) 
Bone 
and 
local 
lymph 
node  
Sync.  AP study  
14
8 
13
5 
M 36 PCC Benign  
sympt. 
(adrenergic
) 
A No  ND No      11/2007 07/2010 
Alive, 
disease 
free 
      
14
9 
13
9 
F 28 PCC Benign  
sympt. 
(adrenergic
) 
NS  No  ND No      02/2002 03/2010 
Alive, 
disease 
free 
      
15
0 
44
1 
M 28 HN-PGL  Benign  NS NS  No  ND Germline SDHD  
c.191_192del
TC, 
p.Leu64Profs
*4 
No surgery, 
diagnosis 
01/2010 
06/2011 
Alive, 
stable 
disease 
(no 
surgery) 
      
15
1 
44
2 
M 20 A-PGL  Benign  
sympt. 
(adrenergic
) 
Nad. 
Froze
n 
ND Germline SDHB  c.423+1G>A 01/2011 06/2011 
Alive, 
local 
residual 
disease 
      
15
2 
44
4 
F 40 HN-PGL  Benign  NS A FFPE  Negative Germline SDHAF2 
c.362G>A, 
p.Trp121* 
02/2007 02/2012 
Alive, 
disease 
free 
      
15
3 
14
6 
M 45 PCC Benign  NS NS  No  ND No      01/2009 10/2010 
Alive, 
disease 
free 
      
15
4 
14
7 
M 67 PCC Benign  
sympt. 
(local mass) 
NS  No  ND No      01/2008 03/2011 
Alive, 
disease 
free 
      
15
5 
44
9 
F 15 A-PGL  Benign  
sympt. 
(adrenergic
) 
Nad. 
Froze
n 
ND  Germline  SDHA c.457-1A>G 11/2011 12/2011 
Alive, 
post-
surgery 
      
15
6 
14
8 
F 64 PCC Benign  
sympt. 
(adrenergic
) 
A No  ND No      02/2011 03/2011 
Alive, 
post-
surgery 
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15
7 
14
9 
M 36 PCC Benign  inc. (image) Nad. No  ND No      02/2011 10/2014 
Alive, 
disease 
free 
      
15
8 
15
8 
F 36 HN-PGL  Benign  
inc. 
(surgery) 
No sec.  No  ND No      11/2000 11/2006 
Alive, 
disease 
free 
      
15
9 
16
8 
F 43 PCC Benign  
sympt. 
(adrenergic
) 
Nad. No  ND No      01/1998 04/2006 
Alive, 
disease 
free 
      
16
0 
17
9 
F 69 PCC Benign  
sympt. 
(adrenergic
) 
Nad. No  ND No      12/2002 12/2002 
Alive, 
post-
surgery 
      
16
1 
18
0 
F 51 PCC Benign  
sympt. 
(adrenergic
) 
High, 
but NS  
No  ND No      02/2002 02/2006 
Alive, 
disease 
free 
      
16
2 
18
9 
M 72 A-PGL  Benign  inc. (image) A No  ND No      02/2001 12/2003 
Alive, 
disease 
free 
      
16
3 
19
0 
M 40 PCC Benign  inc. (image) Nad. No  ND No      03/2002 01/2013 
Alive, 
disease 
free 
      
16
4 
19
1 
F 50 T-PGL  Benign  NS NS  No  ND No      01/1997 01/2003 
Alive, 
disease 
free 
      
16
5 
19
2 
F 27 PCC Benign  NS NS  No  ND No      06/1988 01/2002 
Alive, 
disease 
free 
      
16
6 
20
3 
M 48 PCC Benign  
sympt. 
(adrenergic
) 
NS  No  ND No      03/1997 09/2003 
Alive, 
disease 
free 
      
16
7 
20
6 
F 45 PCC Benign  
sympt. 
(adrenergic
) 
A No  ND No      04/2003 05/2013 
Alive, 
disease 
free 
      
16
8 
23
8 
F 68 PCC Benign  inc. (image) Nad. No  ND No      04/2001 03/2014 
Alive, 
disease 
free 
      
16
9 
25
0 
F 21 A-PGL  Benign  
sympt. 
(adrenergic
) 
Nad. No  ND No      10/2004 10/2004 
Alive, 
post-
surgery 
      
17
0 
26
6 
F 37 HN-PGL  Benign  NS Nad. No  ND No      
01/1999 
diagnosis, 
surgery 
unknown 
06/2005 
Alive, 
unknow
n 
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17
1 
26
7 
F 28 HN-PGL  Benign  
sympt. 
(local mass) 
No sec.  No  ND No      09/2004 09/2004 
Alive, 
post-
surgery  
      
17
2 
27
0 
F 47 PCC Benign  inc. (image) A No  ND No      07/2005 07/2005 
Alive, 
post-
surgery  
      
17
3 
27
1 
F 26 A-PGL  Benign  NS 
High, 
but NS  
No  ND No      07/2005 07/2005 
Alive, 
post-
surgery  
      
17
4 
28
2 
M 32 PCC Benign  NS NS  No  ND No      11/2004 09/2005 
Alive, 
disease 
free 
      
17
5 
47
9 
F 33 HN-PGL  Benign  NS No sec.  No  ND Germline SDHB  
c.419T>A, 
p.Val140Asp 
01/2012 07/2012 
Alive, 
disease 
free 
      
17
6 
28
4 
F 72 T-PGL  Benign  inc. (image) No sec.  No  ND No      
No surgery, 
09/2005 (only 
biopsy) 
03/2014 
Alive, 
stable 
disease 
(no 
surgery) 
      
17
7 
28
9 
F 65 HN-PGL  Benign  NS NS  No  ND No      01/1997 01/1997 
Alive, 
post-
surgery 
      
17
8 
48
3 
F 50 T-PGL  
Malignan
t  
inc. 
(surgery) 
No sec.  No  ND Germline  SDHC 
c.43C>T, 
p.Arg15* 
05/2012 05/2013 
Alive, 
disease 
free 
Bone Sync.  AP study  
17
9 
29
0 
F 46 PCC Benign  
sympt. 
(adrenergic
) 
Nad. No  ND No      01/2005 06/2006 
Alive, 
disease 
free 
      
18
0 
48
5 
F 14 A-PGL  Benign  
sympt. 
(adrenergic
) 
Nad. No  ND Germline  
SDHB-
GD ‡ 
exon 1 gross 
deletion 
12/2009 02/2012 
Alive, 
disease 
free 
      
18
1 
48
7 
M 22 A-PGL  Benign  
sympt. 
(adrenergic
) 
Nad. No  ND Germline  
SDHB-
GD 
exon 1 gross 
deletion 
05/2012 09/2012 
Alive, 
disease 
free 
      
18
2 
29
2 
F 60 HN-PGL  Benign  NS No sec.  No  ND No      
No surgery, 
diagnosis 
01/1985 
06/2006 
Alive, 
stable 
disease 
(no 
surgery) 
      
18
3 
29
3†  
F 72 T-PGL  Benign  NS NS  No  ND No      01/2002 03/2014 
Decease
d 
(unknow
n cause, 
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but 
PPGL 
free) 
18
4 
29
8 
F 37 HN-PGL  Benign  
sympt. 
(local mass) 
No sec.  No  ND No      01/2007 01/2007 
Alive, 
post-
surgery 
      
18
5 
30
6 
F 36 HN-PGL  Benign  
inc. 
(surgery) 
NS  No  ND No      07/2006 07/2006 
Alive, 
post-
surgery  
      
18
6 
49
7 
F 23 T-PGL  Benign  NS No sec.  No  ND Germline SDHB ∆ c.643-2A>C 01/2011 11/2012 
Alive, 
disease 
free 
      
18
7 
31
0† 
M 57 PCC Benign  
inc. 
(surgery) 
NS  No  ND No      02/2007 08/2012 
Decease
d 
(adverse 
effects 
to 
chemot
herapy) 
      
18
8 
50
0 
M 46 HN-PGL  Benign  NS NS  No  ND Germline SDHB  
c.127G>C, 
p.Ala43Pro 
09/2012 
diagnosis, 
surgery 
unknown  
09/2012 
Alive, 
unknow
n 
      
18
9 
31
4 
F 29 HN-PGL  Benign  NS NS  No  ND No      01/2007 12/2007 
Alive, 
disease 
free 
      
19
0 
32
9 
F 16 A-PGL  Benign  
sympt. 
(adrenergic
) 
Nad. No  ND No      01/2007 11/2008 
Alive, 
disease 
free 
      
19
1 
33
6 
M 31 T-PGL  Benign  
sympt. 
(adrenergic
) 
High, 
but NS  
No  ND No      01/2006 01/2006 
Alive, 
post-
surgery 
      
19
2 
33
8 
M 50 PCC Benign  
sympt. 
(adrenergic
) 
Nad. No  ND No      01/2007 02/2014 
Alive, 
disease 
free 
      
19
3 
34
2 
F 43 HN-PGL  Benign  
sympt. 
(local mass) 
A No  ND No      11/2008 07/2013 
Alive, 
disease 
free 
      
19
4 
34
5 
F 59 PCC Benign  NS NS  No  ND No      11/2006 12/2008 
Alive, 
disease 
free 
      
19
5 
51
0†  
M 71 A-PGL  
Malignan
t  
sympt. 
(local mass) 
Nad. FFPE  
Negative 
and 
Germline SDHA c.457-1A>G 04/2013 12/2013 
Decease
d 
(radioth
Bone Sync.  AP study  
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negative 
IHC SDHA 
erapy 
bone 
met.) 
19
6 
34
6 
F NS PCC Benign  NS NS  No  ND No      12/2008 12/2008 
Alive, 
post-
surgery 
      
19
7 
34
7 
M 59 PCC Benign  NS NS  No  ND No      01/2008 11/2008 
Alive, 
disease 
free 
      
19
8 
34
8 
F 35 PCC Benign  NS NS  No  ND No      01/2003 12/2008 
Alive, 
disease 
free 
      
19
9 
34
9 
F NS PCC Benign  NS NS  No  ND No      12/2008 12/2008 
Alive, 
post-
surgery 
      
20
0 
35
0 
M NS PCC Benign  NS NS  No  ND No      12/2008 09/2013 
Alive, 
disease 
free 
      
20
1 
35
9 
F 62 T-PGL  Benign  NS No sec.  No  ND No      01/2009 05/2009 
Alive, 
post-
surgery 
      
20
2 
37
0 
F 57 HN-PGL  Benign  
sympt. 
(local mass) 
No sec.  No  ND No      01/2010 05/2014 
Alive, 
disease 
free 
      
20
3 
37
3 
F 54 PCC Benign  
sympt. 
(adrenergic
) 
Nad. No  ND No      11/2009 03/2010 
Alive, 
disease 
free 
      
20
4 
54
1 
F 65 PCC Benign  inc. (image) Nad. No  ND Germline  SDHB ∆ 
c.725G>A, 
p.Arg242His 
08/2004 10/2004 
Alive, 
disease 
free 
      
20
5 
37
6 
F 77 HN-PGL  Benign  NS NS  No  ND No      12/2009 03/2010 
Alive, 
disease 
free 
      
20
6 
38
5 
M 43 HN-PGL  Benign  NS No sec.  No  ND No      06/2010 05/2014 
Alive, 
disease 
free 
      
20
7 
38
6 
F 38 HN-PGL  Benign  
sympt. 
(local mass) 
No sec.  No  ND No      01/1997 05/2014 
Alive, 
disease 
free 
      
20
8 
38
7 
M 69 HN-PGL  Benign  NS NS  No  ND No      
01/2010 
diagnosis, 
surgery 
unknown  
06/2010 
Alive, 
unknow
n 
      
167 
 
20
9 
38
9 
M 15 PCC Benign  NS NS  No  ND No      01/2007 06/2010 
Alive, 
disease 
free 
      
21
0 
39
3 
M 32 PCC Benign  NS NS  No  ND No      01/2009 07/2010 
Alive, 
disease 
free 
      
21
1 
39
4†  
M 47 PCC 
Malignan
t  
sympt. 
(adrenergic
) 
No sec.  No  ND No      02/2010 07/2010 
Decease
d (met.) 
Liver 
and 
local 
lymph 
node 
Sync.  AP study  
21
2 
40
1 
F 78 HN-PGL  Benign  NS NS  No  ND No      
08/2010 
diagnosis, 
surgery 
unknown 
08/2010 
Alive, 
unknow
n 
      
21
3 
40
2 
F 60 HN-PGL  Benign  NS 
High, 
but NS  
No  ND No      
10/2010 
diagnosis, 
surgery 
unknown 
10/2010 
Alive, 
unknow
n 
      
21
4 
41
0 
F 45 HN-PGL  Benign  
sympt. 
(local mass) 
No sec.  No  ND No      11/2010 05/2014 
Alive, 
disease 
free 
      
21
5 
41
2 
F 68 HN-PGL  Benign  NS NS  No  ND No      
01/2007 
diagnosis, 
surgery 
unknown 
12/2010 
Alive, 
unknow
n 
      
21
6 
41
7 
F 70 HN-PGL  Benign  
sympt. 
(local mass) 
No sec.  No  ND No      
01/2011 
(palliative 
surgery)  
05/2014 
Alive, 
stable 
disease 
(palliativ
e 
surgery)  
      
21
7 
42
0 
F 53 HN-PGL  Benign  
sympt. 
(local mass) 
No sec.  No  ND No      03/2011 05/2014 
Alive, 
disease 
free 
      
21
8 
42
1 
F 41 PCC 
Malignan
t  
sympt. 
(local mass) 
A No  ND No      01/1993 04/2011 
Alive,me
t. 
Bone 
and 
lung  
Metac. 
, 120 
month
s after 
first 
surger
y  
Image (CT) 
and BC 
study 
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21
9 
42
2 
F 25 A-PGL  Benign  
sympt. 
(local mass) 
Nad. No  ND No      01/2010 02/2011 
Alive, 
disease 
free 
      
22
0 
57
8 
F 26 PCC Benign  
sympt. 
(adrenergic
) 
A FFPE  
Not 
available 
No      06/2006 06/2006 
Alive, 
post-
surgery  
      
22
1 
42
3 
F 26 A-PGL  Benign  
sympt. 
(adrenergic
) 
Nad. No  ND No      05/2006 03/2011 
Alive, 
disease 
free 
      
22
2 
42
7 
F 41 PCC Benign  inc. (image) Nad. No  ND No      02/2011 03/2011 
Alive, 
disease 
free 
      
22
3 
42
8 
M 38 PCC Benign  NS A No  ND No      10/2010 08/2011 
Alive, 
disease 
free 
      
22
4 
43
1 
M 38 A-PGL  Benign  NS NS  No  ND No      01/2011 01/2011 
Alive, 
post-
surgery 
      
22
5 
43
2 
F 38 A-PGL  Benign  NS NS  No  ND No      11/2010 05/2011 
Alive, 
disease 
free 
      
22
6 
43
8 
F 46 T-PGL  Benign  
sympt. 
(adrenergic
) 
Nad. No  ND No      06/2001 06/2013 
Alive, 
disease 
free 
      
22
7 
43
9 
F 64 HN-PGL  Benign  
sympt. 
(local mass) 
No sec.  No  ND No      06/2011 05/2014 
Alive, 
disease 
free 
      
22
8 
44
5 
F 58 A-PGL  Benign  
inc. 
(surgery) 
NS  No  ND No      07/2011 07/2013 
Alive, 
disease 
free 
      
22
9 
44
8 
M 42 HN-PGL  Benign  
sympt. 
(local mass) 
No sec.  No  ND No      10/2011 01/2012 
Alive, 
disease 
free 
      
23
0 
45
1 
M 54 HN-PGL  Benign  
sympt. 
(local mass) 
No sec.  No  ND No      12/2011 05/2014 
Alive, 
disease 
free 
      
23
1 
45
7 
F 43 PCC Benign  
sympt. 
(adrenergic
) 
NS  No  ND No      02/2012 02/2012 
Alive, 
post-
surgery 
      
23
2 
45
8 
F NS HN-PGL  Benign  
sympt. 
(local mass) 
No sec.  No  ND No      02/2012 02/2012 
Alive, 
post-
surgery 
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23
3 
45
9 
F 46 HN-PGL  Benign  NS NS  No  ND No      11/2011 02/2012 
Alive, 
disease 
free 
      
23
4 
46
3 
M 45 PCC Benign  
sympt. 
(adrenergic
) 
Nad. No  ND No      01/2007 03/2012 
Alive, 
disease 
free 
      
23
5 
46
6 
F 50 PCC Benign  NS NS  No  ND No      01/2011 01/2012 
Alive, 
disease 
free 
      
23
6 
46
9 
F 52 HN-PGL  Benign  
sympt. 
(local mass) 
No sec.  No  ND No      05/2012 05/2014 
Alive, 
disease 
free 
      
23
7 
47
2 
F 63 HN-PGL  Benign  NS NS  No  ND No      
05/2012 
diagnosis, 
surgery 
unkown 
05/2012 
Alive, 
unknow
n 
      
23
8 
47
3 
M 54 HN-PGL  Benign  NS NS  No  ND No      12/2011 03/2012 
Alive, 
disease 
free 
      
23
9 
47
4 
M 49 HN-PGL  Benign  
sympt. 
(local mass) 
No sec.  No  ND No      06/2012 05/2014 
Alive, 
disease 
free 
      
24
0 
47
6 
M 70 PCC Benign  
sympt. 
(adrenergic
) 
High, 
but NS  
No  ND No      
No surgery, 
diagnosis 
01/2011 
05/2012 
Alive, 
stable 
disease 
(no 
surgery) 
      
24
1 
48
9 
M 59 HN-PGL  Benign  
sympt. 
(local mass) 
No sec.  No  ND No      09/2012 05/2014 
Alive, 
disease 
free 
      
24
2 
49
1 
M 60 A-PGL  Benign  
sympt. 
(local mass) 
Nad. No  ND No      03/2011 03/2014 
Alive, 
disease 
free 
      
24
3 
49
5 
F 55 HN-PGL  Benign  
sympt. 
(local mass) 
NS  No  ND No      11/2012 12/2012 
Alive, 
post-
surgery 
      
24
4 
61
5 
M 70 PCC Benign  inc. (image) A No  ND Germline RET 
c.2410G>T, 
p.Val804Leu 
05/2008 03/2013 
Alive, 
disease 
free 
      
24
5 
61
6 
F 18 PCC Benign  NS Nad. No  ND Germline  VHL ‡ 
c.482G>A, 
p.Arg161Gln 
01/1997 10/2008 
Alive, 
disease 
free 
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24
6 
50
2 
F 50 HN-PGL  Benign  
sympt. 
(local mass) 
No sec.  No  ND No      01/2013 05/2014 
Alive, 
disease 
free 
      
24
7 
50
6 
M 64 PCC Benign  inc. (image) A No  ND No      08/2012 08/2012 
Alive, 
post-
surgery 
      
24
8 
50
9 
F 39 HN-PGL  Benign  
sympt. 
(local mass) 
No sec.  No  ND No      07/2012 03/2013 
Alive, 
disease 
free 
      
24
9 
51
1 
M 63 HN-PGL  Benign  inc. (image) Nad. No  ND No      03/2013 03/2013 
Alive, 
post-
surgery 
      
25
0 
51
5 
F 65 PCC Benign  
sympt. 
(adrenergic
) 
Nad. No  ND No      04/2013 06/2013 
Alive, 
disease 
free 
      
25
1 
53
7†  
M 62 PCC Benign  
sympt. 
(adrenergic
) 
NS  No  ND No      07/2003 09/2011 
Decease
d 
(pancrea
tic 
adenoca
rcinoma
) 
      
25
2 
53
9 
F 43 PCC Benign  
sympt. 
(adrenergic
) 
A No  ND No      01/2004 01/2004 
Alive, 
post-
surgery 
      
25
3 
54
0 
M 37 PCC Benign  NS NS  No  ND No      07/2003 04/2004 
Alive, 
disease 
free 
      
25
4 
55
2 
F 80 PCC Benign  NS NS  No  ND No      01/2001 01/2001 
Alive, 
post-
surgery 
      
25
5 
62
6 
F 26 PCC Benign  
sympt. 
(adrenergic
) 
A FFPE  ND Germline  
TMEM1
27 
c.115_118del
CTGT, 
p.Ile41Argfs*
39 
01/2008 07/2010 
Alive, 
disease 
free 
      
25
6 
55
5 
F 71 PCC Benign  
sympt. 
(adrenergic
) 
Nad. No  ND No      03/2005 12/2005 
Alive, 
disease 
free 
      
25
7 
55
7 
F 31 PCC Benign  NS NS  No  ND No      03/1998 04/2005 
Alive, 
disease 
free 
      
25
8 
55
8 
F 35 PCC Benign  NS NS  No  ND No      01/1997 01/2005 
Alive, 
disease 
free 
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25
9 
63
3 
M 35 PCC Benign  
sympt. 
(adrenergic
) 
Nad. FFPE  Positive Germline  
TMEM1
27 
c.221A>C, 
p.Tyr74Ser 
11/2009 12/2012 
Alive, 
disease 
free 
      
26
0 
55
9 
M 48 PCC Benign  
sympt. 
(adrenergic
) 
High, 
but NS  
No  ND No      02/2005 03/2005 
Alive, 
post-
surgery  
      
26
1 
56
0 
F 74 PCC Benign  inc. (image) Nad. No  ND No      07/2005 06/2013 
Alive, 
disease 
free 
      
26
2 
56
2 
F 43 PCC Benign  
sympt. 
(adrenergic
) 
NS  No  ND No      12/2002 10/2005 
Alive, 
disease 
free 
      
26
3 
56
3 
F 33 PCC Benign  NS NS  No  ND No      09/1993 12/2005 
Alive, 
disease 
free 
      
26
4 
56
9 
M 36 PCC Benign  inc. (image) Nad. No  ND No      12/2005 05/2011 
Alive, 
disease 
free 
      
26
5 
64
0 
M 26 PCC 
Malignan
t  
NS Nad. No  ND Germline  
SDHB-
GD 
exon 1 gross 
deletion 
03/2010 04/2010 
Alive, 
post-
surgery 
Bone Sync.  AP study  
26
6 
57
0 
M 40 PCC 
Malignan
t  
NS Nad. No  ND No      01/1972 01/2012 
Alive, 
met.  
Bone 
Metac. 
, 168 
month
s after 
first 
surger
y  
Image 
(MIBG) and 
BC study  
26
7 
57
1 
F 47 PCC Benign  inc. (image) 
High, 
but NS  
No  ND No      11/1999 02/2006 
Alive, 
disease 
free 
      
26
8 
57
5 
M 56 PCC Benign  
sympt. 
(adrenergic
) 
A No  ND No      02/2006 01/2013 
Alive, 
disease 
free 
      
26
9 
57
7 
F 66 PCC Benign  NS NS  No  ND No      01/2004 01/2006 
Alive, 
disease 
free 
      
27
0 
57
9 
M 44 PCC Benign  NS NS  No  ND No      11/2006 12/2006 
Alive, 
disease 
free 
      
27
1 
58
0 
M 47 A-PGL  Benign  
sympt. 
(adrenergic
) 
Nad. No  ND No      03/2007 05/2007 
Alive, 
disease 
free 
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27
2 
58
8 
M 33 PCC Benign  NS NS  No  ND No      01/2006 04/2007 
Alive, 
disease 
free 
      
27
3 
59
0 
M 41 PCC Benign  
sympt. 
(adrenergic
) 
High, 
but NS  
No  ND No      01/2006 11/2007 
Alive, 
disease 
free 
      
27
4 
59
3 
F 46 PCC Benign  inc. (image) NS  No  ND No      11/2006 05/2007 
Alive, 
disease 
free 
      
27
5 
59
5 
F 51 PCC Benign  NS NS  No  ND No      01/2007 06/2007 
Alive, 
disease 
free 
      
27
6 
59
6 
F 62 PCC Benign  NS NS  No  ND No      01/2007 07/2007 
Alive, 
disease 
free 
      
27
7 
59
8 
F 44 PCC Benign  
sympt. 
(adrenergic
) 
Nad. No  ND No      01/2007 07/2007 
Alive, 
disease 
free 
      
27
8 
60
3 
M 61 PCC Benign  NS NS  No  ND No      01/2007 11/2007 
Alive, 
disease 
free 
      
27
9 
60
4 
M 24 PCC Benign  
sympt. 
(adrenergic
) 
NS  No  ND No      04/2007 01/2010 
Alive, 
disease 
free 
      
28
0 
67
1†  
M 46 PCC 
Malignan
t  
NS Nad. FFPE  ND Germline  SDHB  
c.112C>T, 
p.Arg38* 
01/2000 01/2000 
Decease
d 
(unknow
n) 
Liver 
and 
lung  
Metac. 
, 28 
month
s after 
first 
surger
y  
Image 
(MIBG) and 
BC study  
28
1 
71
5 
M 29 HN-PGL  
Malignan
t  
NS NS  FFPE  ND Germline  SDHD 
c.334_337del
ACTG, 
p.Asp113Met
fs*21 
03/2001 07/2011 
Alive, 
disease 
free 
Bone Sync.  AP study  
28
2 
60
5 
M 55 PCC Benign  
sympt. 
(adrenergic
) 
High, 
but NS  
No  ND No      03/2007 05/2008 
Alive, 
disease 
free 
      
28
3 
60
7 
M 44 PCC Benign  
sympt. 
(adrenergic
) 
Nad. No  ND No      02/2006 07/2011 
Alive, 
disease 
free 
      
28
4 
60
8 
F 54 PCC Benign  NS NS  No  ND No      01/2008 01/2008 
Alive, 
post-
surgery 
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28
5 
60
9 
F 39 PCC Benign  
sympt. 
(adrenergic
) 
Nad. No  ND No      06/2007 02/2014 
Alive, 
disease 
free 
      
28
6 
61
0†  
M 54 PCC Benign  inc. (image) NS  No  ND No      05/2008 08/2008 
Decease
d 
(recurre
nce of 
the 
gallblad
der 
adenoca 
with 
liver 
met) 
      
28
7 
75
7 
M 16 T-PGL  
Malignan
t  
sympt. 
(local mass) 
No sec.  No  ND Germline  
SDHB-
GD 
exon 1 gross 
deletion 
No surgery, 
05/2013 (only 
biopsy) 
06/2013 
Alive, 
met. (no 
surgery) 
Bone Sync.  AP study  
28
8 
61
7 
F 41 PCC Benign  inc. (image) Nad. No  ND No      01/2008 01/2008 
Alive, 
post-
surgery 
      
28
9 
61
8 
M 48 PCC Benign  inc. (image) Nad. No  ND No      09/2008 02/2012 
Alive, 
disease 
free 
      
29
0 
62
0 
M 44 PCC Benign  
sympt. 
(adrenergic
) 
Nad. No  ND No      03/2009 06/2009 
Alive, 
disease 
free 
      
29
1 
62
2 
M 43 PCC Benign  NS NS  No  ND No      01/2009 01/2009 
Alive, 
post-
surgery  
      
29
2 
62
3 
M 21 PCC Benign  
sympt. 
(adrenergic
) 
Nad. No  ND No      07/2009 08/2009 
Alive, 
post-
surgery 
      
29
3 
62
4 
F 19 PCC Benign  NS NS  No  ND No      01/1997 01/2009 
Alive, 
disease 
free 
      
29
4 
81
5 
M 13 PCC Benign  
sympt. 
(adrenergic
) 
NS  
Froze
n and 
FFPE 
ND Germline SDHB ‡ 
c.540G>C, 
p.Leu180Leu 
01/1985 05/2005 
Alive, 
disease 
free 
      
29
5 
62
5 
M 47 PCC Benign  
sympt. 
(adrenergic
) 
Nad. No  ND No      01/2010 03/2011 
Alive, 
disease 
free 
      
29
6 
63
8 
F 32 PCC Benign  
sympt. 
(adrenergic
) 
Nad. No  ND No      01/2002 08/2010 
Alive, 
disease 
free 
      
174 
 
29
7 
63
9 
M 44 PCC Benign  
sympt. 
(adrenergic
) 
Nad. No  ND No      11/2010 10/2012 
Alive, 
disease 
free 
      
29
8 
64
2 
F 62 PCC Benign  NS Nad. No  ND No      01/2009 04/2011 
Alive, 
disease 
free 
      
29
9 
64
4 
M 40 PCC Benign  
sympt. 
(adrenergic
) 
NS  No  ND No      01/2011 01/2011 
Alive, 
post-
surgery 
      
30
0 
64
5 
M 35 PCC Benign  
sympt. 
(adrenergic
) 
Nad. No  ND No      07/2010 10/2012 
Alive, 
disease 
free 
      
30
1 
65
0 
F 74 PCC Benign  NS NS  No  ND No      01/2011 07/2011 
Alive, 
disease 
free 
      
30
2 
89
4 
M 32 PCC Benign  
sympt. 
(adrenergic
) 
A 
Froze
n 
ND Germline RET 
c.1998G>C, 
p.Lys666Asn  
07/2013 09/2013 
Alive, 
disease 
free 
(only 2 
months 
post-
surgery) 
      
30
3 
65
1 
F 47 PCC Benign  
sympt. 
(adrenergic
) 
NS  No  ND No      04/2008 12/2012 
Alive, 
disease 
free 
      
30
4 
65
2 
M NS PCC Benign  NS NS  No  ND No      01/2012 01/2012 
Alive, 
post-
surgery 
      
30
5 
96
5 
M 42 PCC 
Malignan
t  
inc. (image) 
High, 
but NS  
FFPE  Positive Somatic  RET 
c.2753T>C, 
p.Met918Thr  
07/2012 08/2013 
Alive, 
disease 
free 
Local 
lymph 
node 
Sync.  AP study  
30
6 
75
5 
M 42 PCC Benign  
sympt. 
(adrenergic
) 
A No  ND No      01/2012 04/2013 
Alive, 
disease 
free 
      
30
7 
75
6 
F 34 A-PGL  Benign  
sympt. 
(adrenergic
) 
A No  ND No      06/2013 06/2013 
Alive, 
post-
surgery 
      
30
8 
80
3 
F NS PCC Benign  NS NS  No  ND No      04/1999 04/1999 
Alive, 
post-
surgery 
      
30
9 
80
4 
F 42 PCC Benign  NS NS  No  ND No      01/2000 01/2000  
Alive, 
post-
surgery 
      
175 
 
31
0 
80
6†  
M 65 A-PGL  Benign  NS NS  No  ND No      01/2001 03/2001 
Decease
d (met. 
medulla
ry 
thyroid 
carcino
ma) 
      
31
1 
88
1 
M 59 PCC Benign  inc. (image) A No  ND No      06/2012 01/2013 
Alive, 
disease 
free 
      
31
2 
88
7 
F 44 PCC Benign  
sympt. 
(adrenergic
) 
A No  ND No      02/2013 02/2013 
Alive, 
post-
surgery 
      
31
3 
88
8 
F 42 PCC Benign  
sympt. 
(adrenergic
) 
A No  ND No      02/2012 04/2013 
Alive, 
disease 
free 
      
31
4 
95
9 
M 64 A-PGL  Benign  NS A No  ND No      07/2012 11/2012 
Alive, 
disease 
free 
      
31
5 
96
0 
M 68 HN-PGL  Benign  NS NS  No  ND No      01/2001 06/2013 
Alive, 
disease 
free 
      
31
6 
96
6 
F 62 NS PGL 
Malignan
t  
NS NS  No  ND No      06/2013 09/2013 
Alive, 
disease 
free 
(only 3 
months 
post-
surgery) 
Not 
specifie
d 
Sync.  AP study  
31
7 
96
8 
F 67 PCC Benign  inc. (image) No sec.  No  ND No      02/2012 10/2013 
Alive, 
disease 
free 
      
31
8 
96
9 
M 48 PCC Benign  
sympt. 
(adrenergic
) 
A No  ND No      11/2007 12/2013 
Alive, 
disease 
free 
      
31
9 
10
01 
M 39 PCC 
Malignan
t  
sympt. 
(adrenergic
) 
Nad. No  ND No      01/1993 05/2014 
Alive, 
met. 
Bone 
and 
liver 
Metac. 
, 240 
month
s after 
first 
surger
y 
AP study 
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32
0 
10
02 
F 31 PCC Benign  
sympt. 
(adrenergic
) 
Nad. No  ND No      12/2013 02/2014 
Alive, 
disease 
free 
      
32
1 
10
03 
F 43 PCC Benign  inc. (image) A No  ND No      01/2013 05/2014 
Alive, 
disease 
free 
      
32
2 
10
06 
F NS PCC Benign  NS NS  No  ND No      02/2014 02/2014 
Alive, 
post-
surgery 
      
32
3 
10
12 
M 45 PCC Benign  
sympt. 
(adrenergic
) 
Nad. No  ND No      11/2012 01/2014 
Alive, 
disease 
free 
      
32
4 
10
13 
M 44 PCC Benign  NS NS  No  ND No      08/2011 07/2014 
Alive, 
disease 
free 
      
32
5 
10
14 
F 52 PCC Benign  
sympt. 
(adrenergic
) 
A No  ND No      01/2011 07/2014 
Alive, 
disease 
free 
      
32
6 
10
17 
F 23 PCC Benign  
sympt. 
(adrenergic
) 
Nad. No  ND No      
01/2014 
diagnosis, 
surgery 
unknown  
01/2014 
Alive, 
unknow
n 
      
32
7 
10
19 
F 43 PCC Benign  
sympt. 
(adrenergic
) 
Dopa. No  ND No      10/2013 02/2014 
Alive, 
disease 
free 
      
32
8 
10
22 
F 48 PCC Benign  inc. (image) NS  No  ND No      01/2012 04/2014 
Alive, 
disease 
free 
      
32
9 
10
25 
M 74 HN-PGL  
Malignan
t  
sympt. 
(local mass) 
NS  FFPE  Positive Somatic  VHL 
c.197_211del
insCTCGTG, 
p.Val66_Pro7
1delinsAlaAr
gAla  
01/2014 06/2014 
Alive, 
met.  
Bone Sync.  AP study  
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Supplementary table S2. Variant interpretation. 
Gene Variant ID patient Coding 
effect 
Pathogenicity   Public Databases: 
 - ExAC 
 - COSMIC 
Methodology to assess mutations as pathogenic: 
-   Pubmed 
- In silico analysis: SIFT, Mutation Taster and Polyphen2 
EPAS1 c.1592C>T,  
p.Pro531Leu 
335 (S), 657 (S) 
and 967 (S) 
Missense Mutation Not reported 
Not reported  
- Previously reported in a case with multiple PGL and 
erythrocytosis [1].  
- SIFT: deleterious (score 0.02).  
- Mutation Taster: Disease causing (p-value 1) 
- Polyphen 2: Probably damaging with a score of 1.000 
EPAS1 c.1606C>A,  
p.Asp536Tyr 
344 (S) Missense Mutation  Not reported 
Not reported  
- Previously reported:  Hidroxilation point described [1].   
- SIFT: deleterious (score 0.02).  
- Mutation Taster: Disease causing (p-value 1) 
- Polyphen 2: Probably damaging with a score of 1.000  
EPAS1 c.1599_1604delCCCCA
T, p.Ile533_Pro534del 
728 (S) In-frame Mutation  Not reported 
Not reported 
- Previously reported: Hidroxilation point described [1].   
EPAS1 c.1615G>T,  
p.Asp539Tyr 
727 (S) Missense Mutation Not reported 
Not reported 
- Previously reported: Hidroxilation point described [1].   
- SIFT: deleterious (score 0.02).  
- Mutation Taster: Disease causing (p-value 1) 
- Polyphen 2: Probably damaging with a score of 1.000 
HRAS c.181C>A,  
p.Gln61Lys 
167 (S), 379 
(S), 587 (S) 
Missense Mutation Not reported 
COSM496 and 
COSM123649. 
- Reported 2 times [2, 3].  
- SIFT: deleterious (score 0).  
- Mutation Taster: Disease causing (p-value 1) 
- Polyphen 2: Benign with a score of 0.012  
HRAS c.182A>G,  
p.Gln61Arg 
118 (S), 133 
(S), 460 (S), 
475 (S), 636 
(S), 647 (S), 
659 (S) 550 (S), 
658 (S), 764 (S) 
Missense Mutation Not reported 
COSM244958 and 
COSM499 
- Reported 2 times [2, 3].  
- SIFT: deleterious (score 0).  
- Mutation Taster: Disease causing (p-value 1) 
- Polyphen 2: Benign with a score of 0.008  
HRAS c.37G>C,  
p.Gly13Arg 
62 (S), 396 (S) Missense Mutation  Not reported 
COSM486 and 
COSM99938 
- Reported 2 times [2, 3].  
- SIFT: deleterious (score 0).  
- Mutation Taster: Disease causing (p-value 1) 
- Polyphen 2: Probably damaging with a score of 0.997 
NF1 c.6855C>A,  
p.Tyr2285* 
145 (S) Nonsense Mutation 0.000008251/0 hom 
COSM33676 and 
COSM705652. 
 
RET c.1900T>C,  103 (S)  Missense Mutation 0.000008274/0 hom - Described in MEN2 syndrome. First reported 1993 [4, 5]. 
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p.Cys634Arg COSM 966 - SIFT: deleterious (score 0).  
- Mutation Taster: Disease causing (p-value 1) 
- Polyphen 2: Probably damaging with a score of 1.000 
RET c.1998G>C,  
p.Lys666Asn 
894 (G) Missense Mutation 0.000008242/0 hom 
Not reported.  
 
- Described mutations in the same amino acid residue in 
MEN2 syndrome [5].  
- Functional studies have demonstrated that p.K666N 
mutation is associated with a high level of RET and ERK 
phosphorylation and a high transforming potential [6].  
- It has been described in medullary thyroid carcinoma 
patients [7].  
- SIFT: deleterious (score 0).  
- Mutation Taster: Disease causing (p-value 1) 
- Polyphen 2: Probably damaging with a score of 0.999 
RET c.2410G>T,  
p.Val804Leu 
615 (G) Missense Mutation 0.00001569/ 0 hom 
Not reported 
 
- Described in MEN2 syndrome [5]. First described in 1995 
[8].  
- SIFT: deleterious (score 0.05).  
- Mutation Taster: Disease causing (p-value 1) 
- Polyphen 2: Probably damaging with a score of 1.000 
RET c.2753T>C,  
p.Met918Thr 
889 (S), 965 
(S), 63 (S), 553 
(S), 653 (S), 
751 (S), 760 (S) 
Missense Mutation Not reported 
COSM965 
 
- Described in MEN2 syndrome [5]. First described in 1994 
[9].  
- SIFT: deleterious (score 0).  
- Mutation Taster: Disease causing (p-value 1) 
- Polyphen 2: Probably damaging with a score of 0.999 
SDHA c.1754G>A,  
p.Arg585Gln 
424 (G) Missense  Mutation 0.000008282/0 hom 
COSM1067147 
-  Negative SDHB- and SDHA-IHC 
- LOVD: not reported  
- SIFT: deleterious (score 0).  
- Mutation Taster: Disease causing (p-value 1) 
- Polyphen 2: Probably damaging with a score of 1.000 
SDHA c.457-1G>A,  
p? 
510 (G), 449 
(G) 
Splice 
acceptor 
variant  
Mutation Not reported 
Not reported  
- Negative SDHB- and SDHA-IHC (ID 510) 
- LOVD: not reported.  
SDHAF2 c.362G>A,  
p.Trp121* 
444 (G) Nonsense Mutation Not reported 
Not reported  
- Negative SDHB-IHC  
- LOVD: not reported.  
SDHB c.166_170delCCTCA, 
p.Pro56delTyrfs*5 
243 (G), 365 
(G), 368 (G), 
301 (G), 312 
(G), 278 (G) 
Frameshift Mutation Not reported  
Not reported 
 
- LOVD:  Reported 9 times: First time at 2004 [10]. 
SDHB  c.112C>T,  
p.Arg38* 
671 (G) Nonsense Mutation  Not reported  
Not reported 
- LOVD: not described.   
SDHB  c.127G>C,  500 (G) Missense Mutation Not reported  - LOVD: Reported 3 times: First report at 2003 [11].  
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p.Ala43Pro Not reported  
 
- SIFT: Tolerated (score 0.19).  
- Mutation Taster: Disease causing (p-value 0.999) 
- Polyphen 2: Benign with a score of 0.356 
SDHB  c.269G>A,  
p.Arg90Gln 
353 (G) Missense Mutation 0.000008315/0 hom 
Not reported  
 
- LOVD: Reported 3 times:  First report at 2006 [12].  
- SIFT: Deleterious (score 0).  
- Mutation Taster: Disease causing (p-value 1) 
- Polyphen 2: Probably damaging with a score of 1.000 
SDHB  c.287-3C>G,  
p? 
433 (G) Splice site Mutation - 
Not reported  
- LOVD: Not reported.  
- Reported 1 time [13]. 
- We demonstrated the effect on splicing (data not shown). 
SDHB  c.423+1G>A,  
p? 
442 (G) Splice site Mutation - 
Not reported 
- LOVD: Reported 9 times: First report at 2003 [14] 
SDHB  c.464C>G,  
p.Pro155Arg 
403 (S) Missense Mutation Not reported 
Not reported 
- LOVD: Not reported.  
- FFPE tumor not available to perform SDHB-IHC. 
- The second hit was found using SNP array: loss of 1p (data 
not shown).  
- SIFT: Deleterious (score 0).  
- Mutation Taster: Disease causing (p-value 1) 
- Polyphen 2: Probably damaging with a score of 1.000 
SDHB  c.544_550delGGGCTC
T, p.Gly182Thrfs*36 
413 (G) Frameshift Mutation Not reported  
Not reported  
Not ensembl. 
- LOVD: Not reported.  
SDHB  c.557G>A,  
p.Cys186Tyr 
364 (G) Missense Mutation  Not reported  
Not reported  
 
- LOVD: Reported 4 times. First time at 2007[15]. 
- SIFT: Deleterious (score 0).  
- Mutation Taster: Disease causing (p-value 1) 
- Polyphen 2: Probably damaging with a score of 1.000 
SDHB  c.725G>A,  
p.Arg242His 
352 (G), 541 
(G) 
Missense Mutation  0.00002471/0 hom 
Not reported 
 
- LOVD: Reported 12 times: First time at 2002 [16]. 
- SIFT: Deleterious (score 0.01).  
- Mutation Taster: Disease causing (p-value 1) 
- Polyphen 2: Probably damaging with a score of 1.000 
SDHB  c.419T>A,  
p.Val140Asp 
479 (G)  Missense Mutation 
(VUS)  
Not reported 
Not reported  
Not ensembl. 
- LOVD: Not reported. 
- A variant in the same amino acid residue has been 
described 7 times in LOVD: c.418G>T, p.Val140Phe.   
- SIFT: Deleterious (score 0).  
- Mutation Taster: Disease causing (p-value 1) 
- Polyphen 2: Probably damaging with a score of 1.000 
SDHB  c.278G>A,  
p.Cys93Tyr 
175 (G) Missense Mutation Not reported.  
COSM1664073 
- LOVD: Reported 1 time. First time at 2009: [17]. 
- SIFT: Deleterious (score 0).  
- Mutation Taster: Disease causing (p-value 1). 
- Polyphen 2: Probably damaging with a score of 1.000  
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SDHB  c.424-3C>G,  
p? 
330 (G) Splice site Mutation - 
Not reported 
- LOVD: Reported 3 times: First time at 2005 [18]. 
SDHB  c.643-2A>C, 
p? 
497 (G) Splice site Mutation - 
Not reported  
- LOVD: Reported 1 time [17]. 
SDHB  c.540G>C,  
p.Leu180Leu 
815 (G) Synonymo
us 
Mutation 0.000008237/0 hom  
Not reported 
 
- LOVD: Not reported.  
- In silico tools (ESE-finder) predicted this variant affected 
splicing. We demonstrated by sequencing cDNA the lack of 
mutant allele (data not shown).  
SDHB  exon 1 deletion 400 (G), 430 
(G), 487 (G), 
640 (G), 757 
(G), 66 (G), 157 
(G), 327 (G), 
485 (G). 
Deletion Mutation - 
- 
- Previously reported in familial paraganglioma syndrome 
[19]. 
SDHC c.43C>T,  
p.Arg15* 
483 (G) Nonsense Mutation Not reported 
Not reported 
 
- LOVD: Reported 4 times: First time at 2007 [20]. 
SDHC  c.253-255dupTTT, 
p.Phe85dup 
3 (G) In-frame Mutation Not reported 
Not reported 
 
- LOVD: Reported 2 times. First time at 2008 [21].  
SDHD  c.334_337delACTG, 
p.Asp113Metfs*21 
251 (G), 715 
(G) 
Frameshift Mutation Not reported 
Not reported 
- LOVD: Reported 2 times: First time at 2005 [22]. 
SDHD  c.191_192delTC, 
p.Leu64Profs*4 
441 (G) Frameshift Mutation Not reported 
Not reported 
- LOVD: Reported 3 times: First time at 2001 [23]. 
SDHD  c.2T>C,  
p.Met1? 
340 (G) Missense Mutation Not reported 
Not reported 
- LOVD: Not reported.  
- This mutation affects the first methionine and thus the 
correct processing of the gene.  
- Start loss 
SDHD  c.168_169delTT, 
p.Ser57Trpfs*11 
307 (G) Frameshift Mutation Not reported 
Not reported 
- LOVD: Reported 2 times. First time at 2005 [17]. 
SDHD  c.210G>T,  
p.Arg70Ser 
311 (G) Missense Mutation Not reported 
Not reported 
- LOVD. Reported 1 time. First time at 2009 [17].  
- LOVD: Mutations affecting the same codon (p.Arg70Met; 
p.Arg70Gly) have been described. Changes affecting this 
codon destroy hemo interaction and affect the function of 
the protein. 
- SIFT: Deleterious (score 0).  
- Mutation Taster: Disease causing (p-value 1) 
- Polyphen 2: Probably damaging with a score of 1.000 
SDHD c.112C>T,  
p.Arg38* 
1004 (S) Non-sense Mutation Not reported  
Not reported 
- LOVD: Reported 8 times. First time at 2000 [24]. 
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TMEM127 c.115_118delCTGT, 
p.Ile41Argfs*39 
626 (G) Frameshift Mutation Not reported 
Not reported  
 
TMEM127 c.221A>C,  
p.Tyr74Ser 
633 (G) Missense Mutation Not reported 
Not reported 
- We found LOH involving wild-type allele in the 
corresponding tumor DNA.  
- SIFT: Deleterious (score 0.03).  
- Mutation Taster: Disease causing (p-value 1) 
- Polyphen 2: Benign with a score of 0.058 
VHL c.191G>C,  
p.Arg64Pro 
465 (S)  Missense Mutation Not reported  
Not reported 
- The UMD-VHL mutations: Request ID: 190515141147-33 
- SIFT: Tolerated (score 0.13).  
- Mutation Taster: Disease causing (p-value0.999) 
- Polyphen 2: Probably damaging with a score of 1.000  
VHL c.197_211delinsCTCGT
p.Val66_Pro71delinsAl
aArgAla 
1025 (S) In-frame Mutation Not reported  
Not reported 
- UMD-VHL not reported.  
VHL c.227T>A, p.Phe76Tyr 498 (S) Missense  Mutation Not reported  
COSM14321 
- UMD-VHL not reported. 
- SIFT: Deleterious (score: 0) 
- Mutation Taster: Disease causing (p-value: 0.974) 
- Polyphen 2: Probably damaging with a score of 0.935 
VHL c.250G>C,  
p.Val84Leu 
242 (S) Missense  Mutation Not reported  
COSM236660 
- The UMD-VHL mutations: Request ID: 190515142416-21 
- SIFT: Deleterious (score 0).  
- Mutation Taster: Disease causing (p-value0.549) 
- Polyphen 2: Benign with a score of 0.017  
VHL c.260T>C,  
p.Val87Ala 
631 (S), 649 (S)  Missense  Mutation Not reported  
Not reported 
- UMD-VHL not reported.  
- SIFT: Deleterious (score 0.04).  
- Mutation Taster: Polymorphism (p-value0.996) 
- Polyphen 2: Possibly damaging with a score of 0.573  
VHL c.389T>G,  
p.Val130Gly 
480 (S) Missense  Mutation Not reported  
COSM100047 
 
- UMD-VHL not reported.  
- SIFT: Deleterious (score 0).  
- Mutation Taster: Disease causing (p-value 1) 
- Polyphen 2: Probably damaging with a score of 1.000 
VHL c.475A>G,  
p.Lys159Glu 
513 (S) Missense  Mutation Not reported  
COSM144975 
- The UMD-VHL mutations: Request ID: 190515142532-25 
- SIFT: Deleterious (score 0.03).  
- Mutation Taster: Disease causing (p-value 0.996) 
- Polyphen 2: Probably damaging with a score of 0.999 
VHL c.482G>A,  
p.Arg161Gln 
616 (G), 581 
(S) 
Missense  Mutation Not reported  
COSM18097 
- The UMD-VHL mutations: Request ID: 190515142607-149 
- SIFT: Deleterious (score 0).  
- Mutation Taster: Disease causing (p-value 0.999) 
- Polyphen 2: Probably damaging  with a score of 1.000 
VHL c.491A>G,  
p.Gln164Arg 
635 (S) Missense  Mutation Not reported  
COSM14283 
- The UMD-VHL mutations: Request ID: 190515142653-45 
- SIFT: Tolerated (score 0.13).  
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- Mutation Taster: Disease causing (p-value 0.999) 
- Polyphen 2: Probably damaging  with a score of 0.998 
VHL c.496G>T,  
p.Val166Phe 
619 (S) Missense  Mutation Not reported  
COSM17982 
 
- The UMD-VHL mutations: Request ID: 190515142746-49 
- SIFT: Deleterious (score 0.03).  
- Mutation Taster: Disease causing (p-value 0.999) 
- Polyphen 2: Probably damaging  with a score of 0.989   
MAX c.425C>T,  
p.Ser142Leu 
578 (G) Missense VUS   0.00001647/0 hom 
COSM4577970 
- Probably non-pathogenic. Although it has been reported 
two times [25, 26], this variant did not show functional 
effect on MYC regulation and the aminoacid is located 
outside the basic helix-loop-helix leucine zipper domain of 
the MAX protein [27]  
- SIFT: tolerated (score 0.33).  
- Mutation Taster: Disease causing (p-value 1) 
- Polyphen 2: Probably damaging  with a score of 0.999 
SDHC  c.*90T>C,  
p? 
1017 (G) Intronic VUS  Not reported 
Not reported 
- LOVD: Not reported.  
SDHB c.455C>T,  
p.Ser152Phe 
425 (G) Missense VUS 0.00005767/0 hom 
Not reported 
 
- LOVD: Not reported.  
- FFPE tumor not available to perform SDHB-IHC. 
- SIFT: Deleterious (score 0).  
- Mutation Taster: Disease causing (p-value 1) 
- Polyphen 2: Benign with a score of 0.167 
SDHB c.49A>G,  
p.Thr17Ala 
619 (G) Missense  VUS Not reported 
Not reported 
Not ensembl 
- LOVD: Reported 1 time: Probably no pathogenicity.  
- SIFT: Tolerated (score 0.59) 
-Mutation Taster: Polymorphism (p-value 1) 
- Polyphen 2: Benign with a score of 0.000 
SDHAF2 c.451C>G,  
p.Gln151Glu 
405 (G) Missense VUS Not reported 
Not reported 
 
- LOVD: not reported.  
- This change affects a highly conserved residue in the 
phylogenetic tree. According to bioinformatic prediction 
tools, this version is considered as probably pathogenic 
PolyPhen-probably damaging, and it can affect splicing 
according to ESEfinder tool. However, two other tools 
(AGVGD and SIFT-tolerated) classified as a benign variant. 
Therefore, until we cannot show the effect of the change it 
should be considered as a VUS. The patient left the follow-
up and it was not possible to obtain a new blood sample to 
retain RNA extract and analyze the potential effect on 
splicing or FFPE tumor to analyze SDHB-IHC.  
- SIFT: Tolerated (score 0.37).  
- Mutation Taster: Disease causing (p-value 1) 
- Polyphen 2: Probably damaging with a score of 0.982  
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Supplementary table S3. Clinical characteristics of the 21 patients with no amplification of the sample analyzed. FFPE: formalin fixed paraffin-embedded; NA: Not 
amplified per amplicon (< 20 reads); PCC:pheochromocytoma; PGL: paraganglioma; HN: head and neck; A: abdominal; SDHB-IHC: SDHB immunohistochemistry; ND: 
no data; WT: Wild type; GM: germline mutation.  
Number of 
patients  
ID  Excluded Sample  
Amplicon 
coverage   
Previously 
studied  
Number  Tumor Sex 
Age 
(years) 
Behaviour 
Predominant 
secretion 
SDHB-IHC  Type of sample 
1 56 Yes Blood NA Yes Multiple Multiple PGL (HN)  Female  63 Benign No secretion ND WT 
2 66 Yes Frozen  NA Yes Single PCC Male 66 Benign Adrenergic ND WT 
3 158 Yes Frozen  NA Yes Single PCC Female  54 Benign Adrenergic Positive  WT 
4 159 Yes Frozen  NA Yes Single PCC Female  42 Benign Noradrenergic Positive  WT 
5 160 Yes Frozen  NA Yes Single PCC Male 65 Benign Adrenergic Positive  WT 
6 174 Yes Frozen  NA Yes Single PCC Female  58 Benign Unknown ND WT 
7 178 Yes Frozen  NA Yes Single PCC Male 51 Benign No data  ND WT 
8 197 Yes Blood NA Yes Single PCC Female  37 Benign Unknown ND WT 
9 199 Yes Blood NA Yes Multiple Bilateral PCC Male 11 Benign Noradrenergic ND WT 
10 246 Yes Blood NA Yes Single PCC Female  62 Benign No data  ND WT 
11 250 Yes Blood NA Yes Single PCC Male 41 Benign No data  ND WT 
12 263 Yes Blood NA Yes Single PCC Female  41 Benign Noradrenergic ND WT 
13 271 Yes Blood NA Yes Single PCC Female  62 Benign Noradrenergic ND WT 
14 306 Yes Blood NA Yes Single PCC (composite) Female  51 Benign Unknown ND WT 
15 324 Yes Frozen  NA No Single PCC Male 43 Benign Adrenergic ND WT 
16 337 Yes Frozen  NA No Single PCC Female  75 Benign Adrenergic ND WT 
17 341 Yes Blood NA Yes Single PCC (hyperplasia) Female  No data  Benign No data  ND WT 
18 415 Yes FFPE NA Yes Single  A-PGL Female 50 Benign  Noradrenergic Positive WT 
19 418 Yes FFPE NA No  Multiple  Multiple PGL (HN)  Female 14 Benign  No secretion  Negative Control GM SDHB 
20 442 Yes FFPE NA No  Single A-PGL Female 33 Malignant No data  Negative WT 
21 444 Yes FFPE NA No  Single A-PGL Female 19 Benign Noradrenergic    Negative WT 
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Supplementary table S4. Characteristics of the TGPs designed.  
  VUS: Variant of Unknown Significance; E: exon; bp: base pairs.
 Panel I Panel II 
Variants used as positive controls  
(unique variants) 
534 (73) 337 (56) 
Pathogenic category  
Mutation 17 (16) 13  
VUS 3  1 
Polymorphism 514 (54) 323 (42) 
Gene  
SDHB 10 4 
SDHA  28 24 
SDHD  5 3 
SDHAF2  2 2 
SDHC and FH 2 1 
MDH2  5 6 
TMEM127 4 1 
HRAS  1 2 
RET  8 6 
MAX  1 1 
MEN1  2 0 
NF1  3 0 
VHL  0 4 
EPAS1 0 1 
Type of variant 
Single base substitution 65 51 
Small deletion 5 2 
Small duplication  1 2 
Insertion 2 0 
Indel  0 1 
Low coverage regions (≤ 50 reads) 
SDHA (E1), SDHC (E2), MDH2 (E1), FH (E1), TMEM127 (E2), 
NF1 (E1). 
 
SDHA (E10), SDHAF2 (E1), 
RET (E8), MAX (E1), EGLN1 
(E1), KIF1B (E1, E9), NF1 (E7, 
E40), MEN1 (E2). 
MAX (E5), NF1 (E13, E23, 
E37, E46). 
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Supplementary table S5. Control variants previously found by Sanger sequencing used in panel I and II. Hom: Number of patients homozygotes described.  
PANEL-I 
MUTATIONS 
MUT. ID  
Type of 
sample  
Final  Gene 
Alt Read 
Depth 
Read         
Depth 
Alt Variant 
Freq 
Consequence cDNA Protein  
1 72 Blood Control germline mutation SDHA    SDHA 1919 3927 48.87 splice_acceptor c.457-1G>A   
2 111 Blood Control germline mutation SDHA    SDHA 1210 2297 52.68 splice_acceptor c.457-1G>A   
3 78 Blood Control germline mutation SDHA     SDHA 987 2028 48.67 missense c.1754G>A p.Arg585Gln 
4 356 Frozen  Control somatic mutation HRAS  HRAS 68 202 33.7 missense c.37G>C p.Gly13Arg 
5 300 Blood Control germline mutation SDHB SDHB 182 434 42.4 missense c.725G>A p.Arg242His 
6 12 Frozen  Control SDHB (tumor, no blood)  SDHB 501 711 70.5 frameshift c.591delC p.Ser198Alafs*22 
7 168 Frozen  Control NF1 (tumor, no blood)  NF1 999 1194 83.7 splice_donor c.1062+2T>C   
8 363 Frozen  Control NF1 (tumor, no blood)  NF1 142 199 71.4 frameshift c.4239delT p.Phe1413Leufs*15 
9 171 Frozen  Control NF1 (tumor, no blood)  NF1 493 601 82.4 frameshift c.7798_7799insA p.Ser2601Ilefs*7 
10 367 Frozen  Control RET (tumor, no blood) RET 106 198 53.5 missense c.1901G>A p.Cys634Tyr 
11 297 Blood Control germline mutation SDHAF2     SDHAF2 270 518 52.3 stop_gained c.362G>A p.Trp121* 
12 303 Blood Control germline mutation MEN1 MEN1 24 81 30.8 missense c.124G>A p.Gly42Ser 
13 298 Blood Control germline mutation MAX MAX 410 753 54.7 stop_gained c.97C>T p.Arg33* 
14 373 Blood Control germline mutation SDHD SDHD 254 514 49.5 splice_acceptor c.53-2A>G   
15 299 Blood Control germline mutation SDHD SDHD 296 581 50.9 missense c.242C>T p.Pro81Leu 
16 277 Blood Control germline mutation SDHC SDHC 350 838 41.8 stop_gained c.43C>T p.Arg15* 
17 302 Blood Control germline mutation FH FH 788 1604 49.3 missense c.575C>T p.Pro192Leu 
 
VARIANTS OF UNKNOWN SIGNIFICANCE (VUS)  
VUS ID  
Type 
of 
sample  
Final  Gene Alt Read Depth 
Read         
Depth 
Alt 
Variant 
Freq 
Consequence cDNA Protein  
1 218 Blood 
Control VUS germline SDHB, probably non 
pathogenic SDHB 1279 2633 48.6 missense c.455C>T p.Ser152Phe 
2 179 Frozen  Control VUS TMEM127 in tumor, no blood TMEM127 998 1089 92.2 missense c.448G>C p.Ala150Pro 
3 251 Blood 
Control VUS germline TMEM127, probably non 
pathogenic  TMEM127 
Not detected: Low 
coverage region (E2)     synonymous  c.267A>G  p.Thr89Thr 
 
 
 
186 
 
POLYMORPHISMS (SNPs) 
SNPs 
Unique 
SNPs 
dbSNP ID Gene 
HGVSc                 
HGVSp 
Allele 
Freq 
Allele 
Freq 
Amr 
Allele 
Freq 
Asn 
Allele 
Freq      
Af 
Allele 
Freq 
Eur 
Allele 
Freq 
ExAC 
  ID  Sample    
Alt 
Read 
Depth 
Read 
Depth 
Alt 
Variant 
Freq 
1 1 rs377134185 SDHA c.-4A>G 0 0 0 0 0 
0.4656%               
8 hom  
  62 Blood 
Low 
coverage 
region 
(E1-SDHA) 
9 15 60 
2 
2 rs34635677 SDHA 
c.113A>T   
p.Asp38Val 
1 1 0 0 3 
3.529%                      
103 hom 
  
255 Blood   1143 2258 50.8 
3 109 Blood   467 844 55.3 
4 
3 rs1139424 SDHA 
c.309A>G                       
p.Ala103Ala 
17 20 4 42 9 
15.29%                  
2023 
hom  
  
227 Blood   520 1068 49.2 
5 291 Blood   693 1425 48.7 
6 62 Blood   114 225 50.67 
7 175 Frozen    438 838 52.6 
8 
4 rs6555055 SDHA 
c.619A>C                             
p.Arg207Arg 
22 23 5 56 11 
15.68 %              
2372 
hom  
  
35 Blood   456 927 49.4 
9 58 Blood   980 2353 41.9 
10 100 Blood   270 618 43.8 
11 107 Blood   627 1617 38.9 
12 118 Blood   518 1175 44.3 
13 291 Blood   600 1210 49.8 
14 88 Blood   513 1152 44.6 
15 3 Blood   633 1408 45.1 
16 122 Blood   192 515 37.4 
17 62 Blood   432 1005 43.4 
18 175 Frozen    427 1225 34.9 
19 
5 rs2115272 SDHA 
c.684T>C                            
p.Asn228Asn 
22 23 5 56 11 
15.65 %                             
2368 
hom  
  
249 Blood   959 1950 49.4 
20 35 Blood   537 1179 45.7 
21 88 Blood   531 1096 48.5 
22 100 Blood   489 989 49.5 
23 118 Blood   499 1062 47.1 
24 291 Blood   927 2018 46.2 
25 107 Blood   1066 2208 48.5 
26 122 Blood   474 973 48.7 
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27 62 Blood   561 1059 53.1 
28 3 Blood   2003 4040 49.9 
29 262 Blood   963 1958 49.6 
30 175 Frozen    658 1463 45.2 
31 
6 rs2288461 SDHA c.771-11A>G 86 88 69 99 88 
88.10 %           
47377 
hom  
  
14 Blood   662 656 100 
32 31 Blood   707 707 100 
33 24 Blood   488 951 52.7 
34 62 Blood   819 820 100 
35 109 Blood   427 427 100 
36 118 Blood   387 1005 38.7 
37 122 Blood   509 511 99.6 
38 128 Blood   410 410 100 
39 129 Blood   467 467 100 
40 167 Blood   38 38 100 
41 224 Blood   527 1077 49.7 
42 255 Blood   1538 1557 99.7 
43 291 Blood   951 963 99.7 
44 292 Blood   1609 1614 99.9 
45 297 Blood   596 1146 52.8 
46 117 Blood   622 245 39.5 
47 107 Blood   1052 1065 99.7 
48 100 Blood   693 693 100 
49 88 Blood   529 529 100 
50 3 Blood   565 575 100 
51 7 rs34771391 SDHA 
c.822C>T     
p.Gly274Gly 
1 1 0 2 0.13 
0.4620%                     
3 hom 
  128 Blood   409 410 99.8 
52 
8 rs1126417 SDHA 
c.891T>C                                 
p.Pro297Pro 
63 70 33 73 75 
70.78%                    
31200 
hom  
  
35 Blood   893 1886 47.3 
53 3 Blood   575 577 100 
54 24 Blood   488 953 51.3 
55 100 Blood   623 1307 47.7 
56 31 Blood   903 1778 50.8 
57 109 Blood   1774 1778 99.9 
58 122 Blood   851 855 99.5 
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59 224 Blood   529 1076 49.3 
60 255 Blood   726 1557 46.8 
61 291 Blood   958 962 99.9 
62 292 Blood   1609 1611 100 
63 297 Blood   584 1144 51.2 
64 128 Blood   1681 1685 99.9 
65 129 Blood   701 1397 50.3 
66 167 Blood   1290 1292 99.8 
67 107 Blood   492 1065 46.3 
68 118 Blood   864 1861 46.5 
69 117 Blood   1575 737 46.9 
70 88 Blood   1950 1956 99.9 
71 14 Blood   659 662 100 
72 62 Blood   800 1708 46.8 
73 169 Frozen    920 1778 51.8 
74 
9 rs7710005 SDHA c.896-20A>G 22 23 5 55 11 
15.66%                      
2369 
hom  
  
88 Blood   360 798 45.1 
75 291 Blood   326 701 47.2 
76 118 Blood   590 1050 56.2 
77 122 Blood   337 692 48.8 
78 107 Blood   299 616 49.3 
79 62 Blood   563 1071 52.6 
80 10 rs142849100 SDHA 
c.969C>T     
p.Gly323Gly 
0.23 1 0 0 0.4 
0.7017%                       
12 hom  
  255 Blood   530 1112 48 
81 11 rs144252500 SDHA 
c.1002G>A                           
p.Ala334Ala 
0.09 0 0 0 0.26 
0.07907
%                
1 hom 
  169 Frozen    209 412 50.7 
82 12 rs34779890 SDHA 
c.1413C>T                
p.Ile471Ile 
0.14 0.28 0 0.2 0.13 
0.2199%              
1 hom 
  128 Blood   415 422 98.3 
83 
13 rs1041949 SDHA 
c.1038C>G              
p.Ser346Ser 
22 24 5 59 11 
15.97 %               
2574 
hom  
  
3 Blood   135 317 42.6 
84 62 Blood   172 338 50.9 
85 107 Blood   291 616 47.3 
86 100 Blood   188 394 47.7 
87 118 Blood   280 537 52.3 
88 122 Blood   177 342 51.8 
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89 291 Blood   325 701 46.4 
90 88 Blood   505 505 100 
91 35 Blood   236 466 50.6 
92 
14 rs35277230 SDHA 
c.1170C>T                        
p.Phe390Phe 
9 3 0 36 0.13 
3.240%          
579 hom 
  
237 Blood   235 472 49.9 
93 100 Blood   561 1185 47.3 
94 3 Blood   219 412 53.2 
95 
15 rs10039029 SDHA 
c.1680G>A             
p.Thr560Thr 
21 23 4 53 11 
15.27 %       
1873 
hom  
  
62 Blood   603 2358 25.6 
96 88 Blood   710 3289 21.6 
97 175 Frozen    332 1436 23.3 
98 291 Blood   573 1961 29.6 
99 122 Blood   201 397 50.6 
100 118 Blood   769 3815 20.2 
101 107 Blood   556 2049 27.5 
102 3 Blood   456 1518 30.4 
103 35 Blood   613 2653 23.1 
104 
16 rs77210621 SDHA 
c.1752A>G               
p.Ala584Ala 
22 23 4 56 11 
15.59%            
2311 
hom  
  
35 Blood   95 278 34.2 
105 88 Blood   110 382 28.9 
106 100 Blood   75 215 35.2 
107 291 Blood   642 1239 52 
108 107 Blood   714 1414 50.7 
109 118 Blood   104 318 32.7 
110 122 Blood   201 397 50.9 
111 62 Blood   120 373 32.3 
112 3 Blood   493 1015 48.9 
113 175 Frozen    593 1154 51.7 
114 17 rs150831951 SDHA 
c.1305G>T       
p.Leu435Leu 
1 2 0 0.2 3 
1.927%                 
40 hom  
  128 Blood   960 1044 92.1 
115 
18 rs6960 SDHA 
c.1886A>T                
p.Tyr629Phe 
0 0 0 0 0 
15.15%                 
500 hom  
  
55 Blood   85 210 40.9 
116 175 Frozen    359 673 53.7 
117 216 Blood   389 848 46.1 
118 19 rs372662724 SDHA 
c.1909-14_1909-
13delCT 
0 0 0 0 0 
0.000825
5%                    
0 hom   
Positive 
SDHB-IHC 
confirms 
as a SNP  
291 Blood   339 1445 23.5 
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119 
20 rs35549341 SDHA c.1908+15C>T 5 7 0.17 1 11 
Not 
describe
d 
  
211 Blood   329 688 48.1 
120 216 Blood   444 848 52.4 
121 122 Blood   205 260 79.2 
122 297 Blood   51 81 63 
123 167 Blood   674 1411 47.8 
124 109 Blood   441 829 53.2 
125 268 Blood   172 366 47.1 
126 177 Frozen    590 1196 49.4 
127 
21 rs6961 SDHA 
c.1932G>A      
p.Val644Val 
34 32 33 58 20 
17.16%               
2406 
hom  
  
35 Blood   1190 1851 64.3 
128 50 Blood   1265 2043 62.1 
129 3 Blood   1203 2211 54.7 
130 31 Blood   875 2223 39.4 
131 62 Blood   779 1486 52.6 
132 100 Blood   1360 1884 72.2 
133 224 Blood   922 2499 36.9 
134 255 Blood   563 2362 23.9 
135 291 Blood   880 1443 61 
136 292 Blood   871 2604 33.5 
137 297 Blood   482 1933 25 
138 107 Blood   249 524 48 
139 118 Blood   1438 2258 63.7 
140 122 Blood   983 1523 64.5 
141 128 Blood   362 1361 26.7 
142 129 Blood   639 1683 38 
143 167 Blood   735 2145 34.3 
144 109 Blood   724 1971 36.8 
145 88 Blood   958 1500 63.9 
146 24 Blood   760 2093 36.4 
147 14 Blood   679 1900 35.9 
148 58 Blood   2173 3208 67.9 
149 175 Frozen    384 524 73.3 
150 
22 rs148627127 SDHA 
c.1944_1945delTT    
p.Leu649Glufs*4 
3 3 6 3 1 
1.35 %                         
0 hom  
  
122 Blood   435 1523 28.6 
151 297 Blood   483 1935 25 
191 
 
152 
 
 
100 Blood   511 1886 27.1 
153 
23 rs6962 SDHA 
c.1969G>A             
p.Val657Ile 
16 20 4 35 11 
12.98%             
796 hom  
  
35 Blood   749 1851 40.6 
154 3 Blood   1210 2213 54.7 
155 107 Blood   251 524 48 
156 122 Blood   548 1523 36 
157 291 Blood   540 1445 37.4 
158 118 Blood   888 2260 39.3 
159 100 Blood   533 1886 28.3 
160 50 Blood   797 2049 38.9 
161 175 Frozen    184 526 35 
162 
24 rs1042446 SDHA 
c.1974G>C    
p.Pro658Pro 
0 0 0 0 0 
2.348 %                           
0 hom  
  
24 Blood   758 2090 36.3 
163 88 Blood   440 1496 29.4 
164 109 Blood   724 1966 36.9 
165 224 Blood   926 2497 37.2 
166 255 Blood   553 2360 23.5 
167 291 Blood   343 1445 23.8 
168 292 Blood   866 2598 33.4 
169 297 Blood   481 1933 25 
170 122 Blood   430 1518 28.4 
171 128 Blood   359 1355 26.6 
172 129 Blood   632 1681 37.7 
173 167 Blood   718 2133 33.8 
174 118 Blood   547 2256 24.3 
175 100 Blood   830 1879 44.2 
176 31 Blood   890 2223 40.1 
177 14 Blood   665 1895 35.2 
178 
25 rs1042476 SDHA c.*13T>C 0 0 0 0 0 
0.2999%                        
0 hom  
Positive 
SDHB-IHC 
in
samples 
with ID 
14,24, 88, 
24 Blood   746 2093 36.1 
179 100 Blood   837 1886 44.5 
180 122 Blood   435 1523 28.6 
181 128 Blood   363 1361 26.7 
182 224 Blood   937 2505 37.4 
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183 128,129 
and 291.  
255 Blood   568 2362 24.1 
184 291 Blood   344 1445 23.8 
185 297 Blood   486 1933 25.2 
186 167 Blood   738 2147 34.5 
187 109 Blood   729 1971 37.1 
188 88 Blood   449 1500 30 
189 31 Blood   890 2223 40.1 
190 14 Blood   670 1901 35.7 
191 
26 rs200769995 SDHA c.*14G>A 0 0 0 0 0 
0.2982%                        
0 hom  
Positive 
SDHB-IHC 
in 
samples 
with ID 
14,24,31,
100,109,1
28,129,16
7,224,291
,292 and 
297 
confirms 
as a SNP 
24 Blood   758 2091 36.3 
192 109 Blood   724 3215 22.6 
193 224 Blood   925 2502 37.1 
194 255 Blood   561 2358 23.8 
195 292 Blood   869 2598 33.5 
196 297 Blood   482 1933 25 
197 129 Blood   636 2846 22.4 
198 167 Blood   737 3669 20.1 
199 122 Blood   437 2592 16.9 
200 100 Blood   827 3083 26.8 
201 31 Blood   877 3681 23.9 
202 14 Blood   674 1901 35.6 
203 
27 rs33927012 SDHB 
c.487T>C            
p.Ser163Pro 
1 1 0 0.2 2 
1.254%                 
21 hom 
  
27 Blood   2570 5000 51.6 
204 28 Blood   25 38 65.8 
205 109 Blood   1202 1210 99.8 
206 107 Blood   713 1457 49 
207 118 Blood   914 914 100 
208 114 Blood   277 539 51.4 
209 
28 rs34261028 SDHB 
c.424-19_424-
14delTTCTTC 
0 0 0 0 0 
Not 
describe
d 
LARRIBA: 
POP-FT 
(ensembl)
: 1/92 
(1,1%)  
122 Blood   258 758 37.1 
210 11 Blood   588 1118 53.9 
211 
29 rs386134266 SDHB 
c.424-19_424-
14dupTTCTTC 
0 0 0 0 0 
Not 
describe
d 
Previously 
reported 
as an SNP 
in LOVD-
35 Blood   347 949 38.9 
212 79 Blood   182 560 34.8 
213 130 Blood   205 585 38.4 
193 
 
Alrashdi 
(2010) 
214 
30 rs148738139 SDHB 
c.24C>T                  
p.Ser8Ser 
0 0 0 0 0 
0.4299%                      
1 hom   
  
150 Frozen    499 560 89.1 
215 344 Blood   269 599 45.1 
216 31 rs147815442 SDHB 
c.21C>T                   
p.Leu7Leu 
0.05 0 0 0 0.13 
0.05238
%                   
0 hom  
Previously 
reported 
as an SNP 
in LOVD-
Cascon 
(2002) 
90 Blood   513 1018 50.5 
217 
32 rs2746462 SDHB c.18C>A   p.Ala6Ala 95 97 99 87 96 
97.21 %                 
53297 
hom  
  
298 Blood   86 89 100 
218 230 Blood   626 736 85.5 
219 10 
Genomip
hi 
  418 699 60.1 
220 11 Blood   971 1126 86.6 
221 16 Blood   328 620 53.1 
222 243 Blood   888 1270 70.4 
223 40 Blood   756 894 85.1 
224 117 Blood   1169 1157 99.9 
225 100 Blood   407 407 100 
226 107 Blood   696 713 98.6 
227 122 Blood   737 740 100 
228 128 Blood   1124 1130 99.8 
229 129 Blood   902 909 99.9 
230 167 Blood   1866 1877 99.9 
231 31 Blood   1120 1122 100 
232 224 Blood   504 507 99.8 
233 255 Blood   1458 1473 99.5 
234 291 Blood   845 859 99.4 
235 292 Blood   1806 1814 99.8 
236 297 Blood   689 701 99.7 
237 52 Blood   468 842 55.8 
238 14 Blood   684 694 99 
239 88 Blood   1226 1230 99.7 
240 3 Blood   287 292 99 
241 62 Blood   1451 1451 100 
194 
 
242 218 Blood   589 715 82.4 
243 24 Blood   1031 1046 99.3 
244 86 Frozen    346 558 62.5 
245 112 Blood   600 886 67.8 
246 130 Blood   479 559 86.2 
247 319 Blood   1001 1016 98.7 
248 33 rs11203289 SDHB 
c.8C>G                     
p.Ala3Gly 
1 0 0 4 0.13 
0.436%                     
8 hom  
  33 Blood   24 50 48 
249 34 rs77711105 RET 
c.1942G>A                   
p.Val648Ile 
0 0 0 0 0 
0.009076
%                    
0 hom  
Previously 
reported 
as non 
pathogeni
c in ARUP-
Cosci B 
(2011) 
304 
Genomip
hi 
  268 521 51.8 
250 
35 rs148935214 RET 
c.1946C>T           
p.Ser649Leu 
0.09 0.28 0 0 0.13 
0.03217
%                
0 hom  
Previously 
reported 
as an SNP 
in Erlic Z 
(2010) 
116 Frozen    690 1316 52.5 
251 345 Blood   182 337 54.3 
252 
36 rs1799939 RET 
 c.2071G>A                  
p.Gly691Ser 
15 23 10 9 20 
20.33%                   
2840 
hom 
  
2 Blood   179 381 47 
253 223 Blood   23 62 37.1 
254 308 Blood   490 496 98.8 
255 230 Blood   88 193 45.6 
256 14 Blood   82 156 52.6 
257 200 Blood   280 574 49 
258 17 Blood   571 1176 48.6 
259 239 Blood   251 571 44 
260 20 Blood   150 306 49.5 
261 241 Blood   233 597 39.2 
262 242 Blood   26 46 56.5 
263 243 Blood   276 560 49.7 
264 24 Blood   151 270 56.1 
265 291 Blood   70 153 45.8 
266 245 Blood   204 421 48.8 
267 247 Blood   462 466 99.1 
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268 249 Blood   39 90 43.3 
269 256 
Genomip
hi 
  78 202 38.6 
270 266 Blood   104 209 50.2 
271 267 Blood   184 393 46.8 
272 31 Blood   426 428 99.5 
273 57 Blood   154 288 53.8 
274 62 Blood   377 758 49.8 
275 215 Blood   258 518 50 
276 269 Blood   100 255 39.5 
277 176 Frozen    93 201 46.3 
278 179 Frozen    36 79 46.2 
279 183 Frozen    57 227 25.1 
280 184 Frozen    124 256 48.6 
281 86 Frozen    534 1145 46.8 
282 279 Blood   247 454 54.4 
283 129 Blood   309 578 53.5 
284 167 Blood   260 543 48.1 
285 282 Blood   142 333 42.9 
286 108 Blood   95 175 54.3 
287 287 Blood   190 372 51.1 
288 116 Frozen    445 949 47 
289 344 Blood   125 264 47.9 
290 345 Blood   122 278 44.4 
291 349 Blood   154 326 47.2 
292 350 Blood   160 310 52.1 
293 
37 rs1800861 RET 
c.2307G>T                  
p.Leu769Leu 
72 77 49 90 76 
74.19%                   
33769 
hom  
  
304 
Genomip
hi 
  574 1135 50.9 
294 305 Blood   654 1351 48.6 
295 4 Blood   201 384 53 
296 225 Blood   341 737 46.5 
297 5 Blood   262 476 55 
298 6 Blood   78 141 55.3 
299 11 Blood   290 575 50.6 
196 
 
300 13 Frozen    165 283 58.7 
301 237 Blood   240 509 47.5 
302 20 Blood   739 1457 50.8 
303 24 Blood   1230 1260 98.5 
304 244 Blood   529 997 53.5 
305 245 Blood   613 1281 48.1 
306 29 Blood   167 305 55.3 
307 29 Frozen    152 258 58.9 
308 248 Blood   773 1554 49.9 
309 203 Blood   637 1245 51.2 
310 251 Blood   724 1537 47.4 
311 3 Blood   625 642 97.8 
312 31 Blood   363 365 100 
313 14 Blood   747 757 99.5 
314 257 Blood   625 1229 51.3 
315 262 Blood   435 896 48.9 
316 62 Blood   432 434 100 
317 100 Blood   257 257 100 
318 266 Blood   573 1235 46.6 
319 122 Blood   225 464 48.7 
320 128 Blood   390 390 100 
321 129 Blood   280 280 100 
322 167 Blood   357 359 100 
323 172 Blood   910 1846 49.6 
324 109 Blood   180 341 52.9 
325 57 Blood   170 340 50.3 
326 117 Blood   234 112 47.9 
327 224 Blood   502 502 100 
328 255 Blood   913 929 99.1 
329 291 Blood   897 913 98.9 
330 297 Blood   550 564 98.4 
331 107 Blood   671 1441 46.8 
332 215 Blood   624 1182 52.8 
197 
 
333 270 Blood   910 1847 49.5 
334 279 Blood   733 1528 48.2 
335 282 Blood   287 638 45.3 
336 118 Blood   419 419 100 
337 88 Blood   417 418 99.8 
338 288 Blood   758 1558 49 
339 130 Blood   155 313 49.5 
340 292 Blood   875 1725 50.9 
341 294 Blood   111 227 49.3 
342 352 Blood   840 1707 49.6 
343 38 rs77724903 RET 
c.2372A>T   
p.Tyr791Phe 
0 0 0 0 0 
 0.1803%                     
1 hom 
Toledo RA 
(2015) 
discarded 
pathogeni
city of the 
variant 
130 Blood   50,8 313 158 
344 
39 rs1800862 RET 
c.2508C>T                           
p.Ser836Ser 
3 5 0 2 5 
4.666%          
188 hom  
  
221 Blood   948 961 99.3 
345 11 Blood   644 1086 59.3 
346 237 Blood   82 148 55.4 
347 19 Blood   12 50 24 
348 122 Blood   335 549 61.1 
349 244 Blood   513 1064 48.4 
350 172 Blood   679 1548 44 
351 270 Blood   661 1392 47.6 
352 181 Frozen    369 777 47.6 
353 278 Blood   14 44 31.8 
354 279 Blood   456 956 47.7 
355 
40 rs1800863 RET 
c.2712C>G                      
p.Ser904Ser 
16 22 10 11 20 
0.003383 
%                    
0 hom  
  
2 Blood   218 459 47.5 
356 223 Blood   95 195 48.7 
357 230 Blood   246 543 45.6 
358 14 Blood   174 337 51.9 
359 17 Blood   502 1032 48.8 
360 239 Blood   355 700 50.9 
361 20 Blood   240 499 48.5 
362 241 Blood   367 837 44.1 
198 
 
363 242 Blood   101 193 52.3 
364 24 Blood   290 564 51.5 
365 245 Blood   269 520 51.9 
366 247 Blood   552 557 99.5 
367 249 Blood   81 186 43.5 
368 204 Blood   265 544 48.7 
369 256 
Genomip
hi 
  94 159 59.1 
370 44 Blood   215 419 51.3 
371 266 Blood   289 521 55.7 
372 267 Blood   320 674 47.5 
373 172 Blood   292 606 48.3 
374 62 Blood   472 1023 46.2 
375 215 Blood   373 765 48.8 
376 291 Blood   167 338 49.4 
377 31 Blood   845 845 100 
378 269 Blood   185 386 48.1 
379 176 Frozen    562 977 57.6 
380 179 Frozen    309 592 52.2 
381 129 Blood   337 708 47.6 
382 167 Blood   244 460 53 
383 183 Frozen    94 357 26.3 
384 184 Frozen    377 735 51.3 
385 86 Frozen    494 1012 48.8 
386 279 Blood   275 557 49.8 
387 282 Blood   204 436 46.9 
388 287 Blood   211 470 45.2 
389 116 Frozen    783 1512 51.8 
390 344 Blood   162 292 55.5 
391 345 Blood   262 531 49.3 
392 349 Blood   243 431 56.4 
393 350 Blood   199 373 53.8 
199 
 
394 41 rs201389647 
SDHA
F2 
c.37+17 T>C 0.23 0.28 0 1 0 
Not 
describe
d 
  218 Blood   16 33 48.5 
395 
42 rs2071313 
MEN
1 
c.1269C>T                           
p.Asp423Asp 
31 33 40 5 40 
39.34%            
10125 
hom 
  
129 Blood   147 329 44.7 
396 252 Blood   38 65 58.5 
397 
43 
rs17849553, 
rs6720 
MDH
2 
c.26C>T                         
p.Ala9Val 
51 41 62 72 33 
44.54 %                
1657 
hom  
  
72 Blood   518 992 52.22 
398 116 Frozen    72 89 80.9 
399 129 Blood 
Low 
coverage 
region 
(E1-
MDH2)  
12 12 100 
400 258 Blood   51 131 39.2 
401 208 Blood 
Low 
coverage 
region 
(E1-
MDH2)  
8 8 100 
402 215 Blood 
Low 
coverage 
region 
(E1-
MDH2)  
9 9 100 
403 280 Blood   88 275 32.2 
404 3 Blood 
Low 
coverage 
region 
(E1-
MDH2)  
2 4 50 
405 62 Blood   76 141 54.3 
406 109 Blood   23 23 100 
407 107 Blood   273 278 99.6 
408 292 Blood   87 203 44.4 
409 297 Blood 
Low 
coverage 
region 
(E1-
MDH2)  
5 17 31.3 
410 128 Blood   22 22 100 
200 
 
411 129 Blood 
Low 
coverage 
region 
(E1-
MDH2)  
12 12 100 
412 88 Blood   23 42 54.8 
413 285 Blood   212 477 44.9 
414 295 Blood 
Low 
coverage 
region 
(E1-
MDH2)  
4 5 80 
415 222 Blood 
 Low 
coverage 
region 
(E1-
MDH2) 
      
416 
44 rs79663210 
MDH
2 
c.235+10G>A 7 5 2 5 11 
8.615 % 
528 hom  
  
254 Blood   1537 3149 48.8 
417 258 Blood   919 1868 49.3 
418 270 Blood   1204 2461 49.1 
419 297 Blood   1145 2349 48.9 
420 109 Blood   1000 1008 99.6 
421 128 Blood   960 964 99.6 
422 280 Blood   1039 2008 51.9 
423 127 Blood   370 808 45.8 
424 129 Blood   385 745 51.7 
425 
45 rs11538801 
MDH
2 
c.429G>A                             
p.Pro143Pro 
1 0.28 0 0.41 2 
1.866%                   
38 hom  
  
4 Blood   831 1604 51.9 
426 64 Blood   736 1366 53.9 
427 107 Blood   485 1106 44.2 
428 77 Blood   1103 2127 52 
429 285 Blood   845 1939 44.1 
430 133 Frozen    891 1758 50.8 
431 
46 rs1637037 
MDH
2 
c.633+17C>T 53 40 62 81 33 
40.59%                 
11189 
hom  
  
11 Blood   454 953 47.6 
432 16 Blood   215 446 48.3 
433 258 Blood   311 630 49.4 
434 208 Blood   278 519 53.7 
435 62 Blood   385 765 50.3 
201 
 
436 215 Blood   306 600 51 
437 72 Blood   1239 2487 49.82 
438 292 Blood   416 811 51.4 
439 297 Blood   251 511 49.2 
440 76 Blood   365 754 48.7 
441 88 Blood   805 806 99.9 
442 280 Blood   296 588 50.6 
443 103 Blood   201 315 63.8 
444 3 Blood   128 228 56.1 
445 100 Blood   665 666 100 
446 117 Blood   585 278 47.5 
447 107 Blood   441 449 98.7 
448 109 Blood   784 790 99.5 
449 285 Blood   486 985 49.4 
450 116 Frozen    736 1364 54.1 
451 127 Blood   499 1031 48.4 
452 128 Blood   645 647 99.7 
453 129 Blood   274 528 52 
454 133 Frozen    760 1714 44.4 
455 295 Blood   168 280 60.4 
456 
47 rs10256 
MDH
2 
c.902A>G           
p.Lys301Arg 
2 4 0 0.2 5 
3.704 %             
103 hom  
  
231 Blood   604 1204 50.5 
457 262 Blood   355 742 47.9 
458 291 Blood   387 800 48.5 
459 285 Blood   672 1507 44.7 
460 117 Blood   752 395 52.6 
461 122 Blood   258 473 54.5 
462 112 Blood   303 653 46.5 
463 220 Blood   455 837 54.6 
464 
48 rs3852673 
TME
M127 
c.621G>A                  
p.Ala207Ala 
11 13 8 5 18 
16.34 %                
1938 
hom  
  
1 
Genomip
hi 
  335 660 51 
465 8 
Genomip
hi 
  102 229 44.7 
466 8 Blood   244 545 44.9 
467 19 Blood   175 293 59.7 
202 
 
468 261 Blood   389 850 46 
469 207 Blood   348 693 50.2 
470 172 Blood   358 726 49.4 
471 214 Blood   1157 1165 99.8 
472 71 Blood   28 46 63.6 
473 75 Blood   169 240 70.4 
474 109 Blood   275 500 55 
475 272 Blood   92 168 54.8 
476 175 Frozen    43 209 20.6 
477 177 Frozen    188 383 49.6 
478 278 Blood   65 98 66.3 
479 24 Blood   268 608 44.4 
480 255 Blood   294 623 47.4 
481 291 Blood   272 623 43.7 
482 292 Blood   590 1200 49.5 
483 92 Blood   65 73 89 
484 117 Blood   411 229 55.9 
485 94 Blood   292 458 64.2 
486 116 Frozen    561 881 63.8 
487 342 Blood   274 530 51.9 
488 345 Blood   340 735 46.3 
489 348 Blood   321 645 49.8 
490 351 Blood   222 456 48.8 
491 49 rs189327749 
TME
M127 
c.409+7C>T                
p.Ala207Ala 
0.46 1 0 0 1 
0.5177%                     
1 hom  
  230 Blood   767 1631 47.2 
492 
50 rs34677591 SDHD 
c.34G>A                  
p.Gly12Ser 
1 2 0 0.2 1 
0.7268 %                 
5 hom  
  
32 Blood   33 82 40.2 
493 69 Blood   582 1136 51.4 
494 182 Frozen    265 709 37.5 
495 
51 rs11214077 SDHD 
c.149A>G                
p.His50Arg 
1 2 0 0 1 
0.6515 %                 
6 hom  
  
3 Blood   762 1623 47.1 
496 224 Blood   711 1503 47.4 
497 224 Blood   711 1503 47.4 
498 60 Blood   1236 2403 51.5 
203 
 
499 
52 rs9919552 SDHD 
c.204C>T                  
p.Ser68Ser 
10 3 0 39 1 
3.976%              
622 hom  
  
237 Blood   509 1149 44.6 
500 21 Blood   325 838 38.8 
501 32 Blood   467 1081 43.3 
502 69 Blood   301 663 45.7 
503 83 Blood   238 575 41.8 
504 100 Blood   282 600 47.1 
505 
53 
rs35215598, 
rs75726722 
SDHC c.20+9_20+10insGT 14 8 22 23 5 
10.53 %                
891 hom  
  
100 Blood   73 125 58.4 
506 134 Frozen    186 330 56.4 
507 
54 rs61737760 FH 
c.927G>A                    
p.Pro309Pro 
3 2 4 2 3 
3.489 %              
104 hom  
  
1 
Genomip
hi 
  1018 1998 51.3 
508 9 Blood   951 1972 48.3 
509 201 Blood   679 1327 51.2 
510 239 Blood   808 1572 51.5 
511 264 Blood   938 1812 52.1 
512 267 Blood   757 1559 48.7 
513 70 Blood   750 1544 49.1 
514 98 Blood   784 1520 51.8 
 
PANEL-II 
   MUTATIONS 
MUT. ID  
Type of 
sample  
Final  Gene 
Alt 
Read 
Depth 
Read 
Depth 
Alt 
Variant 
Freq 
Consequence cDNA Protein  
1 78 FFPE Control germline mutation SDHA    SDHA 30 32 93.75 missense c.1754G>A p.Arg585Gln 
2 411 FFPE Control somatic mutation HRAS    HRAS 638 2266 28.16 missense c.182A>G p.Gln61Arg 
3 419 FFPE Control somatic mutation HRAS    HRAS 1248 3063 40.74 missense c.37G>C p.Gly13Arg 
4 396 FFPE Control somatic mutation VHL    VHL 
19 71 26.76 missense c.227T>A p.Phe76Tyr 
18 67 26.87 synonymous c.228C>T p.Phe76Phe 
5 422 FFPE Control somatic mutation VHL    VHL 50 338 14.79 missense c.260T>C p.Val87Ala 
6 454 FFPE Control somatic mutation VHL    VHL 196 851 23.03 missense c.482G>A p.Arg161Gln 
7 453 FFPE 
Control germline mutation SDHB 
(c.595delTACTGGTGGAinsGG; p.Tyr199Glyfs*19) 
SDHB 
393 1391 28.25 frameshift c.605delA p.Asn202Thrfs*18 
403 1129 35.7 frameshift c.601_604delTGGA p.Trp201Thrfs*18 
390 1322 29.5 frameshift c.595_601delTACTGGT p.Tyr199Glyfs*19 
410 1331 30.8 frameshift c.595_598delTACT p.Tyr199Glyfs*20 
204 
 
8 380 FFPE Control germline mutation RET RET 45 81 55.56 missense c.1900T>C p.Cys634Arg 
9 386 FFPE Control somatic mutation RET     RET 29 106 27.36 missense c.2753T>C p.Met918Thr 
10 122 FFPE Control somatic mutation EPAS1 EPAS1 1666 6262 26.6 missense c.1591C>G p.Pro531Ala 
11 297 FFPE Control germline mutation SDHAF2    SDHAF2 7526 12709 59.22 stop_gained c.362G>A p.Trp121* 
12 416 FFPE Control germline mutation MDH2    MDH2 195 359 54.32 splice_donor c.429+1G>T   
13 117 FFPE Control somatic mutation SDHD    (VUS SDHD) SDHD 1188 1802 65.93 stop_gained c.112C>T p.Arg38* 
 
VARIANTS OF UNKNOWN SIGNIFICANCE (VUS)  
VUS ID 
Type of 
sample  
Final  Gene 
Alt 
Read 
Depth 
Read 
Depth 
Alt 
Variant 
Freq 
Consequence cDNA Protein  
1 382 FFPE Control VUS germline MAX     MAX 67 126 53.17 missense c.425C>T p.Ser142Leu 
 
POLYMORPHISMS (SNPs) 
rs 
Unique 
rs 
dbSNP ID Gene 
HGVSc                 
HGVSp 
Allele 
Freq 
Allele 
Freq 
Amr 
Allele 
Freq 
Asn 
Allele 
Freq      
Af 
Allele 
Freq 
Eur 
Allele 
Freq 
ExAC 
  ID    
Alt 
Read 
Depth 
Read 
Depth 
Alt 
Variant 
Freq 
1 
1 
rs346356
77 
SDHA 
c.113A>T   
p.Asp38Val 
1 1 0 0 3 
3.529%       
103 
hom 
  
109   1342 2759 48.64 
2 255   503 939 53.57 
3 
2 
rs113942
4 
SDHA 
c.309A>G    
p.Ala103Ala 
17 20 4 42 9 
15.29%     
2023 
hom 
  
62   306 681 44.93 
4 291   253 691 36.61 
5 
3 
rs655505
5 
SDHA 
c.619A>C    
p.Arg103Arg 
22 23 5 56 11 
15.68%   
2372 
hom  
  
100   1079 2698 39.99 
6 62   1526 3549 43 
7 122   1621 3979 40.74 
8 291   1217 2804 43.4 
9 3   1245 2511 49.58 
10 107   1369 2711 50.5 
11 118   2024 5649 35.83 
12 88   639 1267 50.43 
13 
4 
rs211527
2 
SDHA 
c.684T>C     
p.Asn228Asn 
22 23 5 56 11   
100   688 1556 44.22 
14 62   598 1075 55.63 
205 
 
15 
15.65%    
2368 
hom 
122   642 1320 48.64 
16 291   711 1172 60.67 
17 3   466 914 50.98 
18 107   477 1094 43.6 
19 118   247 847 29.16 
20 88   219 463 47.3 
21 
5 
rs228846
1 
SDHA c.771-11A>G 86 88 69 99 88 
88.10 % 
47377 
hom  
  
100   527 527 100 
22 62   819 843 97.15 
23 117   282 1024 27.54 
24 122   754 758 99.47 
25 109   294 294 100 
26 129   514 514 100 
27 31   1278 1284 99.53 
28 291   423 423 100 
29 3   479 487 98.36 
30 297   1087 2562 42.43 
31 108   1118 1125 99.38 
32 24   82 224 36.61 
33 107   735 738 99.59 
34 118   481 1647 29.2 
35 128   561 561 100 
36 14   110 110 100 
37 167   1194 1198 99.67 
38 88   227 227 100 
39 224   567 1435 39.51 
40 255   399 399 100 
41 292   90 103 87.38 
42 6 
rs347713
91 
SDHA 
c.822C>T     
p.Gly274Gly 
1 1 0 2 0.13 
0.4620%       
3 hom 
  128   561 565 99.29 
43 
7 
rs112641
7 
SDHA 
c.891T>C    
p.Pro297Pro 
63 70 33 73 75 
70.78% 
31200 
hom  
  
100   1282 3190 40.19 
44 62   3016 6336 47.6 
45 117   2377 4769 49.84 
46 122   6787 6816 99.57 
206 
 
47 109   4175 4294 97.23 
48 129   723 2669 27.09 
49 31   3582 6981 51.31 
50 291   4131 4272 96.7 
51 3   4929 4996 98.66 
52 297   5887 11684 50.39 
53 108   5980 5984 99.93 
54 24   1084 2325 46.62 
55 107   2080 4045 51.42 
56 118   2406 7321 32.86 
57 128   5439 5493 99.02 
58 14   1342 1404 95.58 
59 167   6283 6323 99.37 
60 88   3326 3337 99.67 
61 224   4731 9334 50.69 
62 255   2386 4502 53 
63 292   1449 1605 90.28 
64 
8 
rs771000
5 
SDHA c.896-20A>G 22 23 5 55 11 
15.66%     
2369 
hom  
  
62   3484 6020 57.87 
65 122   3591 7128 50.38 
66 291   2313 4541 50.94 
67 107   3848 8360 46.03 
68 118   2119 6691 31.67 
69 88   2381 5063 47.03 
70 9 
rs142849
100 
SDHA 
c.969C>T     
p.Gly323Gly 
0.23 1 0 0 0.4 
0.7017%        
12 hom  
  255   256 598 42.81 
71 
10 
rs104194
9 
SDHA 
c.1038C>G      
p.Ser346Ser 
22 24 5 59 11 
15.97 %     
2574 
hom  
  
100   521 1004 51.89 
72 62   532 1205 44.15 
73 122   795 1536 51.76 
74 291   465 1089 42.7 
75 3   348 838 41.53 
76 107   631 1197 52.72 
77 118   486 1361 35.71 
78 88   229 413 55.45 
207 
 
79 
11 
rs352772
30 
SDHA 
c.1170C>T    
p.Phe390Phe 
9 3 0 36 0.13 
3.24%        
579 
hom 
  
100   239 415 57.59 
80 3   414 746 55.5 
81 12 
rs150831
951 
SDHA 
c.1305G>T       
p.Leu435Leu 
1 2 0 0.2 3 
1.927%        
40 hom  
  128   4339 6185 70.15 
82 13 
rs347798
90 
SDHA 
c.1413C>T                
p.Ile471Ile 
0.14 0.28 0 0.2 0.13 
0.2199%          
1 hom 
  128   6814 6831 99.75 
83 
14 
rs100390
29 
SDHA 
c.1680G>A           
p.Thr560Thr 
21 23 4 53 11 
15.27 %   
1873 
hom 
  
62   396 1697 23.34 
84 122   701 3379 20.75 
85 291   694 2814 24.66 
86 3   551 2335 23.6 
87 107   404 1901 21.25 
88 118   703 4637 15.16 
89 88   236 1221 19.33 
90 
15 
rs772106
21 
SDHA 
c.1752A>G             
p.Ala584Ala 
22 23 4 56 11 
15.59 %    
2311 
hom 
  
100   1094 2411 45.38 
91 62   2190 3977 55.07 
92 122   1511 2968 50.91 
93 291   2110 4106 51.39 
94 3   1208 2634 45.86 
95 107   1341 2525 53.11 
96 118   1454 4030 36.08 
97 88   628 1272 49.37 
98 
16 
rs355493
41 
SDHA 
c.1908+15C>
T 
5 7 0.17 1 11 
Not 
describe
d 
  
122   476 484 98.35 
99 109   287 613 46.82 
100 297   951 1909 49.82 
101 167   700 1319 53.07 
102 17 
rs372662
724 
SDHA 
c.1909-
14_1909-
13delCT 
0 0 0 0 0 
0.00082
55%    0 
hom   
Positive 
SDHB-IHC 
confirms 
as a SNP  
291   164 717 22.87 
103 
18 rs6961 SDHA 
c.1932G>A     
p.Val644Val 
34 32 33 58 20 
17.16%    
2406 
hom 
  
100   1402 1817 77.16 
104 62   410 793 51.7 
105 122   1561 2319 67.31 
106 109   615 1566 39.27 
208 
 
107 129   815 1408 57.88 
108 31   595 1546 38.49 
109 291   568 719 79 
110 3   442 753 58.7 
111 297   690 3046 22.65 
112 24   263 648 40.59 
113 107   455 1130 40.27 
114 118   713 1293 55.14 
115 128   221 1369 16.14 
116 14   168 506 33.2 
117 167   958 2606 36.76 
118 88   375 574 65.33 
119 224   708 2381 29.74 
120 255   201 719 27.96 
121 292   81 425 19.06 
122 
19 
rs148627
127 
SDHA 
c.1944_1945
delTT    
p.Leu649Gluf
s*4 
3 3 6 3 1 
1.35 %             
0 hom  
  
100   360 1829 19.68 
123 122   475 2329 20.4 
124 297   683 3085 22.14 
125 
20 rs6962 SDHA 
c.1969G>A    
p.Val657Ile 
16 20 4 35 11 
12.98 %    
796 
hom 
  
100   718 1821 39.43 
126 122   1063 2324 45.74 
127 291   369 726 50.83 
128 3   444 751 59.12 
129 107   460 1141 40.32 
130 118   296 1288 22.98 
131 
21 
rs104244
6 
SDHA 
c.1974G>C    
p.Pro658Pro 
0 0 0 0 0 
2.348 %         
0 hom  
  
100   657 1818 36.14 
132 122   492 2327 21.14 
133 109   612 1574 38.88 
134 129   794 1390 57.12 
135 31   587 1550 37.87 
209 
 
136 291   187 723 25.86 
137 297   670 3072 21.81 
138 24   256 650 39.38 
139 118   388 1279 30.34 
140 128   221 1372 16.11 
141 14   158 507 31.16 
142 167   938 2595 36.15 
143 88   79 575 13.74 
144 224   705 2383 29.58 
145 255   191 721 26.49 
146 292   55 419 13.13 
147 
22 
rs104247
6 
SDHA c.*13T>C 0 0 0 0 0 
0.2999%        
0 hom  
Positive 
SDHB-IHC 
in 
samples 
with ID 
14,24, 88, 
128,129 
and 291.  
291   20 112 17.86 
148 24   93 288 32.29 
149 128 
Low coverage 
region (E1-SDHA) 
12 162 7.41 
150 14   61 238 25.63 
151 88   28 279 10.04 
152 255   77 340 22.65 
153 
23 
rs200769
995 
SDHA c.*14G>A 0 0 0 0 0 
0.2982%        
0 hom  
Positive 
SDHB-IHC 
in 
samples 
with ID 
14,24,31,
100,109,1
28,129,16
7,224,291
,292 and 
297 
confirms 
as a SNP 
100 
Low coverage 
region (E1-SDHA) 
193 4089 4.72 
154 109 
Low coverage 
region (E1-SDHA) 
254 4263 5.96 
155 129 
Low coverage 
region (E1-SDHA) 
252 3396 7.42 
156 31   806 5197 15.51 
157 297 
Low coverage 
region (E1-SDHA) 
453 8968 5.05 
158 24   258 1810 14.25 
159 14   183 1162 15.75 
160 167 
Low coverage 
region (E1-SDHA) 
530 5356 9.9 
161 224 
Low coverage 
region (E1-SDHA) 
610 6414 9.51 
210 
 
162 255 
Low coverage 
region (E1-SDHA) 
187 2717 6.88 
163 292 
Low coverage 
region (E1-SDHA) 
76 1415 5.37 
164 
22 and 
23 
rs104247
6 and 
rs200769
995 
SDHA 
c.*13_*14inv
TG 
0 0 0 0 0 
Not 
describe
d 
Positive 
SDHB-IHC 
in 
samples 
31,100,10
9,122,167 
and 224 
confirms 
as a SNP.  
100   651 1806 36.05 
165 122   417 2289 18.22 
166 109   581 1556 37.34 
167 31   565 1542 36.64 
168 297   255 1487 17.15 
169 167   361 1209 29.86 
170 224   275 1127 24.4 
171 24 
rs636508
60 
VHL 
c.183C>G    
p.Pro61Pro 
0 0 0 0 0.05 
0.2542%        
0 hom  
Previously 
reported 
as a SNP 
in Gallou 
(1999) 
412   275 358 76.82 
172 25 
rs339270
12 
SDHB 
c.487T>C            
p.Ser163Pro 
1 0 0.2 2 0.95 
1.254 %         
21 hom  
  107   318 689 46.15 
173 26 
rs386134
266 
SDHB 
c.424-
19_424-
14dupTTCTTC 
0 0 0 0 0 
Not 
describe
d  
Previously 
reported 
as a SNP 
in 
Rattenber
ry (2013)  
122 Positive SDHB-IHC  316 1625 19.45 
174 
27 
rs274646
2 
SDHB 
c.18C>A     
p.Ala6Ala 
97 99 87 96 95.15 
97.21 % 
53297 
hom  
  
100   1220 1225 99.59 
175 62   1192 1215 98.11 
176 117   952 954 99.79 
177 122   1447 1476 98.04 
178 109   1858 1866 99.57 
179 129   578 578 100 
180 31   1248 1248 100 
181 291   1255 1263 99.37 
182 3   536 538 99.63 
183 297   1626 1636 99.39 
184 108   960 963 99.69 
211 
 
185 24   207 207 100 
186 107   462 462 100 
187 118   1494 1506 99.2 
188 128   1016 1051 96.67 
189 14   238 240 99.17 
190 167   1256 1258 99.84 
191 88   164 164 100 
192 224   746 748 99.73 
193 255   368 408 90.2 
194 292   177 177 100 
195 
28 
rs179993
9 
RET 
c.2071G>A           
p.Gly691Ser 
23 10 9 20 15.7 
2033%    
2840 
hom 
  
379   552 1151 47.96 
196 381   666 1480 45 
197 385   313 728 42.99 
198 62   674 1346 50.07 
199 404   307 766 40.08 
200 410   713 1366 52.2 
201 129   360 763 47.18 
202 413   427 968 44.11 
203 31   1409 1415 99.58 
204 428   554 897 61.76 
205 291   467 1105 42.26 
206 451   313 434 72.12 
207 382   201 405 49.63 
208 108   783 1433 54.64 
209 399   321 668 48.05 
210 24   177 324 54.63 
211 14   121 210 57.62 
212 167   795 1071 74.23 
213 
29 
rs180086
1 
RET 
c.2307G>T            
p.Leu769Leu 
77 49 90 76 80.26 
74.19 %    
33769 
hom  
  
379   1406 2917 48.2 
214 100   2319 2327 99.66 
215 62   2191 2227 98.38 
216 117   1291 2163 59.69 
217 122   2404 4835 49.72 
212 
 
218 410   1907 3467 55 
219 109   1628 3311 49.17 
220 411   1077 2100 51.29 
221 129   2158 2169 99.49 
222 412   1097 3304 33.2 
223 419   1000 2207 45.31 
224 31   3028 3041 99.57 
225 291   2942 3033 97 
226 434   1135 2227 50.97 
227 3   2584 2588 99.85 
228 297   4331 4343 99.72 
229 108   3333 3344 99.67 
230 24   1395 1436 97.14 
231 405   600 1097 54.69 
232 107   1153 2285 50.46 
233 118   4521 4531 99.78 
234 128   2429 2475 98.14 
235 14   1069 1114 95.96 
236 416   2328 4373 53.24 
237 167   2428 2457 98.82 
238 88   1112 1142 97.37 
239 224   3440 3448 99.77 
240 255   1623 1752 92.64 
241 292   246 805 30.56 
242 
30 
rs180086
2 
RET 
c.2508C>T           
p.Ser836Ser 
5 0 2 5 4.24 
4.666%      
188 
hom  
  
379   2116 4346 48.69 
243 122   1809 3541 51.09 
244 410   2060 3963 51.98 
245 412   1012 1937 52.25 
246 414   951 2043 46.55 
247 416   3639 7029 51.77 
248 
31 
rs180086
3 
RET 
c.2712C>G          
p.Ser904Ser 
22 10 11 20 16.09 
20.57 % 
2745 
hom  
  
379   491 1021 48.09 
249 381   817 1591 51.35 
250 62   367 806 45.53 
213 
 
251 404   198 491 40.33 
252 410   636 1326 47.96 
253 129   473 912 51.86 
254 413   408 909 44.88 
255 31   1033 1038 99.52 
256 291   274 642 42.68 
257 451   371 805 46.09 
258 382   201 257 78.21 
259 108   690 1430 48.25 
260 399   421 770 54.68 
261 24   153 233 65.67 
262 14   57 168 33.93 
263 167   960 1309 73.34 
264 421   410 655 62.6 
265 32 
rs370174
263 
SDHAF2 
c.451C>G                
p.Gln151Glu 
0 0 0 0 0.01 
Not 
describe
d  
Positive 
SDHB-IHC 
confirms 
as a SNP.  
395   296 835 35.45 
266 
33 
rs178495
53, rs6720 
MDH2 
c.26C>T            
p.Ala9Val 
41 62 72 33 39.15 
44.54%     
1657 
hom  
  
292   144 213 67.61 
267 451   122 361 33.8 
268 3   303 703 43.1 
269 297   422 968 43.6 
270 385   460 1018 45.19 
271 62   626 1121 55.84 
272 107   316 316 100 
273 109   2402 2458 97.72 
274 129   333 636 52.36 
275 128   1175 1193 98.49 
276 88   112 204 54.9 
277 377 
Low coverage 
region (E1-MDH2) 
      
278 412 
Low coverage 
region (E1-MDH2) 
      
214 
 
279 
34 
rs796632
10 
MDH2 c.235+10G>A 5 2 5 11 8.99 
8.615%     
528 
hom 
  
297   1756 3250 54.03 
280 385   889 1494 59.5 
281 109   1779 1781 99.89 
282 129   720 1254 57.42 
283 128   1599 1627 98.28 
284 
35 
rs115388
01 
MDH2 
c.429G>A        
p.Pro143Pro 
0.28 0 0.41 2 1.16 
1.866%         
38 hom  
  
107   65 111 58.56 
285 412   88 158 55.7 
286 
36 
rs163703
7 
MDH2 c.633+17C>T 40 62 81 33 44.02 
40.59%    
11189 
hom 
  
3   2460 4798 51.27 
287 297   5726 12555 45.61 
288 385   1692 3365 50.28 
289 100   2629 2699 97.41 
290 62   1938 3806 50.92 
291 396   965 1982 48.69 
292 117   2148 4110 52.26 
293 107   3770 3782 99.68 
294 109   4032 4052 99.51 
295 129   1562 3005 51.98 
296 412   2952 7192 41.05 
297 128   4638 4714 98.39 
298 88   1684 3194 52.72 
299 292   636 1484 42.86 
300 451   1772 3478 50.95 
301 
37 rs10256 MDH2 
c.902A>G          
p.Lys301Arg 
4 0 0.2 5 3.6 
3.704%      
103 
hom  
  
389   544 1205 45.15 
302 117   808 1631 49.54 
303 122   891 1453 61.32 
304 291   688 1383 49.75 
305 
38 
rs385267
3 
TMEM1
27 
c.621G>A           
p.Ala207Ala 
13 8 5 18 13.87 
16.34%    
1938 
hom 
  
381   897 1739 51.58 
306 117   754 1251 60.27 
307 410   902 1883 47.9 
308 109   390 870 44.83 
309 291   660 1083 60.94 
310 24   148 294 50.34 
311 405   143 279 51.25 
215 
 
312 255   134 398 33.67 
313 292   147 373 39.41 
314 
39 
rs112140
77 
SDHD 
c.149A>G       
p.His50Arg 
2 0 0 1 0.63 
0.6515%         
6 hom  
  
378   520 1271 40.91 
315 389   643 1282 50.16 
316 3   757 1522 49.74 
317 405   319 621 51.37 
318 224   337 1684 20.01 
319 
40 
rs991955
2 
SDHD 
c.204C>T  
p.Ser68Ser 
3 0 39 1 12.01 
3.976%    
622 
hom  
  
384   181 482 37.55 
320 100   422 878 48.06 
321 
41 
rs352155
98, 
rs757267
22 
SDHC 
c.20+11_20+
12dupTG 
8 22 23 5 11.22 
10.53%       
891 
hom  
  
100   335 923 36.29 
322 411   296 653 45.33 
323 42 
rs617377
60 
FH 
c.927G>A   
p.Pro309Pro  
2 4 2 3 2.21 
3.489 %    
104 
hom   
  108   1279 2490 51.37 
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Supplementary table S6. Variants (mutations and VUS) found by TGPs and validated by Sanger sequencing. Mut.:Mutation; Mutu: Unique mutation; IHC: SDHB-immunohistochemistry; M or VUS: mutation or Variant of 
Unknown Significance; ExAC database: Prevalence described in the The Exome Aggregation Consortium (ExAC); LOVD: Presence described in the Leiden Open (source) Variation Database; ND: not described; Pubmed: 
Previously published; Alt.: Altered; FFPE: Formalin fixed paraffin-embedded tumor tissue; Neg.: Negative SDHB-IHC; Pos: Positive SDHB-IHC; SM: Somatic mutations, GM: Germline mutation; Tumor, no blood: Mutation 
found in tumor DNA sample, and no germline DNA available to check if the variant is somatic or germline; SIFT/Polyphen: protein functional prediction in SIFT and Polyphen 2; tol.: tolerated; del.:deleterious; COSMIC: 
prevalence in COSMIC: Catalogue of Somatic Mutations in Cancer; AF: Allele Frequency; Amr: Americans; Asn: Asian; Eur: European population; LOHLoss Of Heterozygosity; qPCR: quantitative PCR; RBP1: Retinol Binding 
Protein 1; 5hmC: 5-hydroxymethylcytosine; 2SC: 2-Succinocysteine. 
Mut Mutu 
M  
or 
VUS 
Gene cDNA Protein  ExAC database LOVD Pubmed ID  Sample  IHC  
Alt Read 
Depth 
Read 
Depth 
Alt Variant 
Freq 
Type 
1 1 M SDHA c.91C>T p.Arg31* 
20 of 121408 allele count. 0 
homozygotes. 0.0001647 allele 
frequency. 
Reported 2 times 
as pathogenic 
(r.1065_1260del 
(exon 9 
skipping)) in 
Netherlands: 
Nijmegen 
Previously reported Korpershoek (2011) as 
pathogenic (Neg. SDHB/SDHA-IHC) 
368 Blood 
Neg. 754 1643 46.1 
GM 
2 2 M SDHA 
c.1334C
>T 
p.Ser445Leu ND ND 
Previously reported Papathomas (2015)  as 
pathogenic (Neg. SDHB/SDHA-IHC) 
124 Blood 
Neg. 834 1538 54.3 
GM 
3 
3 
M 
HRAS 
c.182A>
G 
p.Gln61Arg ND ND Previously reported Crona (2013) 
88 FFPE 
Pos. 425 934 45.5 
SM 
            
 Blood 
       
 
4 M HRAS 
c.182A>
G 
p.Gln61Arg ND ND Previously reported Crona (2013) 
151 Frozen  
Pos.  15 24 62.5 
SM 
5 M HRAS 
c.182A>
G 
p.Gln61Arg ND ND Previously reported Crona (2013) 
359 Frozen  
ND 116 313 37.1 
SM 
6 M HRAS 
c.182A>
G 
p.Gln61Arg ND ND Previously reported Crona (2013) 
360 Frozen  
ND 55 185 29.9 
SM 
7 M HRAS 
c.182A>
G 
p.Gln61Arg ND ND Previously reported Crona (2013) 
376 Frozen  
ND 25 210 11.9 
SM 
8 M HRAS 
c.182A>
G 
p.Gln61Arg ND ND Previously reported Crona (2013) 
433 FFPE 
Pos. 470 1961 23.97 
SM 
9 M HRAS 
c.182A>
G 
p.Gln61Arg ND ND Previously reported Crona (2013) 
436 FFPE 
Pos. 1006 2266 44.4 
SM 
10 4 M HRAS 
c.182A>
T 
p.Gln61Leu ND ND 
ND. but reported p.Gln61Arg in Crona (2013)  and 
p.Gln61Lys in Oudijk (2013)  
449 FFPE 
Pos. 222 1272 17.45 
SM 
11 5 M HRAS c.37G>C p.Gly13Arg ND ND Previously reported Crona (2013) 
320 Frozen  
ND 353 911 38.8 
SM 
217 
 
12 M HRAS c.37G>C p.Gly13Arg ND ND Previously reported Crona (2013) 
375 Frozen  
ND 55 345 16.1 
SM 
13 
6 
M VHL 
c.193T>
G 
p.Ser65Ala ND ND 
VHL alliance database: Previously reported in 
Neumann (2002) in VHL disease and in Burnichon 
(2011) in PPGL; UMD-VHL: ND. but reported 
p.Ser65Pro; p.Ser65Trp and p.Ser65Leu 
148 Frozen  
Pos.  81 192 44.8 
SM 
14 M VHL 
c.193T>
G 
p.Ser65Ala ND ND 
VHL alliance database: Previously reported in 
Neumann (2002) in VHL disease and in Burnichon 
(2011) in PPGL; UMD-VHL: ND. but reported 
p.Ser65Pro; p.Ser65Trp and p.Ser65Leu 
153 Frozen  
Pos.  48 172 29.1 
SM 
16 M VHL 
c.193T>
G 
p.Ser65Ala ND ND 
VHL alliance database: Previously reported in 
Neumann (2002) in VHL disease and in Burnichon 
(2011) in PPGL; UMD-VHL: ND. but reported 
p.Ser65Pro; p.Ser65Trp and p.Ser65Leu 
372 Frozen  
ND 9 67 13.6 
? 
15 7 M 
VHL 
c.193T>
A 
p.Ser65Thr ND ND 
Previously reported in Crona (2014); UMD-VHL: ND. 
but reported p.Ser65Pro; p.Ser65Trp and 
p.Ser65Leu 
190 Frozen  
ND 36 135 27.7 
SM 
            
 Blood 
       
 
17 8 M VHL 
c.233A>
G 
p.Asn78Ser ND ND 
VHL alliance database: Previously reported in Chen 
(1995); UMD-VHL: Reported 6 times 
326 Frozen  
ND 30 52 57.7 
SM 
18 9 M 
VHL 
c.244C>
G 
p.Arg82Gly ND ND 
Previously reported in Burnichon (2011); UMD-VHL: 
ND. but described p.Arg82Cys and p.Arg82Pro 
291 FFPE 
Pos. 194 283 68.55 
SM 
            
 Blood 
       
 
19 10 M VHL 
c.376G>
A 
p.Asp126Asn ND ND 
VHL alliance database: Previously reported in Brauch 
(2004); UMD-VHL: ND. but reported p.Asp126Gly 
355 Frozen  
ND 577 885 65.6 
? 
20 11 M VHL 
c.407T>
G 
p.Phe136Cys ND ND 
VHL alliance database: Previously reported in 
Whaley (1994); UMD-VHL: Reported 1 time 
323 Frozen  
ND 255 1892 13.6 
SM 
21 
12 
M VHL 
c.414A>
G 
p.Pro138Pro ND ND 
Previously reported in  A. Giménez Roqueplo 
P11.242 European-society-of-human-genetics 
Meeting; UMD-VHL: ND 
182 Frozen  
Pos.  239 913 26.4 
SM 
22 M VHL 
c.414A>
G 
p.Pro138Pro ND ND 
Previously reported in  A. Giménez Roqueplo 
P11.242 European-society-of-human-genetics 
Meeting; UMD-VHL: ND 
353 Frozen)  
ND 227 716 31.7 
SM 
23 13 M VHL 
c.464T>
G 
p.Val155Gly ND ND 
UMD-VHL: ND. but reported p.Val155Met and 
p.Val155Leu 
274 Frozen  
ND 25 179 14 
SM 
24 14 M 
VHL 
c.494T>
G 
p.Val165Gly ND ND 
VHL alliance database: Previously reported in Baker 
(2000); UMD-VHL: ND 
100 FFPE 
Pos. 58 1240 4.68 
SM 
            
 Blood 
       
 
25 15 M VHL 
c.500G>
A 
p.Arg167Gln ND ND 
VHL alliance database: Previously reported in 
Crossey (1994); UMD-VHL: Reported 28 times 
327 Frozen  
ND 194 458 42.5 
SM 
218 
 
26 16 M VHL 
c.598C>
T 
p.Arg200Trp ND 
Reported 2 times 
as pathogenic  
VHL alliance database: Previously reported in 
Kishida. Stackhouse et al. (1995); UMD-VHL: 
Reported 3 times 
374 Blood 
ND 253 515 49.1 
GM 
27 17 M 
            
125 Blood 
Pos.        
SM 
VHL 
c.284C>
G  
p.Pro95Arg ND ND 
VHL alliance database: Previously reported in Gallou 
(1999)  
 FFPE 
  123 256  48.0  
 
28 
18 
M SDHB 
c.649C>
T 
p.Arg217Cys ND 
Reported 2 times 
(somatic 
mutation in 1) 
Previously described Burnichon (2009)  
149 Frozen  
Neg. 315 404 78 
GM 
29 M SDHB 
c.649C>
T 
p.Arg217Cys ND 
Reported 2 times 
(somatic 
mutation in 1) 
Previously described Burnichon (2009)  
334 Frozen  
ND 241 375 64.4 
GM 
30 19 M SDHB 
c.591del
C 
p.Ser198Alafs*22 ND Reported 2 times Previously described Burnichon (2009)  
162 Blood 
Neg. 252 607 41.7 
GM 
31 
20 
M SDHB 
c.503du
pA 
p.Gln169Alafs*10 ND ND   
329 Frozen  
ND 1158 1452 80.2 
GM 
32 M SDHB 
c.503du
pA 
p.Gln169Alafs*10 ND ND   
331 Frozen  
ND 769 971 79.6 
GM 
33 21 M SDHB 
c.424-
3C>G 
  ND 
Reported 1 time: 
Proven splice 
defect: United 
States. exon 5 
skipping and 
truncation at 
248aa. Spain 
Previously reported Papathomas (2015)  as 
pathogenic (Neg. SDHB/SDHA-IHC) 
2 Blood 
Neg. 345 738 46.7 
GM 
34 22 M SDHB 
c.393du
pA 
p.His132Thrfs*23 ND ND 
ND, but previously reported Maier-Woelfle (2004) as 
pathogenic c.395A>C; p.His132Pro 
441 Blood 
Neg. 2591 5000 52.0 
GM 
35 23 M SDHB 
c.380T>
G 
p.Ile127Ser ND 
Reported 1 time: 
concluded 
pathogenicity: 
unknown 
Previously reported Papathomas (2015) as 
pathogenic (Neg. SDHB/SDHA-IHC) 
371 Frozen  
ND 1003 1667 60.3 
? (probably 
GM) 
36 24 GD SDHB  
exon 1 
deletion  
  ND Reported 2 times  Previously reported in Cascon (2006) 
152 Frozen  
ND       
GM 
37 25 M NF1 
c.349del
A 
p.Ile117Serfs*48 ND ND Previously reported in Pros (2008) in NF1 patient  
365 Frozen  
ND 264 365 72.3 
? (probably 
SM. LOH) 
38 
26 
M(X2) 
NF1 
c.517G>
C 
p.Asp173His ND ND   
434 FFPE 
Pos. 410 893 45.91 
SM 
27 NF1 
c.519del
T 
p.Asp173Glufs*5 ND ND   
  
 410 892 45.96 
 
39 28 M NF1 
c.574C>
T 
p.Arg192* 
1 of 119128 allele count. 0 
homozygotes. 0.000008394 allele 
frequency. 
Reported 23 
times as 
pathogenic 
Previously described in Messiaen (2000) 
135 Frozen  
Pos.  339 522 64.9 
SM 
40 29 M NF1 
c.654+1
G>A 
  ND 
Reported 2 times 
as pathogenic 
ND, but previously reported in  Laycock-van Spyk 
(2011) in a case with NF1 the variant c.654+1G>T as 
pathogenic  
330 Frozen  
ND 898 1070 83.9 
SM 
41 30 M NF1 
c.889-
1G>T 
  ND 
ND, but c.889-
1G>C reported 
as pathogenic in 
Netherlands: 
Rotterdam  
ND, but reported in Laycock-van Spyk (2011) as 
pathogenic in NF1  c.889-2A>G 
385 FFPE 
Pos. 659 1094 60.24 
SM 
42 31 M NF1 
c.901_9
09delG
ACAGTC
TA 
p.Asp301_leu303del   ND ND   
407 FFPE 
Pos. 758 1519 49.9 
SM 
219 
 
43 32 M NF1 
c.980del
T 
p.Leu327Argfs*49 ND ND   
409 FFPE 
Pos. 1117 1996 55.96 
SM 
44 
33 
M 
NF1 
c.1607C
>G 
p.Ser536* ND 
Reported as 
pathogenic in 
Netherlands: 
Rotterdam  
ND, but previously reported in Messiaen (2000) as 
pathogenic the variant c.1607 C>A; P.Ser536* 
194 Frozen  
ND 1505 1725 87.4 
SM 
            
 Blood 
       
 
45 M 
NF1 
c.1607C
>G 
p.Ser536* ND 
Reported as 
pathogenic in 
Netherlands: 
Rotterdam  
ND, but previously reported in Messiaen (2000) as 
pathogenic the variant c.1607 C>A; P.Ser536* 
195 Frozen  
ND 808 830 97.6 
SM 
            
 Blood 
       
 
46 34 M NF1 
c.1642-
1G>A 
  ND 
Reported as 
pathogenic in 
Netherlands: 
Rotterdam  
  
313 Frozen  
ND 148 221 67.6 
SM 
47 35 M NF1 
c.1706_
1707ins
AT 
p.Phe570Tyrfs*17 ND ND   
325 Frozen  
ND 108 179 61 
GM 
48 36 M NF1 
c.2125T
>C 
p.Cys709Arg ND 
Reported as 
pathogenic in 
Netherlands: 
Rotterdam  
  
388 FFPE 
Pos. 73 343 21.28 
SM 
49 37 M NF1 
c.2364_
2385del
AAAGCT
AATCCT
TAACTA
TCCA 
p.Leu790Profs*24 ND ND   
381 FFPE 
Pos. 764 889 85.94 
SM 
50 38 M NF1 
c.2464G
>T 
p.Gly822* ND 
Reported as 
pathogenic in 
Netherlands: 
Rotterdam  
Previously reported in Bausch (2007) in patients with 
NF1 and PCC  
357 Blood 
ND 220 485 45.5 
GM 
51 39 M NF1 
c.2592_
2593del
CC 
p.Pro865Thrfs*7 ND ND   
447 FFPE 
Pos. 1401 2048 68.41 
? (probably 
SM. LOH) 
52 40 M NF1 
c.2666d
elC 
p.Thr889Asnfs*13 ND ND Previously reported in Fahsold (2000) in NF1 
404 FFPE 
Pos. 1628 2774 58.69 
SM 
53 41 M NF1 
c.2703d
elA 
p.Met902Trpfs*22 ND ND   
430 FFPE 
Pos. 6147 7940 77.42 
? (probably 
SM. LOH) 
54 42 M 
NF1 
c.3114-
1delG 
p.Asn1039Ilefs*4  ND ND   
129 FFPE 
Pos. 1001 2010 49.8 
SM 
            
 Blood 
       
 
55 43 M NF1 
c.3132C
>A 
p.Tyr1044* ND ND   
176 Frozen  
ND 146 151 98.6 
SM 
56 44 M NF1 
c.3783_
3787del
TTCTA 
p.Phe1261Leufs*21 ND ND   
133 Frozen  
Pos.  860 1145 75.2 
SM 
57 45 M NF1 
c.5609+
1G>A 
  ND ND   
424 FFPE 
Pos. 842 2131 39.51 
SM 
220 
 
58 46 M NF1 
c.6236d
elC 
p.Ala2079Valfs*3 ND ND   
332 Frozen  
ND 769 931 82.6 
GM 
59 47 M NF1 
c.6585_
6586du
pGA 
p.Thr2196Argfs*5 
1 (Latino) of 121402 allele count. 0 
homozygotes. 0.000008237 allele 
frequency.  
ND   
392 FFPE 
Pos. 659 2035 32.38 
SM 
60 48 M NF1 
c.6854_
6855ins
T 
p.Asn2286Glnfs*21 ND ND   
437 FFPE 
Pos. 4493 8490 52.92 
SM 
61 49 M NF1 
c.7199A
>G 
p.His2400Arg ND ND   
394 FFPE 
Pos. 1274 3909 32.59 
SM 
62 50 M NF1 
c.7909C
>T 
p.Arg2637* ND ND Previously described in Toledo (2015)  
431 FFPE 
Pos. 890 1770 50.28 
SM 
63 
51 M NF1 
c.3974G
>T 
p.Arg1325Met ND 
ND, but 
c.3974G>C 
reported as 
pathogenic in 
Netherlands: 
Rotterdam and 
France: Paris  
  
382 FFPE 
Pos. 807 1622 49.75 
SM 
  VUS MAX 
c.425C>
T 
p.Ser142Leu 
2 of 121410 allele count. 0 
homozygotes. 0.00001647 allele 
frequency.  
ND 
Previously described in Comino (2015) as 
nonpathogenic  
  
 67 126 53.17 
GM 
64 
52 M NF1 
c.6350d
elC 
p.Arg2119Glufs*31 ND ND   
166 Frozen  
Pos.  404 851 47.5 
SM 
  VUS MEN1 
c.-
10G>A 
  ND ND UMD-MEN1: Reported 3 times: likely neutral  
  
 115 368 31.3 
GM (no 
LOH)  
65 53 M RET 
c.2326T
>C 
p.Phe776Leu ND ND Previously reported in Niederle (2014) in MTC 
283 Blood 
ND 650 1240 52.8 
GM 
66 54 M 
RET 
c.2647G
>T 
p.Ala883Ser ND ND Previously reported in Gimm O (1997) 
354 Frozen  
ND 136 427 31.9 
? (probably 
SM)  
RET 
c.2648C
>T 
p.Ala883Val ND ND Previously reported in Gimm O (1997) 
  
 137 427 32.2 
 
67 
55 
M RET 
c.2753T
>C 
p.Met918Thr ND ND ARUP: First reference: Hofstra (1994) 
116 Frozen  
Pos.  638 1629 39.4 
SM 
68 M RET 
c.2753T
>C 
p.Met918Thr ND ND ARUP: First reference: Hofstra (1994) 
138 Frozen  
Pos.  188 662 28.4 
SM 
69 M RET 
c.2753T
>C 
p.Met918Thr ND ND ARUP: First reference: Hofstra (1994) 
164 Frozen  
Pos.  178 832 21.4 
SM 
70 M RET 
c.2753T
>C 
p.Met918Thr ND ND ARUP: First reference: Hofstra (1994) 
340 Frozen  
Pos.  255 622 41.2 
SM 
71 M RET 
c.2753T
>C 
p.Met918Thr ND ND ARUP: First reference: Hofstra (1994) 
369 Frozen  
ND 553 1378 40.4 
? (probably 
SM)  
72 M RET 
c.2753T
>C 
p.Met918Thr ND ND ARUP: First reference: Hofstra (1994) 
370 Frozen  
ND 247 649 38.1 
? (probably 
SM)  
221 
 
73 M RET  
c.2753T
>C 
p.Met918Thr ND ND ARUP: First reference Hofstra (1994) 
393 FFPE 
Pos. 1454 3580 40.61 
SM 
74 
  VUS EPAS1 
c.1199T
>C 
p.Leu400Pro ND ND   
275 Frozen  
Pos.  179 353 50.9 
? (probably 
SM)  
56 M EPAS1 
c.1591C
>A 
p.Pro531Thr ND ND Previously reported Toledo (2013) as pathogenic  
  
 253 1040 24.4 
 
75 57 M EPAS1 
c.1592C
>T 
p.Pro531Leu ND ND Previously reported Comino (2013) 
154 Frozen  
Pos.  211 555 38 
SM 
76 
  VUS EPAS1 
c.1611G
>C 
p.Gly537Gly ND ND   
322 Frozen  
ND 323 934 34.6 
SM 
58 M EPAS1 
c.1615G
>C 
p.Asp539His ND ND ND. but reported p.Asp539Tyr in Comino (2013) 
  
 323 934 34.7 
 
77 59 M SDHAF2 
c.232G>
A 
p.Gly78Arg ND 
Reported 2 
times: Dutch 
Founder 
mutation. 
Spanish 
recurrent 
mutation 
Previously reported in Hao (2009) as pathogenic 
145 Frozen  
Neg. 491 822 60 
GM 
78 60 M MAX c.1A>G p.Met1Val ND 
Reported 2 times 
in Spain  
Previously reported in Comino (2011) 
191 Blood 
Pos.  61 103 60.4 
GM 
79 61 M SDHD c.49C>T p.Arg17* ND Reported 2 times Previously reported in Neumann (2009)  
147 Frozen  
Neg. 176 331 53.2 
GM 
80 62 M SDHD 
c.169+5
G>T 
  ND 
ND, but reported 
1 time 
c.169+5G>A. 
Netherlands. 
France. 
Splicesite 
mutation? 
cDNA: SDHD 
exon 2 skipping 
Previously described Burnichon (2009)  
336 Frozen  
ND 461 574 80.5 
? (probably 
GM) 
81 63 M SDHD 
c.239T>
G 
p.Leu80Arg ND ND Previously described Burnichon (2009)  
328 Frozen  
ND 463 888 52.4 
GM 
82 64 M SDHD 
c.334_3
37delAC
TG 
p.Asp113Metfs*21 ND ND Previously described Burnichon (2009)  
50 Blood 
Neg. 439 806 54.5 
GM 
83 65 M 
SDHD 
c.443G>
A 
p.Gly148Asp ND 
Reported 1 time 
in France 
Previously described Burnichon (2009)  
296 Blood 
Neg. 198 1055 18.8 
GM 
SDHD 
c.443G>
A 
p.Gly148Asp ND 
Reported 1 time 
in France 
Previously described Burnichon (2009)  
 Saliva  
 201 1042 19.3 
 
84 66 M SDHC c.43C>T p.Arg15* ND 
Reported 2 times 
as pathogenic 
Previously described Burnichon (2009)  
67 Blood 
ND 729 1504 48.5 
GM 
85 67 M SDHC 
c.214C>
T 
p.Arg72Cys 
 1 (East Asian) of 121412 allele 
count. 0 homozygotes. 
0.000008236 allele frequency. 
Reported 2 times 
as probably 
pathogenic: 
functional 
domain. 
conserved 
residue. 0/164 
controls 
Previously described Burnichon (2009)  
106 Blood 
Neg. 839 1635 51.4 
GM 
86 68 M SDHC 
c.379C>
T 
p.His127Tyr ND ND Previously reported in Buffet (2012)  
141 Frozen  
Neg. 492 1062 46.3 
GM 
222 
 
87 69 M FH 
c.1431_
1433du
pAAA 
p.Lys477dup 
110 of 121266 allele count. 0 
homozygous. 0.0009071.  
Reported 9 times  Previously described in Coughlin (1998)  
114 Blood 
Pos.  193 497 40 
GM 
88 70 M FH 
c.580G>
A 
p.Ala194Thr 
10 of 120820 allel count. 0 
homozygotes. 0.00008277 allele 
frequency 
ND Previously described in Castro (2014) 
358 Frozen  
ND 736 1314 56.1 
GM 
89 71 M FH 
c.555+1
G>A 
  ND 
Reported 2 times 
as probably 
pathogenic   
Previously described in Gardie (2011) in HLRCC 
247 Blood 
Pos.  745 1426 52.3 
GM 
 
VUS 
V
U
Su 
Gene cDNA Protein  Sift PolyPhen dbSNP ID 
COSMIC 
ID 
AF 
AF 
Amr 
AF 
Asn 
AF Af 
AF 
Eur 
LOVD Pubmed ExAC database ID ALL 
Sampl
e  
Alt Read 
Depth 
Read 
Depth 
Alt 
Var. 
Freq 
Type 
VUS 
Additio
nal 
studies 
Final decision  
1 1 SDHA c.125G>A 
p.Arg42Ly
s 
tol benign     0 0 0 0 0 ND 
  
1 (Latino) of 121410 
allele count. 0 
homozygotes. 
0.000008237 allele 
frequency. 
310 
Blood 412 885 47.1 
G 
Negativ
e SDHB-
IHC; 
Positive 
SDHA-
IHC.  
Probably non 
pathogenic 
FFPE 446 1058 42.16 
2 2 SDHA c.155C>T 
p.Ser52Ph
e 
del. 
possibly_
damaging 
    0 0 0 0 0 ND   
15 of 121302 allele 
count. 0 
homozygotes. 
0.0001237 allele 
frequency. 
165 Frozen  89 160 55.6 G 
Positive 
SDHB-
IHC 
Probably non 
pathogenic 
3 3 SDHA c.354C>T 
p.Asn118
Asn  
                  ND   ND 362 Frozen  530 1136 46.9 
Tumor. 
no 
blood  
FFPE 
slide to 
perfor
m 
SDHB/S
DHA-
IHC 
request
ed 
Probably non 
pathogenic 
4 4 SDHA c.456+6G>T       
rs371735
891 
            ND   
34 of 119486 allele 
count. 0 
homozygotes. 
0.0002846 allele 
frequency.  
361 Blood 735 1433 51.7 G 
FFPE 
slide to 
perfor
m 
SDHB/S
DHA-
IHC 
request
ed 
Probably non 
pathogenic 
5 5 SDHA c.723C>T 
p.Asp241
Asp 
    
rs146653
693 
  0 0 0 0 0 ND   
 59 of 121404 allele 
count. 0 
homozygotes. 
0.0004860 allele 
frequency. 
253 Blood 1833 3596 51.2 G 
FFPE 
slide to 
perfor
m 
SDHB/S
DHA-
IHC 
request
ed  
Probably non 
pathogenic 
223 
 
6 6 SDHA 
c.770+12A>
G 
      
rs201245
536 
  0 0 0 0 0 ND   
5 of 120462 allele 
count. 0 
homozygotes. 
0.00004151 allele 
frequency. 
65 Frozen  850 1552 54.9 G 
FFPE 
slide to 
perfor
m 
SDHB/S
DHA-
IHC 
request
ed  
Probably non 
pathogenic 
7 7 SDHA 
c.1432+16A
>G 
          0 0 0 0 0 ND   
2 of 121330 allele 
count. 0 
homozygotes. 
0.00001648 alelel 
frequency.  
90 Blood 234 429 54.8 G 
FFPE 
slide to 
perfor
m 
SDHB/S
DHA-
IHC 
request
ed  
Probably non 
pathogenic 
8 8 SDHA c.1456C>A 
p.Pro486T
hr 
tol. benign 
rs138190
937 
  0 0 0 0 0 ND   ND 89 Blood 489 894 54.8 G 
FFPE 
slide to 
perfor
m 
SDHB/S
DHA-
IHC 
request
ed  
Probably non 
pathogenic 
9 9 SDHA c.1644C>T 
p.His548H
is 
    
rs112642
7 
  0 0 0 0 0 ND   
2 (European non-
Finnish) of 121394 
allele count. 0 
homozygotes. 
0.00001648 allele 
frequency. 
192 
Blood 550 1200 45.9 
G 
FFPE 
slide to 
perfor
m 
SDHB/S
DHA-
IHC 
request
ed  
Probably non 
pathogenic 
Frozen  613 1125 54.7 
10 10 KIF1B c.146C>A 
p.Ser49Ty
r 
del 
possibly_
damaging 
rs143654
307 
COSM347
0408.COS
M347040
9 
          ND ND 
10 of 121406 allele 
count. 0 
homozygotes. 
0.00008237. 
170 Blood 1358 2505 54.3 G   Unknown  
11 11 KIF1B c.635A>C 
p.Glu212A
la 
tol. 
probably
_damagin
g 
    0 0 0 0 0 ND ND ND 110 Blood 932 1845 50.7 G   Unknown  
12 
12 KIF1B c.1456C>G 
p.Pro486A
la 
del. 
possibly_
damaging 
rs201500
946 
  0.05 0 0 0 0.13 ND ND ND 
26 Frozen  719 1365 52.8 G   Unknown  
13 86 Frozen  508 1624 31.4 G 
Positive 
SDHB-
IHC 
Unknown  
14 270 Blood 1016 1925 53.3 G   Unknown  
15 13 SDHB c.455C>T 
p.Ser152P
he 
del. Benign 
rs200414
835 
  0 0 0 0 0 ND   
7 (African) of 121370 
allele count. 0 
homozygotes. 
0.00005767 allele 
frequency.  
218 Blood 1279 2633 48.6 G 
FFPE 
slide to 
perfor
m 
SDHB/S
DHA-
IHC 
request
ed  
Probably 
nonpathogenic 
(patient origin in 
Africa)  
224 
 
16 14 SDHB c.221A>G 
p.Asp74Gl
y 
del. 
probably
_damagin
g 
    0 0 0 0 0 ND   ND 163 Blood 83 196 42.6 G 
FFPE 
slide to 
perfor
m 
SDHB/S
DHA-
IHC 
request
ed  
Posible 
pathogenic 
17 15 NF1 c.4118G>T 
p.Cys1373
Phe 
del. 
possibly_
damaging 
    0 0 0 0 0 ND   ND 68 Blood 330 718 46 G 
No NF1 
phenot
ypic 
feature
s 
Probably non 
pathogenic 
18 16 NF1 
c.4430+1G>
T 
          0 0 0 0 0 ND   ND 180 Frozen  858 1086 79.2 G 
No NF1 
phenot
ypic 
feature
s 
Probably non 
pathogenic 
19 17 NF1 c.4796C>T 
p.Ser1599
Phe 
del. 
probably
_damagin
g 
    0 0 0 0 0 ND   ND 397 FFPE 118 658 17.93 
Tumor. 
no 
blood  
No NF1 
phenot
ypic 
feature
s. 
Positive 
SDHB-
IHC 
Probably non 
pathogenic 
20 18 NF1 c.5477A>G 
p.His1826
Arg 
del. 
possibly_
damaging 
    0 0 0 0 0 ND   ND 139 Frozen  335 738 45.4 G 
No NF1 
phenot
ypic 
feature
s 
Probably non 
pathogenic 
21 19 NF1 
c.7269_727
0delCA 
p.His2423
Glnfs*4 
                  ND   ND 445 FFPE 249 519 47.98 G 
No NF1 
phenot
ypic 
feature
s. 
Positive 
SDHB-
IHC 
Probably non 
pathogenic 
22 20 NF1 
c.7971-
7C>A 
          0 0 0 0 0 ND   ND 287 Blood 1036 2110 49.3 G 
No NF1 
phenot
ypic 
feature
s 
Probably non 
pathogenic 
23 21 NF1 
c.7985_798
6delAC 
p.Asp266
2Valfs*2 
                  ND   ND 366 Frozen  758 1705 44.6 
Tumor. 
no 
blood  
No LOH 
and no 
phenot
ypic 
feature
s 
Probably non 
pathogenic 
24 22 RET c.1941C>T p.Ile647Ile     
rs752251
91 
  0 0 0 0 0 ND 
Previous
ly 
reporte
d in 
Auricchi
o (1999) 
in 
Hirschsp
rung's 
disease 
as 
11 of 121202 allele 
count. 0  
homozygotes. 
0.00009076 allele 
frequency. 
429 FFPE 271 538 50.37 G 
More 
blood 
request
ed to 
perfor
m 
splicing 
study. 
Positive 
SDHB-
IHC 
Posible 
pathogenic 
225 
 
pathoge
nic 
25 23 SDHC c.24C>T p.His8His         0 0 0 0 0 ND 
Previous
ly 
reporte
d in 
Bayley 
(2006) 
as a 
polymor
phism in 
Duth 
populati
on (1%) 
ND 278 Blood 905 1911 47.4 G 
FFPE 
slide to 
perfor
m 
SDHB/S
DHA-
IHC 
request
ed  
Probably non 
pathogenic 
26 
24 EPAS1 c.1700T>C 
p.Met567
Thr 
tol. benign     0 0 0 0 0 ND 
Previous
ly 
reporte
d: 
Comino 
(2013): 
probabl
y non 
pathoge
nic  
14 of 121324 allele 
count. 0 
homozygotes. 
0.0001154 allele 
frequency.  
405 FFPE 1020 1964 51.93 G 
Positive 
SDHB-
IHC 
Probably non 
pathogenic 
27 450 FFPE 1587 3744 42.39 G 
Positive 
SDHB-
IHC 
Probably non 
pathogenic 
28 25 EPAS1 c.1675A>G 
p.Thr559A
la 
tol. benign     0 0 0 0 0 ND   ND 
123 Blood Not detected in blood 
S 
  
Probably non 
pathogenic 
123 FFPE 
No amplified (previously 
detected by SS)  
Positive 
SDHB-
IHC 
29 26 MEN1 c.628G>A 
p.Asp210
Asn 
del. 
probably
_damagin
g 
    0 0 0 0 0 ND 
UMD-
MEN1: 
ND 
ND 118 Blood 967 1936 50 G 
No LOH 
in the 
tumor. 
Positive 
SDHB-
IHC 
Probably non 
pathogenic 
30 27 MDH2 c.8C>T p.Ser3Phe del. unknown     0 0 0 0 0 ND   ND 137 Frozen  54 98 55.1 G 
qPCR 
RBP1: 
High 
levels 
Probably non 
pathogenic 
31 28 MDH2 c.45C>T 
p.Arg15Ar
g 
    
rs782800
852 
  0 0 0 0 0 ND   
 7 of 14064 allele 
count. 0 
homozygotes. 
0.0004977 allele 
frequency. 
257 Blood 137 223 62 G 
Tumor 
to 
perfor
me 
RBP1/
MDH2 
qPCR 
request
ed  
Unknown  
32 29 MDH2 c.389A>G 
p.Gln130A
rg 
tol. benign     0 0 0 0 0 ND   ND 61 Blood 576 1207 47.8 G 
Tumor 
to 
perfor
me 
RBP1/
Unknown  
226 
 
MDH2 
qPCR 
request
ed  
33 30 MDH2 c.478G>A 
p.Val160
Met 
del. 
possibly_
damaging 
rs138541
865 
  0 0 0 0 0 ND   
20 of 121274 allele 
count. 0 
homozygotes. 
0.0001649 allele 
frequency. 
255 
Blood 129 229 56.3 
G 
Negativ
e SDHB-
IHC 
Probably non 
pathogenic 
FFPE 135 285 47.37   
34 31 MDH2 c.555+8C>T       
rs200420
048 
  0.09 0.28 0 0 0.13 ND   ND 335 Frozen  117 201 58.2 
Tumor. 
no 
blood  
Tumor 
to 
perfor
me 
RBP1/
MDH2 
qPCR 
request
ed  
Unknown  
35 32 MDH2 c.999C>T 
p.Phe333
Phe 
    
rs146761
624 
  0 0 0 0 0 ND   
60 of 120964 allele 
count. 0 
homozygotes. 
0.0004960. 
51 Blood 418 852 49.2 G 
Tumor 
to 
perfor
me 
RBP1/
MDH2 
qPCR 
request
ed  
Unknown  
36 33 
TMEM
127 
c.448G>C 
p.Ala150P
ro 
tol. 
probably
_damagin
g 
    0 0 0 0 0 ND   ND 179 Frozen  998 1089 92.2 
Tumor. 
no 
blood  
  Unknown  
37 34 
TMEM
127 
c.267A>G     
p.Thr89Th
r 
    
rs773384
410 
  0 0 0 0 0 ND   
1 of 121216 allele 
count. 0 
homozygotes. 
0.000008250. 
251 Blood 
Not detected (low coverage 
region ) 
G   
Probably non 
pathogenic 
38 35 FH c.1237-9C>T           0 0 0 0 0 ND   
 6 of 119660 allele 
count. 0 
homozygotes. 
0.00005014.  
294 Blood 182 609 29.9 G 
Reques
ted 
blood 
(RNA) 
and 
FFPE 
slide to 
perfor
m 
5hmC/
2SC 
Probably non 
pathogenic    
39 36 FH c.952C>A 
p.His318A
sn 
tol. benign     0 0 0 0 0 
ND. but 
reporte
d 4 
times 
the 
variant 
:c.952C>
T 
p.H318Y 
as 
ND. but 
reporte
d as 
pathoge
nic the 
variant 
c.952C>
T (FH 
enzymat
ic 
ND 400 FFPE 6901 11778 58.59 
Tumor. 
no 
blood  
IHC 
5hmC 
negativ
e. FFPE 
slide to 
perfor
m 2SC 
request
ed. 
Positive 
Possible 
pathogenic  
227 
 
pathoge
nic 
activity 
reduced
)  
SDHB-
IHC.   
40 37 FH c.700A>G 
p.Thr234A
la 
del. 
probably
_damagin
g 
              ND   ND 364 Frozen  640 752 85.2 
Tumor. 
no 
blood  
Reques
ted 
blood 
and 
FFPE 
slide to 
perfor
m 
5hmC/
2SC 
Unknown  
41 38 FH c.555+4A>G           0 0 0 0 0 ND   
 3 of 121390 
(European Non-
Finnish) allele count. 0 
homozygotes. 
0.00002471. 
312 Blood 692 1398 49.7 G 
Reques
ted 
blood 
(RNA) 
and 
FFPE 
slide to 
perfor
m 
5hmC/
2SC 
Probably non 
pathogenic 
42 39 FH c.-9C>T       
rs200159
437 
  0 0 0 0 0 ND 
Previous
ly 
reporte
d in 
Castro 
(2015) 
as a SNP  
1 (South Asia) of 
14190 allele count. 0 
homozygotes.  
0.00007047.  
210 Blood 39 64 60.9 G 
Reques
ted 
blood 
(RNA) 
and 
FFPE 
slide to 
perfor
m 
5hmC/
2SC 
Probably non 
pathogenic 
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Supplementary table S7. Variants reported by TGPs and not validated by Sanger sequencing. FFPE: formalin fixed paraffin-embedded tumor tissue; Alt: Altered; Freq: frequency; 
Low coverage: low coverage of the altered variant. 
ID  Reason  Sample  Gene cDNA Protein  Alt Read Depth Read Depth Alt Variant Freq 
229 Homopolymeric Blood KIF1B c.1905-8A>T   137 614 23.1 
23 Homopolymeric Blood KIF1B c.1905-4C>T   116 554 21.2 
105 Low coverage Blood MAX c.296-4T>C   4 20 20 
259 Low coverage Blood FH c.1237-8A>T   69 678 10.5 
 
ID  Reason Sample  Gene cDNA Protein  Alt Read Depth Read Depth Alt Variant Freq 
355 Low coverage Frozen  VHL c.269A>G p.Asn90Ser 3 15 20.0 
139 Low coverage Frozen  SDHB c.490C>A p.Gln164Lys 6 60 10 
338 Low coverage Frozen  NF1 c.5789G>T p.Cys1930Phe 13 115 11.4 
137 Low coverage Frozen  SDHC c.158C>A p.Ser53Tyr 10 62 16.1 
 
ID  Reason Sample  Gene cDNA Protein  Alt Read Depth Read Depth Alt Variant Freq 
291 Low coverage FFPE HRAS c.179G>A p.Gly60Asp 75 1453 5.16 
451 Low coverage FFPE HRAS c.175G>A p.Ala59Thr 78 2286 3.41 
378 Low coverage FFPE VHL c.231C>A p.Cys77* 22 494 4.45 
398 Low coverage FFPE NF1 c.227delA p.Asn78Ilefs*7 91 2302 3.95 
403 Low coverage FFPE NF1 c.2834T>C p.Phe945Ser 56 1538 3.64 
412 Low coverage FFPE NF1 c.5806delA p.Lys1936Asnfs*6 150 4753 3.16 
398 Low coverage FFPE NF1 c.6535C>T p.Arg2179Cys 507 9128 5.55 
450 Low coverage FFPE NF1 c.7195A>G p.Arg2399Gly 41 1289 3.18 
292 Low coverage FFPE EPAS1 c.1734C>T p.Ala578Ala 95 2916 3.26 
413 Low coverage FFPE MAX c.247C>T p.Gln83* 47 1467 3.2 
395 Low coverage FFPE TMEM127 c.480_482delGCA p.Gln160del 248 2726 9.1 
420 Low coverage FFPE FH c.1219G>A p.Val407Ile 46 794 5.79 
395 Low coverage FFPE FH c.952C>T p.His318Tyr 321 6534 4.91 
432 Low coverage FFPE FH c.679C>T p.Gln227* 187 2872 6.51 
421 Low coverage FFPE FH c.578C>T p.Thr193Ile 37 765 4.84 
 
Low coverage FFPE FH c.7C>T p.Arg3* 44 447 9.84 
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ABSTRACT: 
BACKGROUND: Nowadays, 65-80% of pheochromocytoma and paraganglioma (PPGL) cases are 
explained by germline or somatic mutations in one of 22 genes. Several genetic testing 
algorithms have been proposed, but they usually exclude sporadic-PPGLs (S-PPGLs) and none 
include somatic testing. We aimed to genetically characterise S-PPGL cases and propose an 
evidence-based algorithm for genetic testing, prioritising DNA source. 
METHODS: The study included 329 probands fitting three criteria: single PPGL, no  syndromic 
and no PPGL family history. Germline DNA was tested for point mutations in RET and for both 
point mutation and gross deletions in VHL, the SDH genes, TMEM127, MAX and FH. 99 tumours 
from patients negative for germline screening were available and tested for RET, VHL, HRAS, 
EPAS1, MAX and SDHB.  
RESULTS: Germline mutations were found in 46 (14.0%) patients, being more prevalent in 
paragangliomas (PGLs) (28.7%) than in pheochromocytomas (PCCs) (4.5%) (p=6.62×10(-10)). 
Somatic mutations were found in 43% of those tested, being more prevalent in PCCs (48.5%) 
than in PGLs (32.3%) (p=0.13). A quarter of  S-PPGLs had a somatic mutation, regardless of age 
at presentation. Head and neck PGLs (HN-PGLs) and thoracic-PGLs (T-PGLs) more commonly had 
germline mutations (p=2.0×10(-4) and p=0.027, respectively). Five of the 29 metastatic cases 
harboured a somatic mutation, one in HRAS. 
CONCLUSIONS: We recommend prioritising testing for germline mutations in patients with HN-
PGLs and T-PGLs, and for somatic mutations in those with PCC. Biochemical secretion and SDHB-
immunohistochemistry should guide genetic screening in abdominal-PGLs. Paediatric and 
metastatic cases should not be excluded from somatic screening. 
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ABSTRACT: 
Background: Genetic diagnosis is recommended for all pheochromocytoma and paraganglioma 
(PPGL) cases, as driver mutations are identified approximately 80%. As the list of related genes 
expands, genetic diagnosis becomes more time-consuming, and targeted next generation 
sequencing (NGS) has emerged as a cost-effective tool. This study aimed to optimize targeted-
NGS in PPGL genetic diagnostics.   
Methodology: A workflow based on 2 customized targeted-NGS assays was validated to study 
the 18 main PPGL genes in germline and frozen tumor DNA, being one of them specifically 
directed towards formalin-fixed paraffin-embedded tissue. The series involved 453 unrelated 
PPGL patients, of which 30 had known mutations and were used as controls. Partial screening 
using Sanger had been performed in 275 (WTPS). NGS results were complemented with a study 
of gross deletions 
Results: NGS assay sensitivity was ≥99.4%, regardless of DNA source. We identified 45 variants 
of unknown significance and 89 pathogenic mutations, the latter being germline in 29 (7.2%) 
and somatic in 58 (31.7%) of the 183 tumors studied. In 13 WTPS the causal mutation could be 
identified.   
Conclusions: We demonstrated that both assays are an efficient and accurate alternative to 
conventional sequencing. Their application facilitates the study of minor PPGL genes, and 
enables genetic diagnoses in patients with incongruent or missing clinical data, that would 
otherwise be missed. 
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ABSTRACT: 
Pheochromocytomas (PCCs) and paragangliomas (PGLs) are tumors arising from the adrenal 
medulla and sympathetic/parasympathetic paraganglia, respectively.  
Approximately 40% of PCCs/PGLs are due to germline mutations in one of 16 susceptibility 
genes, and a further 30% are due to somatic alterations in 5 main genes. Recently, somatic ATRX 
mutations have been found in succinate dehydrogenase (SDH)-associated hereditary PCCs/PGLs. 
In the present study we applied whole-exome sequencing to the germline and tumor DNA of a 
patient with metastatic composite PCC and no alterations in known PCC/PGL susceptibility 
genes. A somatic loss-of-function mutation affecting ATRX was identified in tumor DNA. 
Transcriptional profiling analysis classified the tumor within cluster 2 of PCCs/PGLs (without SDH 
gene mutations) and identified downregulation of genes involved in neuronal development and 
homeostasis (NLGN4, CD99 and CSF2RA) as well as upregulation of Drosha, an important gene 
involved in miRNA and Rrna processing. CpG island methylator phenotype typical of SDH gene-
mutated tumors was ruled out, and SNP array data revealed a unique profile of gains and losses.  
Finally, we demonstrated the presence of alternative lengthening of telomeres in  the tumor, 
probably associated with the failure of ATRX functions. In conclusion, somatic variants affecting 
ATRX may play a driver role in sporadic PCC/PGL. 
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ABSTRACT: 
The presence of germline mutations affecting the MYC-associated protein X (MAX) gene has 
recently been identified as one of the now 11 major genetic predisposition factors for the 
development of hereditary pheochromocytoma and/or paraganglioma. Little is known regarding 
how missense variants of unknown significance (VUS) in MAX affect its pivotal role in the 
regulation of the MYC/MAX/MXD axis. In the present study, we propose a consensus 
computational prediction based on five "state-of-the-art" algorithms. We also describe a PC12-
based functional assay to assess the effects that 12 MAX VUS may have on MYC's E-box 
transcriptional activation. For all but two of these 12 VUS, the functional assay and the 
consensus computational prediction gave consistent results; we classified seven variants as 
pathogenic and three as nonpathogenic. 
The introduction of wild-type MAX cDNA into PC12 cells significantly decreased MYC's ability to 
bind to canonical E-boxes, while pathogenic MAX proteins were not able to fully repress MYC 
activity. Further clinical and molecular evaluation of variant carriers corroborated the results 
obtained with our functional assessment. In the absence of clear heritability, clinical 
information, and molecular data, consensus computational predictions and functional models 
are able to correctly classify VUS affecting MAX.KEY  
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MESSAGES: A functional assay assesses the effects of MAX VUS over MYC transcriptional activity. 
A consensus computational prediction and the functional assay show high concordance. Variant 
carriers' clinical and molecular data support the functional assessment. 
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DNA Methylation Profiling in Pheochromocytoma and Paraganglioma Reveals 
Diagnostic and Prognostic Markers. 
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ABSTRACT: 
PURPOSE: Pheochromocytoma and paraganglioma (PPGL) are rare neuroendocrine tumors, 
associated with highly variable postoperative evolution. The scarcity of reliable PPGL prognostic 
markers continues to complicate patient management. In this study, we explored genome-wide 
DNA methylation patterns in the context of PPGL malignancy to identify novel prognostic 
markers. 
EXPERIMENTAL DESIGN: We retrospectively investigated DNA methylation patterns in PPGL with 
and without metastases using high-throughput DNA methylation profiling  data (Illumina 27K) 
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from two large, well-characterized discovery (n = 123; 24 metastatic) and primary validation (n 
= 154; 24 metastatic) series. Additional validation of candidate CpGs was performed by bisulfite 
pyrosequencing in a second independent set of 33 paraffin-embedded PPGLs (19 metastatic). 
RESULTS: Of the initial 86 candidate CpGs, we successfully replicated 52 (47 genes), associated 
with metastatic PPGL. Of these, 48 CpGs showed significant associations with time to 
progression even after correcting for SDHB genotype, suggesting their value as prognostic 
markers independent of genetic background. Hypermethylation of RDBP (negative elongation 
factor complex member E) in metastatic tumors was further validated by bisulfite 
pyrosequencing [Δβmetastatic-benign = 0.29, P = 0.003; HR, 1.4; 95% confidence interval (CI), 
1.1-2.0; P = 0.018] and may alter transcriptional networks involving (RERG, GPX3, and PDZK1) 
apoptosis, invasion, and maintenance of DNA integrity.  
CONCLUSIONS: This is the first large-scale study of DNA methylation in metastatic PPGL that 
identifies and validates prognostic markers, which could be used for stratifying patients 
according to risk of developing metastasis. Of the three CpGs selected for further validation, one 
(RDBP) was clearly confirmed and could be used for stratifying patients according to the risk of 
developing metastases. 
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multicenter interobserver variation analysis using virtual microscopy: a Multinational 
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ABSTRACT: 
Despite the established role of SDHB/SDHA immunohistochemistry as a valuable tool to identify 
patients at risk for familial succinate dehydrogenase-related pheochromocytoma 
/paraganglioma syndromes, the reproducibility of the assessment methods has not as yet been 
determined. The aim of this study was to investigate  interobserver variability among seven 
expert endocrine pathologists using a web-based virtual microscopy approach in a large 
multicenter pheochromocytoma/paraganglioma cohort (n=351): (1) 73 SDH mutated, (2) 105 
non-SDH mutated, (3) 128 samples without identified SDH-x mutations, and (4) 45 with 
incomplete SDH molecular genetic analysis. Substantial agreement among all the reviewers was 
observed either with a two-tiered classification (SDHB κ=0.7338; SDHA κ=0.6707) or a three-
tiered classification approach (SDHB κ=0.6543; SDHA κ=0.7516). Consensus was achieved in 315 
cases (89.74%) for SDHB immunohistochemistry and in 348 cases (99.15%) for SDHA 
immunohistochemistry. Among the concordant cases, 62 of 69 (~90%) SDHB-/C-/D-/AF2-
mutated cases displayed SDHB immunonegativity and SDHA immunopositivity, 3 of 4 (75%) with 
SDHA mutations showed loss of SDHA/SDHB protein expression, whereas 98 of 105 (93%) non-
SDH-x-mutated counterparts demonstrated retention of SDHA/SDHB protein expression. Two 
SDHD-mutated extra-adrenal paragangliomas were scored as SDHB immunopositive, whereas 9 
of 128 (7%) tumors without identified SDH-x mutations, 6 of 37 (~16%) VHL-mutated, as well as 
1 of 21 (~5%) NF1-mutated tumors were evaluated as SDHB immunonegative. Although 14 out 
of those 16 SDHB-immunonegative cases were nonmetastatic, an overall significant correlation 
between SDHB immunonegativity and malignancy was observed (P=0.00019). We conclude that 
SDHB/SDHA immunohistochemistry is a reliable tool to identify patients with SDH-x mutations 
with an additional value in the assessment of genetic variants of unknown significance. If SDH 
molecular genetic analysis fails to detect a mutation in SDHB-immunonegative tumor, SDHC 
promoter methylation and/or VHL/NF1 testing with the use of targeted next-generation 
sequencing is advisable. 
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ABSTRACT: Disruption of the Krebs cycle is a hallmark of cancer. IDH1 and IDH2 mutations are 
found in many neoplasms, and germline alterations in SDH genes and FH predispose to 
pheochromocytoma/paraganglioma and other cancers. We describe a paraganglioma family 
carrying a germline mutation in MDH2, which encodes a Krebs cycle enzyme. Whole-exome 
sequencing was applied to tumor DNA obtained from a man age 55 years diagnosed with 
multiple malignant paragangliomas. Data were analyzed with the two-sided Student's t and 
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Mann-Whitney U tests with Bonferroni correction for multiple comparisons. Between six- and 
14-fold lower levels of MDH2 expression were observed in MDH2-mutated tumors compared 
with control patients. Knockdown (KD) of MDH2 in HeLa cells by shRNA triggered the 
accumulation of both malate (mean ± SD: wild-type [WT] = 1±0.18; KD = 2.24±0.17,  P = .043) 
and fumarate (WT = 1±0.06; KD = 2.6±0.25, P = .033), which was reversed by transient 
introduction of WT MDH2 cDNA. Segregation of the mutation with disease and absence of 
MDH2 in mutated tumors revealed MDH2 as a novel pheochromocytoma/paraganglioma 
susceptibility gene.J Mol Med (Berl). 2015 Nov;93(11):1247-55.  
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Germline mutations in FH confer predisposition to malignant pheochromocytomas 
and paragangliomas. 
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Author information: (1)INSERM, UMR970, Paris-Cardiovascular Research Center, F-75015, Paris, 
France. 
ABSTRACT: 
Malignant pheochromocytoma (PCC) and paraganglioma (PGL) are mostly caused by germline 
mutations of SDHB, encoding a subunit of succinate dehydrogenase. Using  whole-exome 
sequencing, we recently identified a mutation in the FH gene encoding fumarate hydratase, in a 
PCC with an 'SDH-like' molecular phenotype. Here, we investigated the role of FH in PCC/PGL 
predisposition, by screening for germline FH mutations in a large international cohort of 
patients. We screened 598 patients with PCC/PGL without mutations in known PCC/PGL 
susceptibility genes. We searched for FH germline mutations and large deletions, by direct 
sequencing and multiplex ligation-dependent probe amplification methods. Global alterations 
in DNA methylation and protein succination were assessed by immunohistochemical staining for 
5-hydroxymethylcytosine (5-hmC) and S-(2-succinyl) cysteine (2SC), respectively. We identified 
five pathogenic germline FH mutations (four missense and one splice mutation) in five patients. 
Somatic inactivation of the second allele, resulting in a loss of fumarate hydratase activity, was 
demonstrated in tumors with FH mutations. Low tumor levels of 5-hmC, resembling those in 
SDHB-deficient tumors, and positive 2SC staining were detected in tumors with FH  mutations. 
Clinically, metastatic phenotype (P = 0.007) and multiple tumors (P = 0.02) were significantly 
more frequent in patients with FH mutations than those without such mutations. This study 
reveals a new role for FH in susceptibility to malignant and/or multiple PCC/PGL. Remarkably, 
FH-deficient PCC/PGLs display the same pattern of epigenetic deregulation as SDHB-mutated 
malignant PCC/PGL. 
Therefore, we propose that mutation screening for FH should be included in PCC/PGL genetic 
testing, at least for tumors with malignant behavior. 
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ABSTRACT:  
PURPOSE: Neuropathy is the dose-limiting toxicity of paclitaxel and a major cause for decreased 
quality of life. Genetic factors have been shown to contribute to paclitaxel neuropathy 
susceptibility; however, the major causes for interindividual differences remain unexplained. In 
this study, we identified genetic markers associated with paclitaxel-induced neuropathy through 
massive sequencing of candidate genes. 
EXPERIMENTAL DESIGN: We sequenced the coding region of 4 EPHA genes, 5 genes involved in 
paclitaxel pharmacokinetics, and 30 Charcot-Marie-Tooth genes, in 228 cancer patients with 
no/low neuropathy or high-grade neuropathy during paclitaxel treatment. An independent 
validation series included 202 paclitaxel-treated patients. Variation-/gene-based analyses were 
used to compare variant frequencies among neuropathy groups, and Cox regression models 
were used to analyze neuropathy along treatment. 
RESULTS: Gene-based analysis identified EPHA6 as the gene most significantly associated with 
paclitaxel-induced neuropathy. Low-frequency nonsynonymous variants in EPHA6 were present 
exclusively in patients with high neuropathy, and all affected the ligand-binding domain of the 
protein. Accumulated dose analysis in the discovery series showed a significantly higher 
neuropathy risk for EPHA5/6/8 low-frequency nonsynonymous variant carriers [HR, 14.60; 95% 
confidence interval (CI), 2.33-91.62; P = 0.0042], and an independent cohort confirmed an 
increased neuropathy risk (HR, 2.07; 95% CI, 1.14-3.77; P = 0.017). Combining the series gave an 
estimated 2.5-fold higher risk of neuropathy (95% CI, 1.46-4.31; P = 9.1 × 10(-4)). 
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CONCLUSIONS: This first study sequencing EPHA genes revealed that low-frequency variants in 
EPHA6, EPHA5, and EPHA8 contribute to the susceptibility to paclitaxel-induced neuropathy. 
Furthermore, EPHA's neuronal injury repair function suggests that these genes might constitute 
important neuropathy markers for many neurotoxic drugs. Clin Cancer Res; 1-9. ©2016 AACR. 
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High frequency and founder effect of the CYP3A4*20 loss-of-function allele in the 
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ABSTRACT: 
Cytochrome P450 3A4 (CYP3A4) is a key drug-metabolizing enzyme. Loss-of-function  variants 
have been reported as rare events, and the first demonstration of a CYP3A4 protein lacking 
functional activity is caused by CYP3A4*20 allele. Here we characterized the world distribution 
and origin of CYP3A4*20 mutation. CYP3A4*20 was determined in more than 4000 individuals 
representing different populations, and haplotype analysis was performed using CYP3A 
polymorphisms and microsatellite markers. CYP3A4*20 allele was present in 1.2% of the Spanish 
population (up to 3.8% in specific regions), and all CYP3A4*20 carriers had a common haplotype.  
This is compatible with a Spanish founder effect and classifies CYP3A4 as a polymorphic enzyme. 
This constitutes the first description of a CYP3A4 loss-of-function variant with high frequency in 
a population. CYP3A4*20 results together with the key role of CYP3A4 in drug metabolism 
support screening for rare CYP3A4 functional alleles among subjects with adverse drug events 
in certain populations.
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VEGF, VEGFR3, and PDGFRB protein expression is influenced by RAS mutations in 
medullary thyroid carcinoma. 
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Author information: (1)1 Hereditary Endocrine Cancer Group, Spanish National Cancer Research 
Centre , Madrid, Spain . 
ABSTRACT: 
BACKGROUND: Tyrosine kinase inhibitors (TKIs) have achieved remarkable clinical results in 
medullary thyroid carcinoma (MTC) patients. However, the considerable variability in patient 
response to treatment with TKIs remains largely unexplained. There is evidence that it could be 
due, at least in part, to alterations in genes associated with the disease via their effect on the 
expression of TKI targets. The objective of this study was to evaluate the influence of RAS 
mutations on the expression levels in MTC tumors of eight key TKI target proteins. 
METHODS: We assessed by immunohistochemistry the expression of EGFR, KIT, MET, PDGFRB, 
VEGF, VEGFR1, VEGFR2, and VEGFR3 in a series of 84 primary MTC tumors that had previously 
been molecularly characterized, including 14 RAS-positive, 18 RET(M918T)-positive, and 24 
RET(C634)-positive tumors, as well as 15 wild-type tumors with no mutations in the RET or RAS 
genes. 
RESULTS: In contrast to RET-positive tumors, RAS-positive tumors expressed neither PDGFRB nor 
MET (p=0.0060 and 0.047, respectively). Similarly, fewer RAS-positive than RET-related tumors 
expressed VEGFR3 (p=0.00062). Finally, wild-type tumors expressed VEGF more often than both 
RAS- and RET-positive tumors (p=0.0082 and 0.011, respectively). 
CONCLUSIONS: This is the first study identifying that the expression of TKI targets differs 
according to the presence of RAS mutations in MTC. This information could potentially be used 
to select the most beneficial TKI treatment for these patients.
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ABSTRACT: 
Thyroid cancer is a heterogeneous disease with several subtypes characterized by  cytological, 
histological and genetic alterations, but the involvement of epigenetics is not well understood. 
Here, we investigated the role of aberrant DNA methylation in the development of well-
differentiated thyroid tumors. We performed genome-wide DNA methylation profiling in the 
largest well-differentiated thyroid tumor series reported to date, comprising 83 primary tumors 
as well as 8 samples of adjacent normal tissue. The epigenetic profiles were closely related to 
not only tumor histology but also the underlying driver mutation; we found that follicular tumors 
had higher levels of methylation, which seemed to accumulate in a progressive manner along 
the tumorigenic process from adenomas to carcinomas. Furthermore, tumors harboring a BRAF 
or RAS mutation had a larger number of hypo- or hypermethylation events, respectively. The 
aberrant methylation of several candidate genes potentially related to thyroid carcinogenesis 
was validated in an independent series of 52 samples.  
Furthermore, through the integration of methylation and transcriptional expression data, we 
identified genes whose expression is associated with the methylation status of their promoters. 
Finally, by integrating clinical follow-up information with methylation levels we propose 
etoposide-induced 2.4 and Wilms tumor 1 as novel prognostic markers related to recurrence-
free survival. This comprehensive study provides insights into the role of DNA methylation in 
well-differentiated thyroid cancer development and identifies novel markers associated with 
recurrence-free survival.
 
 
 
 
 
 
 
 
 
 
